The Associations of Malaria and Linear Growth Faltering in Infants and Young Children in Malawi by Bendabenda, Jaden
Tampere University Dissertations 201
The Associations of 
Malaria and Linear 
Growth Faltering in 
Infants and Young 
Children in Malawi
JADEN BENDABENDA

Tampere University Dissertations 201 
JADEN BENDABENDA 
The Associations of Malaria and  
Linear Growth Faltering in Infants and  
Young Children in Malawi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
To be presented, with the permission of 
the Faculty of Medicine and Health Technology 
of Tampere University, 
for public discussion in the Jarmo Visakorpi auditorium 
of the Arvo Building, Arvo Ylpön katu 34, Tampere, 
on 24 January 2020, at 12 o’clock. 
   
ACADEMIC DISSERTATION 
Tampere University, Faculty of Medicine and Health Technology 
Finland 
 
 
Responsible 
supervisor 
and Custos 
Professor Per Ashorn 
Tampere University 
Finland 
 
Supervisor Professor Kenneth Maleta 
College of Medicine 
Malawi 
 
 
Pre-examiners Docent Terhi Tapiainen 
University of Oulu 
Finland 
Docent Tuula Pelkonen 
University of Helsinki 
Finland 
Opponent Docent Päivi Tapanainen 
University of Oulu 
Finland 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The originality of this thesis has been checked using the Turnitin OriginalityCheck service. 
 
 
Copyright ©2020 author 
 
 
Cover design: Roihu Inc. 
 
 
ISBN 978-952-03-1415-6 (print) 
ISBN 978-952-03-1416-3 (pdf) 
ISSN 2489-9860 (print) 
ISSN 2490-0028 (pdf) 
http://urn.fi/URN:ISBN:978-952-03-1416-3 
 
 
PunaMusta Oy – Yliopistopaino 
Tampere 2020 
i 
ABSTRACT 
The geographic overlap between stunting (small length for age) and malaria 
suggests there is a relationship between the two conditions, but current evidence is 
inconclusive. Interventions aimed to prevent stunting include improving the quality 
of complementary foods through home fortification with products such as lipid-
based nutrient supplements (LNS). However, there are concerns that LNS, which 
contains iron, can increase the risk of malaria in children. Hence the need to 
establish whether a causal relationship exists between stunting and malaria; and 
whether LNS provision to prevent stunting can increase the risk of malaria. 
The present study was therefore designed to determine: whether linear growth 
faltering can predict the risk of malaria; whether malaria causes linear growth 
faltering and poor child development; and whether LNS provision does not increase 
the risk of malaria. These aims were addressed using data from children enrolled in 
the International Lipid-based Nutrient Supplements Project (iLiNS) trials (iLiNS-
DOSE and iLiNS-DYAD-M), conducted in rural Malawi between 2009 and 2015.  
A total of 2,725 six-month old children were enrolled and followed during 
weekly morbidity home visits, where a diagnosis of presumed malaria was made. 
Additional malaria data were collected at clinic visits. Anthropometry data were 
collected at 6 months’ and 18 months’ clinic visits where length-for-age z scores 
[LAZ] were obtained. Stunting was defined as LAZ <-2. Developmental outcomes 
(fine motor scores, gross motor scores, language scores and Profile of Social and 
Emotional Development [PSED] scores) were assessed at 18 months’ clinic visit. 
At 18 months, 2,561 (94%) children had complete morbidity data and reported 
28,032 morbidity episodes, 9.7% of which were episodes of presumed malaria. The 
mean (SD) incidence of all illnesses combined was 16.2 (13.1) episodes per child 
year, of which 1.1 (1.6) were episodes of presumed malaria. On average, the 
children made 5.5 visits to the hospital due to illness, of which 1.7 were due to 
malaria. The prevalence of malaria confirmed by microscopy increased from 4.7% 
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to 9.6% between 6 months and 18 months. There was no association of LAZ at 6 
months with subsequent 12-month incidence of presumed malaria (incidence rate 
ratio [IRR] = 1.03; 95% CI = 0.98 to 1.09; p =0.394) or prevalence of malaria 
parasitaemia at 18 months (prevalence ratio = 1.11; 95% CI = 0.93 to 1.33; p = 
0.259). 
Between 6 months and 18 months, the mean (SD) change in LAZ was -0.44 
(0.77) and the prevalence of stunting increased from 26.7% to 41.2%. At 18 
months, the mean (SD) for fine motor, gross motor, language and PSED scores 
were 20.9 (2.2), 17.3 (2.6), 26.2 (5.0) and 16.2 (5.4) respectively. There was no 
statistically significant association of presumed malaria incidence with change in 
LAZ (ȕ = -0.02, 95% CI = -0.04 to 0.01, p = 0.069). Presumed malaria incidence 
was significantly associated with increased proportion of children with stunting at 
18 months (risk ratio = 1.04, 95% CI = 1.01 to 1.07, p = 0.023). The association of 
presumed malaria incidence with child development at 18 months was significant 
for PSED scores (ȕ= -0.21; 95% CI = 0.39 to -0.03; p = 0.041), but not for the 
other domains of child development. 
Regarding the safety of LNS, there were no significant differences in the 
incidence of presumed malaria, clinical malaria nor confirmed malaria across the 
different doses of LNS. Compared to the control group, the 95% CIs of the IRRs for 
presumed malaria, clinical malaria, and confirmed malaria were entirely below 1.20 
(suggestive of non-inferiority) in all the intervention groups, except for the 40 g/d 
LNS where the incidence of confirmed malaria was 21% higher in this group than 
the control.  
In conclusion, in a rural Malawian population, where both stunting and malaria 
are common, but with active surveillance and early treatment of infections, linear 
growth faltering at 6 months does not predict malaria incidence from 6 months to 
18 months. In this population, malaria is not associated with change in LAZ but 
may increase the risk of stunting and reduce socio-emotional development. Finally, 
long term provision of iron-containing LNS at certain doses does not increase the 
risk of malaria in this population where iron deficiency and mosquito bed net 
utilization is high. These findings could be useful when designing growth 
promotion and malaria control interventions for infants and young children in 
malaria-endemic areas.  
TIIVISTELMÄ 
Kasvun hidastumisen (ikäisekseen lyhyt) ja malarian maantieteellinen 
päällekkäisyys viittaa siihen, että ne olisivat yhteydessä toisiinsa, mutta tästä ei 
toistaiseksi ole selvää näyttöä. Kasvun hidastumista pyritään estämään mm. 
parantamalla kotona annettavaa täydennysravintoa. Tähän käytetään esimerkiksi 
rasvapohjaisia ravintolisiä (lipid-based nutrient supplements, LNS). On kuitenkin 
oltu huolissaan siitä, että rautaa sisältävät LNS-valmisteet voivat lisätä lasten 
malariariskiä. Siksi pitää selvittää, onko kasvun hidastumisen ja malarian välillä 
syy-yhteys ja voiko LNS-valmisteiden käyttö estämään kasvun hidastumista lisätä 
malarian riskiä. 
Tämän tutkimuksen tavoitteena oli siksi selvittää, voiko pituuskasvun häiriö 
ennustaa malariariskiä, aiheuttaako malaria pituuskasvun häiriöitä, hidastaako se 
lapsen kehitystä, ja lisääkö LNS-valmisteiden käyttö malariariskiä. Näitä selvitettiin 
käyttäen kansainväliseen iLiNS-projektin (International Lipid-based Nutrient 
Supplements Project) tutkimuksiin (iLiNS-DOSE ja iLiNS-DYAD-M) Malawin 
maaseudulla vuosina 2009–2015 osallistuneiden lasten tietoja.  
Tutkimuksiin otettiin kaikkiaan 2 725 kuuden kuukauden ikäistä lasta, joiden 
sairastuvuutta seurattiin viikoittain kotikäynneillä, joilla syntyi malariaepäily. 
Malariasta kerättiin lisätietoa klinikkakäynneillä. Antropometrisia tietoja kerättiin 6 
kuukauden ja 18 kuukauden klinikkakäynneillä, joilla määritettiin LAZ-pistemäärä 
(length-for-age z), joka kuvaa pituutta ikään nähden. Kasvun hidastumisesta 
katsottiin olevan kyse, jos LAZ-pistemäärä oli < -2. Kehitystä (hieno- ja 
karkeamotoriikkaa, kielen kehitystä sekä sosiaalisen ja emotionaalisen kehityksen 
profiilia [Profile of Social and Emotional Development, PSED]) kuvaavat 
pistemäärät arvioitiin 18 kuukauden klinikkakäynnillä. 
Täydelliset sairastuvuustiedot saatiin 18 kuukauden iässä 2 561 lapselta (94 %), 
ja heillä ilmoitettiin olleen 28 032 sairausjaksoa, joista 9,7 % oli oletettavasti 
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malariaa. Kaikkien sairauksien esiintyvyyden keskiarvo (SD) oli 16,2 (13,1) jaksoa 
lapsivuotta kohti, ja näistä 1,1 (1,6) oli oletettavasti malariaa. Lapset kävivät 
sairauden vuoksi keskimäärin 5,5 kertaa sairaalassa, ja näistä käynneistä 1,7 johtui 
malariasta. Mikroskoopilla varmistetun malarian esiintyvyys kasvoi 4,7 prosentista 
6 kuukauden iässä 9,6 prosenttiin 18 kuukauden iässä. LAZ-pistemäärä 6 
kuukauden iässä ei ollut yhteydessä oletetun malarian ilmaantuvuuteen 12 
kuukauden iässä (ilmaantumistiheyksien suhde [IRR] = 1,03, 95 %:n luottamusväli 
= 0,98–1,09, p = 0,394) eikä malarialoisen esiintyvyyteen veressä 18 kuukauden 
iässä (vallitsevuussuhde [PR] = 1,11, 95 %:n luottamusväli = 0,93–1,33, p = 0,259). 
Kuuden ja 18 kuukauden iän välillä keskimääräinen (SD) LAZ-pistemäärän 
muutos oli -0,44 (0,77) ja kasvun hidastumisen esiintyvyys lisääntyi 26,7 
prosentista 41,2 prosenttiin. 18 kuukauden iässä pistemäärien keskiarvot (SD) olivat 
seuraavat: hienomotoriikka 20,9 (2,2), karkeamotoriikka 17,3 (2,6), kielen kehitys 
26,2 (5,0) ja PSED 16,2 (5,4). Oletetun malarian ilmaantuvuuden ja LAZ-
pistemäärän muutoksen välillä ei ollut tilastollisesti merkitsevää yhteyttä (ȕ = -0,02, 
95 %:n luottamusväli = -0,04–0,01, p = 0,069). Oletetun malarian ilmaantuvuus oli 
merkitsevästi yhteydessä niiden lasten lisääntyneeseen osuuteen, joiden kasvu oli 
hidastunut 18 kuukauden iässä (riskisuhde = 1,04, 95 prosentin luottamusväli = 
1,01–1,07, p = 0,023). Yhteys oletetun malarian ilmaantuvuuden ja lapsen 
kehityksen välillä 18 kuukauden iässä oli merkitsevä PSED-pistemäärien osalta (ȕ= 
-0,21, 95 prosentin luottamusväli = 0,39 – -0,03; p = 0,041) mutta ei muilla lapsen
kehityksen osa-alueilla.
LNS-valmisteiden turvallisuudesta todettiin, että oletetun, kliinisen tai 
varmistetun malarian ilmaantuvuudessa ei ollut eroa erisuuruisia LNS-annoksia 
käyttäneillä. Verrokkiryhmään verrattuna niin oletetun, kliinisen kuin 
varmistetunkin malarian IRR-arvojen 95 prosentin luottamusvälit olivat alle 1,20 
(mikä tarkoittaa vertailukelpoisuutta [non-inferiority]) kaikissa interventioryhmissä, 
paitsi 40 g/vrk LNS-valmistetta saaneessa ryhmässä, jossa varmistetun malarian 
ilmaantuvuus oli 21 % suurempi kuin verrokkiryhmässä.  
Lv 
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Yhteenvetona voidaan sanoa, että malawilaisessa maalaisväestössä sekä kasvun 
hidastuminen että malaria ovat yleisiä, mutta jos lapsia seurataan aktiivisesti ja 
infektiot hoidetaan hyvissä ajoin, pituuskasvun häiriö 6 kuukauden iässä ei ennusta 
malarian ilmaantuvuutta 6–18 kuukauden iässä. Tässä populaatiossa malaria ei liity 
LAZ-arvon muutokseen mutta voi lisätä kasvun hidastumisen riskiä ja heikentää 
sosioemotionaalista kehitystä. Lopuksi rautaa sisältävien LNS-valmisteiden 
pitkäaikainen käyttö tietyn suuruisina annoksina ei lisää malarian riskiä tässä 
populaatiossa, jossa raudanpuute ja moskiittoverkon käyttö sängyn ympärillä ovat 
yleisiä. Näistä löydöksistä saattaa olla hyötyä suunniteltaessa vauvojen ja 
pikkulasten kasvun edistämiseen ja malarian hallintaan tähtääviä toimenpiteitä 
malarian endeemisillä alueilla.
vi 
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1 INTRODUCTION 
Good nutrition is essential for children’s growth, hence undernutrition has 
detrimental effects on the growth and development of children (1). To underline the 
global importance,  indicators of undernutrition, specifically stunting (small length 
for age) and wasting (low weight in relation to height) (2,3) are among the selected 
indicators for the 17 Sustainable Development Goals (SDGs) endorsed by the 
United Nations General Assembly in 2015 aimed at mobilizing resources to end 
global hunger and poverty, as well as improve education and health, among others 
(4). The global focus on undernutrition has helped to reduce stunting in children 
under 5 years of age from 32.6% in 2000 to 22.2% in 2017 (1).  
Globally, 151 million children under 5 years of age were considered stunted 
(length-for-age z-scores [LAZ] <-2) in 2017. More than one third of these children 
lived in sub-Saharan Africa (SSA), where malaria burden is also very high: 90% of 
the 219 million cases and 435,000 deaths due to malaria occur in this region(1,5,6). 
The interaction between undernutrition and infections in children in low- and 
middle-income countries (LMICs) can create a vicious cycle of repeated infections 
and worsening nutritional status (1). The geographic overlap of undernutrition and 
infections suggests that linear growth faltering may play an important role in 
malaria epidemiology (7–9). However, four reviews on the relationship between 
undernutrition and malaria were inconclusive; explained by the differences in the 
populations studied and the malaria parasite species, among others (10–13). 
Nutrition interventions aimed to improve the quality of complementary foods 
only have modest impact on growth (14), possibly due to a high burden of infections 
in children (15,16). Studies in which morbidity treatment was integrated with a 
complementary feeding intervention demonstrated improved linear growth (17) and 
developmental outcomes in children (18,19), suggesting the importance of reducing 
the burden of infections along with improved diet to promote child growth and 
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development. There is a plethora of studies showing a significant inverse association 
of diarrhoea with growth (20–22), but few on malaria, which has limited 
conclusions on the effect of malaria on stunting (23). 
One of the contributing factors to stunting in children in LMICs is believed to be 
consumption of low quality complementary foods (24). To improve the quality of 
complementary foods, home fortification with products such as small quantity lipid-
based nutrient supplements (LNS) has been explored as one of the novel strategies 
(25). However, LNS fortified with iron may raise concerns of increased risk of 
malaria in children in malaria-endemic areas (26–28). Currently, iron 
supplementation is not recommended in children in malaria-endemic countries 
unless effective malaria control interventions are certain to be provided (28). This 
recommendation was based on evidence from studies that provided iron tablets or 
multiple micronutrients (29–31). Few studies have reported that food fortificants 
such as LNS may be safe (15,32–34), but this evidence is still deemed inconclusive 
(35,36). More evidence on the safety of LNS in malaria-endemic areas is still 
needed. 
The present study was designed to determine whether linear growth faltering is 
associated with higher risk of malaria, whether malaria is associated with linear 
growth faltering, and whether LNS provision aimed to reduce linear growth 
faltering increases the risk of malaria.
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2 REVIEW OF LITERATURE 
2.1 Approach to the literature review 
The purpose of this literature review is to provide the evidence on the associations 
between growth faltering and malaria, and the safety of LNS in malaria-endemic 
settings available at the time of designing this study. The review provides 
background of the two conditions such as: prevalence and trends of stunting and 
malaria that reveal the importance of the two conditions; methods of assessing the 
two conditions; possible role of malaria in growth faltering and the role of stunting 
in malaria epidemiology; as well as the safety of LNS for promotion of growth in 
malaria-endemic settings. Finally, the review provides a summary of the knowledge 
gaps on this topic, which forms the basis for the current study. 
Published electronic references were obtained from PubMed, HINARI, and 
Google Scholar databases using Medical Subject Headings (MeSH). Some of the 
keywords used in the search were: malaria AND “linear growth faltering OR 
stunting” OR "nutritional status" AND children; “LNS” OR supplements AND 
“malaria” OR morbidity. Initial searches were conducted in 2014 and were constantly 
updated when the study aims were modified, with the latest review conducted in 
December 2018. Additional articles were obtained from the references of the 
extracted articles. Further information was collected from websites of international 
organizations (i.e. the WHO, UNICEF, World Bank, etc), governmental and non-
governmental organizations. 
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2.2 Growth faltering 
2.2.1 Definitions 
Human growth and development is defined by the increase in somatic size, shape, 
and functional maturity associated with age (37,38). Growth faltering refers to the 
child’s failure to achieve the growth and developmental milestones at the 
appropriate age. Linear growth faltering specifically refers to an abnormally slow 
rate of gain in a child’s length or height determined by length-for-age z-score 
(LAZ) or height-for-age z-score (HAZ) (39). The degree of linear growth faltering 
in a population is expressed as the mean LAZ or the prevalence of stunting (i.e. 
percentage of children with LAZ <-2) (40).  
2.2.2 Assessment and classification of linear growth in children 
2.2.2.1 Anthropometry 
Anthropometry is the commonly used method of assessment of nutrition status of a 
child or a population (41). The commonly used measures of anthropometric status 
are weight and length (or height1) in combination with age and sex. These 
measurements are used to calculate indices and indicators2 of nutritional status of a 
child or a population (42).  
                                                   
1 Length or height is measured based on the child’s age and whether the child is sitting or lying down 
during the assessment. If the child is lying down (recumbent), length is measured; if the child is 
standing, height is measured. Generally, length is measure in children less than 2 years of age, while if 
the child is aged 2 years or older and able to stand, height is measured. Standing height is believed to 
be 0.7 cm less than recumbent length (144). For this thesis, all children were aged less than 2 years, 
hence length was used throughout. 
2 Indices are defined as combinations of measurements, useful for interpretation of the measurements 
e.g. weight for length; indicators involve the use or application of indices e.g. proportion of children 
below a certain cut-off in the particular index which can be used to describe nutrition status of a 
community (42). 
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2.2.2.2 Anthropometric indices: length-for-age 
Anthropometric variables (length and weight) used in combination with sex and age 
provide useful information about a child’s nutritional status, referred to as an index 
(42). The widely used indices are length-for-age, weight-for-age, and weight-for-
length. Length-for-age provides information on linear growth of a child.  
2.2.2.3 Evaluation of anthropometric indices using z-scores: length-for-age z-scores 
The anthropometric indices can be calculated either as z-scores, percentiles, or 
percentage of median, to enable comparison of an individual with a reference 
population (43). Z-scores are particularly useful to avoid spurious interpretations of 
correlations in length and weight (44).  
The means of the z-scores for length-for-age, weight-for-length, and weight-for-
age are used as summary statistics when describing the nutritional status of children 
in a population, often compared to the WHO growth standards (43). WHO growth 
standards were developed to demonstrate the full genetic growth potential of 
healthy, breast-fed children living in optimal environments. To allow for global 
applicability, the data were analysed from six study sites (Brazil, Ghana, India, 
Norway, Oman and the USA) across five continents, using rigorous statistical 
methods (41).   
2.2.2.4 Nutritional conditions identified using anthropometric indices: stunting 
Three indices: length-for-age; weight-for-age; and weight-for-length are used to 
identify three nutritional conditions: stunting, underweight, and wasting, 
respectively. Children with LAZ <-2 standard deviations (SD) from the median of 
the WHO growth standards are classified as moderately stunted, whereas children 
with LAZ <-3 SD from the median of the WHO growth standards are classified as 
severely stunted (41).  However, negative mean LAZ of a population demonstrates 
a downward shift of the entire distribution, suggesting that most children in the 
population, not only those who are categorized as stunted, are affected (45). 
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2.2.3 Global prevalence and trends of stunting in children 
Globally, 151 million children under 5 years of age were considered stunted (LAZ 
<-2) in 2017, and more than 30% of them lived in Africa (1). However, the number 
of children experiencing suboptimal growth in LMICs is believed to be significantly 
larger since the mean LAZ in these populations are usually below zero (45). In 
addition, some children present with more than one form of malnutrition (e.g. 
stunting and wasting) but the estimates for these combined conditions are currently 
unavailable (1). 
Although globally there has been a reduction in stunting in children under 5 
years of age from 32.6% (198 million children) in 2000 to 22.2% (151 million 
children) in 2017, there exist large disparities within/between regions/sub-regions. 
For example, Asia managed to reduce stunting from 38.2% to 23.3% while Africa 
only reduced stunting from 38.0% to 30.3% during the same time period.  The 
African region is evidently lagging behind in efforts to reach the 2025 targets set by 
the World Health Assembly and the SDGs to reduce stunting by 40% (4,46). 
2.2.4 Timing of linear growth faltering  
In LMICs, growth faltering typically starts in utero, and continues to two years of 
age, hence the first 1000 days are known as the optimal “window of opportunity” 
for growth promoting interventions (40,47,48). Within the 1000 days, the period 
from 6 months to 24 months is very critical because rapid development of the brain 
and body is expected to occur while at the same time, the children are introduced to 
complementary foods which, in LMICs, are usually contaminated and poor in both 
quality and quantity. The children also begin to crawl and are exposed to various 
pathogens at the time they are losing immunity from maternal antibodies while their 
own immunity is nascent (5,49).  
2.2.5 Linear growth faltering in the context of Malawi 
In the past two decades, Malawi has made strides in reducing the rate of stunting in 
children under 5 years of age by nearly 20 percentage points (50), with the greatest 
decrease reported between 2010 (47%) and 2016 (37%) (51). However, the 
prevailing rates of stunting are still very high based on the WHO-UNICEF 
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threshold of 30% (53, Figure 1). In the same population, the prevalence of wasting 
is only 3%, which is within the global low threshold of less than 5% (51,52). 
Malawi therefore has a population of children who are generally very short but not 
thin. 
Similar to global estimates, most of the linear growth faltering in Malawian 
children occurs between 6 months and 24 months which coincides with high 
incidence of infectious diseases (53). 
2.2.6 Child development 
Childhood development is the acquisition of a range of skills including cognitive, 
language, and socio-emotional as part of the normal maturation process (37). Child 
development is assessed using standardized tools that measure achievement of 
milestones through testing and evaluating the child’s ability to perform a series of 
tasks (54). These assessments serve either as screening tests or tests to evaluate the 
child’s abilities (55). Aggregation of individual assessments creates population-based 
estimates which can be compared to the WHO Child Growth Standards (56).  
In the first 1000 days, impairments in brain development can potentially cause 
permanent damage to growth, hence the optimal “window of opportunity” for 
improving child development (48). In LMICs, 249 million (43%) of the children 
under 5 years of age are believed to be at risk of not reaching their developmental 
potential, with children from Sub-Saharan Africa being the most affected (57). The 
full extent of the problem is difficult to estimate because of paucity of reliable 
measurement standards for child development, as well as context-specific data for 
children in LMICs (57). 
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Figure 1.  Percentage of stunted children under 5, by United Nations sub-region, 2017 
 
Source: UNICEF / WHO / World Bank Group Joint Child Malnutrition Estimates  
(1). 
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2.3 Malaria 
2.3.1 Definition 
Malaria is an infectious disease caused by protozoan parasite Plasmodium. Malaria 
in humans is mainly caused by four different species of Plasmodium: P. falciparum; 
P. malariae; P. ovale; and P. vivax, with occasional infections by P. knowlesi (58). 
2.3.2 Assessment of malaria  
Traditionally, malaria was diagnosed and treated symptomatically using presence of 
fever because microscopy tests were only available in hospitals with laboratory 
facilities. From 2010, the WHO recommended malaria confirmation by rapid 
diagnostic test (RDT) or microscopy test before administering antimalarials (59).  
Malaria RDT uses lateral flow immune-chromatography to detect histidine-rich 
protein 2 (HRP2) for Plasmodium species. Malaria RDT has increased access to 
confirmatory tests in underserved populations because of its simplicity to use. 
Inability of some RDT kits to distinguish new infections from recently treated 
infections and poor sensitivity to detect other Plasmodium species are some of its 
limitations (59).  
Malaria microscopy uses Giemsa staining and light microscopy to identify the 
Plasmodium presence, species and density. With a well-trained reader, light 
microscopy provides accurate parasite counting, distinguishes new infections and 
species of malaria parasites. However, the skill-set and equipment required for 
microscopy is often not available in LMICs where malaria is endemic. Worse still, 
in these countries, most malaria patients are treated at home or within the 
community rendering microscopy less useful (59). 
Definitive diagnostic tests for malaria exist based on nucleic-acid amplification 
techniques (e.g. loop-mediated isothermal amplification or polymerase chain 
reaction (PCR), but these hitherto exist for research purposes (59). 
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2.3.3 Global prevalence and trends of malaria in children 
Malaria is one of the most serious public health problems in the world, with 3.4 
billion people in 92 countries estimated to be at risk of being infected with malaria 
and developing disease (60, Figure 2). An estimated 219 million cases and 435,000 
deaths reported in 2017, 90% of which occurred in the African Region. Of great 
concern is that between 2010 and 2017, there has been no significant reduction in 
global malaria incidence, with some countries in Africa reporting an increase in 
incidence (61).  
Globally, malaria contributes to 1.8% of the disability-adjusted life years 
(DALYs) while in sub-Saharan Africa, malaria is responsible for 11.5% of the 
DALYs in in children under 5 years of age. With more than 70% of the malaria 
deaths occurring in this age group, malaria is the fourth leading cause of death 
among children in this region. Simply put, malaria is believed to kill a child every 
two minutes in Africa (6,62). 
2.3.4 Timing of malaria infections 
Children aged < 6 months may experience few or no malaria episodes due to 
protection by maternal antibodies, circulating foetal haemoglobin, and minimal 
exposure to mosquito bites (63–66). With age, the risk for malaria changes in 
severity and mortality, peaking at 6–24 months (61), which coincides with the peak 
of linear growth faltering. Thereafter, the risk for severe malaria and death declines 
as humoral immunity improves following repeated exposures to parasites. In 
malaria-endemic areas, this immunity protects against symptomatic malaria but not 
against infection (67), hence older children (5–15 years) have highest malaria 
parasitaemia while children under 5 years of age suffer more severe disease 
(11,68,69). 
2.3.5 Malaria in the context of Malawi 
Malawi is one of the malaria-endemic countries with around 6.5 million malaria 
cases reported in 2016. Of these, 2.7 million cases (41.5%) occurred in children 
under 5 years of age, with an incidence rate of 976 new cases per 1000 children and 
prevalence of malaria (confirmed by microscopy) of 24.3% (70). Malaria is 
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responsible for 40% of the deaths in Malawian children in this age group (71). 
Plasmodium falciparum is the most dominant species and causes about 98% of all 
malaria infections with highest transmission rates occurring between November and 
April (rainy season), especially in low-lying and high temperature areas (70,71).  
In 2013, Malawi rolled out the testing of all malaria cases using RDTs. 
However, by 2016, malaria tests were done on 76.9% of all suspected cases, and 
antimalarial drugs were administered to 86.1% of all suspected malaria cases, 
indicating the persistent challenges in diagnosing and treating malaria, especially by 
the health surveillance assistants (HSAs) when implementing the integrated 
management of childhood illness (IMCI) protocols (70).
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Figure 2.  Global distribution of malaria 
 
Source: World Malaria Report 2018 (60). 
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2.4 The role of linear growth faltering in malaria epidemiology 
More than one third of the stunted children live in Africa, where the burden of 
parasitic infections such as malaria is also very high: 90% of the infections and 
deaths due to malaria occur in Africa (1,5,61). In malaria-endemic countries, a 
small proportion of children suffer repeated malaria infections, and are responsible 
for most of the malaria cases (72–74). The risk factors for the repeated malaria 
infections in these children are not fully understood, believed to be genetic (73), 
behavioural (75), and environmental (74). Other authors believe linear growth 
faltering could be a risk factor for malaria because of the geographic overlap of 
stunting and malaria and the synergistic interactions between nutrition and 
infections (7–9).  
Undernutrition in children below 2 years of age is associated with reduction in 
leptin hormone and reduced antibody-mediated antimalarial immunity (76–79). The 
vicious cycle of undernutrition and infection further weakens the immune response, 
making children susceptible to repeated infections (80,81). In addition, a capacity 
load  model developed to demonstrate the impact of early undernutrition on later 
health suggests that undernutrition in children leads to depletion of the metabolic 
capacity, predisposing to further infections (82).  
These mechanisms suggest that theoretically, stunting may play a role in 
increasing the risk of malaria infections, which has also been reported in several 
studies. In the Gambia, a short (20 weeks follow-up) study of 487 children under 5 
years of age reported an increased risk of malaria associated with stunting (crude 
RR = 1.35; 95% CI 1.08–1.69) (7). In Kenya, a cross-sectional study of 1,862 
children under 3 years of age reported that undernourished children had more 
malaria episodes (8), while in Uganda, a one-year cohort study involving 351 
children under 2.5 years of age found that stunting was associated with increased 
incidence of malaria parasitaemia (9). 
However, other studies of similar designs have reported no association between 
stunting and malaria (83–86) and one study reported a protective effect of stunting 
on malaria in 136 children aged 10–120 months in Papua New Guinea – though the 
biological mechanisms for this finding were not fully explained (87).  
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Hence, several reviews on this topic have determined  that the role of stunting in 
malaria epidemiology is still inconclusive; attributed to the heterogeneity in the 
study populations, malaria parasite species, and host-parasite relationship which 
warrant further studies (10–12).   
2.5 The role of malaria in growth faltering 
High burden of infections is one of the nutrition-specific indicators associated with 
stunting (88). Just like stunting may predispose children to infections through 
immune dysfunction, infections may predispose children to growth faltering 
through the same pathway (Figure 1). Repeated infections result in sustained high 
levels of cytokines, increasing the metabolic demand and suppressing appetite 
through satiety hormones: ghrelin and leptin (89). High concentration of circulating 
cytokines may also suppress the release of insulin-like growth factors (IGF) (78,90). 
Immune system activation may also affect the concentration of nutrients (e.g. iron, 
vitamin A and zinc), restricting the availability of these nutrients for growth (91).  
All common childhood infections probably contribute to growth faltering as the 
body’s adaptive mechanism to prioritize survival at the expense of growth (91). 
However, the role of malaria in growth faltering is still controversial. While some 
studies reported an increased risk of stunting associated with malaria, others have 
reported no association, limiting the drawing of conclusions on the effect of malaria 
on stunting. For instance, in a short (3 months follow-up) study of 165 Zambian 
children aged <2 years, presence of infections including falciparum malaria was 
associated with short-term linear growth faltering (92). In Peru, a 3.5 years’ follow-
up study reported that in 442 children aged <6 years vivax malaria had a larger 
effect on growth compared to diarrhoea (93). In Ghana, a study aimed to estimate 
the causal effect between malaria and stunting, by combining methods of 
Mendelian randomization and matching on 884 children aged <2 years, reported an 
increased risk of stunting by 32% associated with malaria (94). However, a 2 years’ 
follow-up study of 340 children under 5 years of age in Kenya did not find any 
association (83). In rural Malawi, treatment of malaria and other infections with 
monthly sulfadoxine-pyrimethamine and 2 doses of azithromycin (AZI-SP) during 
pregnancy reduced the incidence and prevalence of childhood stunting, while 
monthly treatment with sulfadoxine-pyrimethamine alone did not show similar 
effect (95). Hence a systematic review on this topic reported that the evidence of 
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malaria as a determinant of stunting is inconclusive owing to the paucity and 
heterogeneity of the available literature, as well as the ethical requirement to 
immediately treat  all children diagnosed with malaria (23). 
2.6 The role of nutrition supplementation in malaria epidemiology 
Consumption of complementary foods that are dominated by staple foods poor in 
nutrient density and micronutrient bioavailability is considered one of the 
contributing factors for high rates of stunting in children in LMIC (24). To improve 
the quality of complementary foods, home fortification with products such as LNS 
has been explored as one of the novel strategies (25).  
However, LNS is fortified with iron, and like with other iron-containing 
supplements, there are concerns of the potential increase in the risk of malaria in 
children in malaria-endemic areas following findings from a few studies. In a 
randomised, placebo-controlled trial in Zanzibar, iron supplementation to 24,076 
children under 3 years of age increased the risk of malaria infection and deaths in 
children who were iron-replete (31). In Pakistan, a randomised trial involving 256 
urban and rural clusters, provision of iron-containing (MMN) powders daily to 
2,746 children between 6 and 18 months of age was associated with increased risk 
of diarrhoea and reported chest in-drawing in children (29). Excess iron is believed 
to promote proliferation of bacteria and Plasmodium parasites (35,96,97). 
Consequently, oral iron supplementation is not recommended in children in 
malaria-endemic countries unless effective malaria control interventions are certain 
to be provided (28). However, this evidence is contentious because while the 
studies cited above have reported harmful effects, some studies suggest that iron-
containing home fortificants (e.g. multiple micronutrient powders) are safe (98,99) 
and may even reduce morbidity (100). 
Reports from the few studies on LNS provision suggest that it is safe (15,32–34), 
but the evidence is not conclusive because those studies had either a relatively short 
duration i.e. 6 months or less, or did not have sufficient power because of small 
sample sizes (35,36).  
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2.7 Justification of the present study 
The literature review revealed that high incidence of malaria and high prevalence of 
linear growth faltering overlap geographically, affecting the same age-groups 
(children aged 6–24 months). A small number of children are responsible for most 
of the malaria infections, but the predisposing factors are not fully understood, with 
some authors believing linear growth faltering plays a role. The geographic overlap 
between stunting and malaria suggests malaria may be associated with linear 
growth faltering. Home fortificants such as LNS, aimed to promote growth, may 
also increase risk of malaria in children in malaria-endemic countries.  
Therefore, it is possible that children who have faltered linear growth also suffer 
from repeated malaria infections, but the evidence is inconclusive. It is also possible 
that malaria may be associated with linear growth faltering rendering nutrition 
interventions ineffective, but the evidence is scant. Finally, it is likely that LNS may 
not increase the risk of malaria, but the evidence of safety is limited.  
With this background, we formulated the concept of the present study, which was 
later modified and adapted from the review of the possible links between stunting 
and malaria through the immune dysfunction pathway (78) (Figure 3)
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Figure 3.  Conceptual diagram of the potential associations between nutrition supplementation, malaria 
and linear growth faltering 
 
Conceptual diagram showing the possible links between stunting and malaria 
through the immune dysfunction pathway, and the potential role of nutritional 
supplements in malaria-endemic settings. Adapted from Bourke et al, 2016 
(78). Cells highlighted in BLUE represent the stages in the original pathway 
that were the focus of this study. Cells in GREEN represent the specific 
variables for our study, and their theoretical relationship connected by dotted 
arrows which generated the three study aims. 
Abbreviations: HPA, hypothalamus–pituitary–adrenal axis; IGF-1, insulin-
like growth factor 1; LNS, lipid-based nutrient supplements
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3 AIMS 
The aim of this study was to determine the associations between malaria infection 
and linear growth faltering among infants and young children. The safety of iron-
containing LNS in a setting where malaria is endemic was also determined. The 
specific objectives were:  
 
1. To test the hypothesis that linear growth faltering predicts malaria incidence 
and prevalence in infants and young children (Study I). 
 
2. To test the hypothesis that malaria incidence is positively associated with 
linear growth faltering and development in infants and young children (Study 
II). 
 
3. To determine whether long-term provision of iron-containing LNS increases 
the risk of malaria in infants and young children living in a malaria-endemic 
setting (Study III). 
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4 METHODS 
4.1 Approach to the study 
The three study aims were addressed using data from the International Lipid-
based Nutrient Supplements Project (iLiNS) which implemented the iLiNS-DOSE 
and iLiNS-DYAD trials: two large community-based randomized nutrition 
intervention trials in Malawi. Details of the design, randomization and enrolment 
for the two trials are presented in the main outcome papers (101,102). 
The overall study design for this thesis is summarized in Figure 4. For study 
aims I and II, the data were pooled from the two trials while for study aim III, the 
data was drawn from the iLiNS-DOSE trial only.
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4.2 Study setting and participants  
4.2.1 Study area  
The study was conducted in Mangochi district, one of the 29 districts in Malawi, 
located in the country’s south-eastern region. Malawi is one of the LMICs in the SSA, 
neighbours with Tanzania in the north, Zambia in the west, and Mozambique in the 
south and east (Figure 5).  
Mangochi district was selected as study site because of its poor demographic 
indicators (Table 1) and convenience. The College of Medicine established a research 
site in Mangochi district which has helped establish and maintain close relationship with 
the communities within the catchment areas, facilitating easy implementation of research 
studies. Before this study, the lead researchers have had ongoing child health-related 
research projects in the district for almost 15 years.
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At the time of conducting the study (2009 – 2014), Malawi had an estimated 
population of 13.9 million people, 85% of which lived in rural community and 
subsisted on small scale farming (103,104). With a per capita gross domestic 
product (GDP) of 479 United States Dollars (USD), Malawi is one of the low-
income countries and majority of the people live below the poverty line (<USD 
1.90 per day) (105). The tropical climate comprising a warm, wet season 
(November to April), a cool, dry cold season (May to August), and a hot, dry season 
(September to October) favours the proliferation of Anopheles mosquitoes which 
transmit Plasmodium parasites (106). 
The Malawi demographic and health survey (MDHS) results at the time of 
conducting this study showed that Mangochi district had one of the worst health 
indicators for children under 5 years of age in Malawi: 88.5% were reported to have 
problems accessing health care; 76.4% received vaccinations by 24 months; and 
34.2% were reported to have slept under insecticide-treated mosquito bed net (ITN). 
The prevalence of fever, diarrhoea and acute respiratory infections (ARI) was 
26.0%, 11.1% and 5.9%, respectively. The prevalence of stunting, underweight, and 
wasting was 48.3%, 15.9%, and 5.9% respectively (104).  
Within Mangochi district, the study was conducted in four health facilities: 
Namwera, Malindi, Lungwena and Mangochi, with a total catchment population of 
180,000 that mainly subsisted on farming and fishing. Mangochi site was more 
urban than the other three sites. Two of the study sites (Lungwena and Malindi) are 
low-lying along the eastern shore of Lake Malawi at an altitude of ~485 metres 
above sea level. Mangochi site is also low-lying at a similar altitude (~485 metres) 
but traversed by the Shire River (the largest river in Malawi). In contrast, Namwera 
lies at the top of Namwera Hills, bordering Mozambique, at an altitude of ~900 
metres above sea level and is far from the large water bodies. Namwera experienced 
higher rainfall and cooler temperatures than the other three study sites (107,108).  
The Malawi health care system is largely managed by the public sector, free of 
charge and divided into three levels of health care delivery: primary, secondary and 
tertiary. The primary level care (village clinics and health centres) provides 
preventive and outpatient services through health surveillance assistants, nurses and 
medical assistants. The secondary level care provides preventive, curative 
outpatient and inpatient care led by medical officers. Tertiary level care provides 
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specialized inpatient services. A few semi-private health facilities also exist, owned 
by religious organizations providing primary and secondary care.  
At the primary health care level, the current IMCI strategy is implemented, 
aimed to provide simplified assessment and treatment for sick children using a 
syndromic approach (109). At both primary and secondary health care levels, 
growth monitoring and promotion clinics exist, aimed to provide health and 
nutrition surveillance and treatment, and provide linkage to existing nutrition 
programmes (110). During the study period, Lungwena and Namwera provided 
services at primary health care level while Malindi and Mangochi provided services 
at secondary health care level.  
Table 1 shows the key health, demographic, geographic and socio-economic 
indicators for Malawi, compared, where applicable, with Mangochi district where 
the study was conducted.
 25 
 
 Basic demographic, socio-economic, geographic and health indicators for Malawi and 
Mangochi 
 
Measure1 
Indicator Mangochi Malawi 
Total area (km2) 6,273 118,484 
Total population (2010 estimate) 855,663  13,947,592 
Population density (per km2) 136 117 
Total fertility rate2 7.0 5.7 
Per capita gross domestic product (USD) n.a. 458 
Proportion reporting problems in accessing health 
care (%) 
88.5% 82.1% 
Women literacy rate3 (%) 51.5% 67.6% 
HIV prevalence (15-49 years, %) n.a. 10.6% 
Life expectancy (years) 50.2 – 53.7 51.0 – 54.0  
Maternal mortality ratio (per 100,000 live births) n.a. 675 
Infant mortality rate (per 1,000 live births) n.a. 66 
Under-five mortality rate (per 1,000 live births) n.a. 112 
Proportion children who received basic 
vaccinations by 24 months (%) 
76.4% 80.9% 
Proportion children who slept under ITN (%) 34.2% 35.2% 
Proportion children < 5 years stunted (%) 48.3% 47.1% 
Proportion children < 5 years underweight (%) 15.9% 12.8% 
Proportion children < 5 years wasted (%) 5.9% 4.0% 
Proportion infants < 6 months exclusively 
breastfed (%) 
n.a. 71.4% 
Prevalence of fever4 in children < 5 years (%) 26.0% 34.5% 
Prevalence of diarrhoea in children < 5 years (%) 11.1% 17.5% 
Prevalence of ARI symptoms5 in children < 5 
years (%) 
5.9% 6.8% 
Annual average rainfall (2009 – 2015, mm) 725 – 1,133 685 – 2,500 
Annual average temperatures (2009 – 2015, min-
max degrees Celsius) 
19.1 - 31 4 - 37 
ARI, acute respiratory infection; HIV, human immune deficiency virus; ITN, 
insecticide treated mosquito bed net 
1Values are n, proportions, or ranges 
2Average number of children per woman 
3Women aged 15–49 who completed secondary school (or those who didn’t but could 
read all or part of a sentence when asked) 
4Proxy for malaria 
5Symptoms of ARI (cough accompanied by short, rapid breathing) are considered a 
proxy for pneumonia 
n.a. = data not available 
Sources: National Statistical Office (NSO) and ICF Macro, 2011; National 
Statistical Office (NSO), 2008; Malawi Meteorological Department 
(www.metmalawi.com).
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4.2.2 Study participants  
The study participants were children enrolled in the iLiNS-DOSE and iLiNS-
DYAD-M trials. 
In the iLiNS-DOSE trial, we identified potential participants in the catchment 
areas through community surveys and invited them to the study clinic for further 
eligibility assessment. Children aged 5.50 to 6.49 months, whose guardians signed 
informed consent and planned to be available during the entire study follow-up 
were considered eligible. Exclusion criteria included any severe illness warranting 
hospital referral, weight-for-length z-score < -2.0, bipedal oedema, haemoglobin 
<50g/L, history of peanut allergy or concurrent participation in another clinical trial.  
In the iLiNS-DYAD-M trial, the study sample comprised children born to 
mothers who were enroled in the maternal cohort with the following characteristics 
at enrolment: pregnancy of <20 completed gestation weeks confirmed by ultrasound 
scan, permanent resident in catchment area, and provided informed consent. 
Exclusion criteria were age <15 years, chronic health condition requiring regular 
medical attention, severe illness that warranted hospital referral, history of allergy 
to peanuts, history of anaphylaxis, pregnancy complications, earlier participation in 
the iLiNS-DYAD-M trial (during a previous pregnancy), or concurrent participation 
in other clinical trials.  
The iLiNS-DOSE trial recruited participants from two facilities (Mangochi and 
Namwera). The iLiNS-DYAD-M trial recruited participants from four health 
facilities (Namwera, Malindi, Lungwena and Mangochi), but children from 
Namwera were not followed up intensively, i.e. they belonged to a “simplified 
follow-up” group, with no morbidity visits after birth, but were examined at 6 and 
18 months of age, to assess their growth. 
4.2.3 Nutrition supplements  
In the iLiNS-DOSE trial, children were randomly assigned to six groups to receive 
a daily dose of either 10 g, 20 g or 40 g milk-containing LNS or 20 g or 40 g milk-
free LNS and a control group which did not receive LNS during the one-year 
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follow-up. These LNS doses were designed to provide about 55–241 kcal per day 
and meet the recommended daily allowance of 22 micronutrients, with all the LNS 
doses containing similar micronutrient concentrations. The milk-free formulations 
had lower protein content compared to the milk-containing LNS. The nutrient 
contents of the five different doses of LNS are summarized in Table 2. 
In the iLiNS-DYAD-M trial, pregnant mothers were randomly assigned to 
receive either iron and folic acid (IFA), multiple micronutrients (MMN) or 20 g of 
LNS daily. After delivery, women in the IFA group received placebo tablets, while 
MMN and LNS supplementation was continued up to 6 months postpartum. 
Children of mothers in the LNS group also received LNS 10 g twice daily from 6 
months to 18 months. Both LNS products contained the same micronutrients as the 
MMN capsules plus 4 additional minerals, protein, and fat, and their daily dose also 
provided 118 kcal of energy. The nutrient compositions of the supplements are 
summarized in Table 3. 
In both studies, the LNS was produced and packed by Nutriset S.A.S, Malaunay, 
France. The ingredients were soybean oil, dry skimmed milk powder, peanut paste, 
premade micronutrient mixture, and sugar. Maltodextrine was use as substitute for 
milk in the milk-free LNS. The data collectors delivered supplements fortnightly to 
each participant’s home from enrolment until the children were aged 18 months. At 
each visit, the data collectors counted and collected any unused supplement sachets 
from the participants. 
All children received the routine growth monitoring and promotion services, 
including vaccinations according the national Expanded Program on Immunization 
(EPI) schedule at the time. Following the Malawi public health system, free medical 
treatment was available to all children at the health facilities in the study areas. 
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 Nutrient and energy contents of the food supplements provided in the iLiNS-DOSE trial 
1Encapsulated ferrous sulphate 
Nutrient/Intervention 10g milk 
LNS 
20g milk 
LNS 
20g no-
milk LNS 
40g milk 
LNS 
40g no-
milk LNS 
Daily ration (g) 10 20 20 40 40 
Total energy (kcal) 55 117 117 241 241 
Protein (g) 1.3 2.5 1.0 5.0 2.0 
Fat (g) 4.7 9.5 9.4 18.9 18.8 
Linoleic acid (g) 2.22 4.44 4.44 8.88 8.88 
Į-Linolenic acid (g) 0.29 0.58 0.58 1.16 1.16 
9LWDPLQ$ȝJ5( 400 400 400 400 400 
Vitamin C (mg) 30 30 30 30 30 
Vitamin B1(mg) 0.3 0.3 0.3 0.3 0.3 
Vitamin B2 (mg) 0.4 0.4 0.4 0.4 0.4 
Niacin (mg) 4 4 4 4 4 
)ROLFDFLGȝJ 80 80 80 80 80 
Pantothenic acid (mg) 1.8 1.8 1.8 1.8 1.8 
Vitamin B6 (mg) 0.3 0.3 0.3 0.3 0.3 
9LWDPLQ%ȝJ 0.5 0.5 0.5 0.5 0.5 
Vitamin D (IU) 200 200 200 200 200 
Vitamin E (mg) 6 6 6 6 6 
9LWDPLQ.ȝJ 30 30 30 30 30 
Iron1 (mg) 6 6 6 6 6 
Zinc (mg)  8 8 8 8 8 
Cu (mg) 0.34 0.34 0.34 0.34 0.34 
Calcium (mg) 240 240 240 240 240 
Phosphorus (mg) 208 208 208 208 208 
Potassium (mg) 265 265 265 265 265 
Magnesium (mg) 50 50 50 50 50 
6HOHQLXPȝJ 20 20 20 20 20 
,RGLQHȝJ 90 90 90 90 90 
Manganese (mg) 1.2 1.2 1.2 1.2 1.2 
Phytate (mg) 28 56 56 112 112 
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 Nutrient and energy contents of the food supplements provided in the iLiNS-DYAD-M trial 
IFA, iron and folic acid; LNS, lipid-based nutrient supplements; MMN, multiple 
micronutrients; P&L, pregnancy and lactation. 
1Encapsulated ferrous sulphate 
Nutrient/Intervention IFA tablet MMN tablet LNS P&L LNS 20 g 
Recipient Mothers, 
pregnancy only 
Mothers, P&L Mothers, P&L Infants aged 6 
to 18 months 
Daily ration  1 tablet 1 tablet 20 g 20 g 
Total energy (kcal) 0 0 118 118 
Protein (g) 0 0 2.6 2.6 
Fat (g) 0 0 10 9.6 
Linoleic acid (g) 0 0 4.59 4.46 
Į-Linolenic acid (g) 0 0 0.59 0.58 
9LWDPLQ$ȝJ5( 0 800 800 400 
Vitamin C (mg) 0 100 100 30 
Vitamin B1(mg) 0 2.8 2.8 0.3 
Vitamin B2 (mg) 0 2.8 2.8 0.4 
Niacin (mg) 0 36 36 4 
)ROLFDFLGȝJ 400 400 400 80 
Pantothenic acid (mg) 0 7 7 1.8 
Vitamin B6 (mg) 0 3.8 3.8 0.3 
Vitamin B12 ȝJ 0 5.2 5.2 0.5 
Vitamin D (IU) 0 400 400 200 
Vitamin E (mg) 0 20 20 0.5 
9LWDPLQ.ȝJ 0 45 45 200 
Iron1 (mg) 60 20 20 6 
Zinc (mg)  0 30 30 8 
Cu (mg) 0 4 4 0.34 
Calcium (mg) 0 0 280 280 
Phosphorus (mg) 0 0 190 190 
Potassium (mg) 0 0 200 200 
Magnesium (mg) 0 0 65 40 
6HOHQLXPȝJ 0 130 130 20 
,RGLQHȝJ 0 250 250 90 
Manganese (mg) 0 2.6 2.6 1.2 
 30 
 
4.3 Data collection 
4.3.1 Enrolment and follow-up  
Enrolment of children in the iLiNS-DOSE trial was conducted between November 
2009 and May 2011. The group allocation for each participant was sealed in an 
individual opaque randomization envelope and stored in a locked cabinet until use. 
When the guardian consented to let her infant participate and the infant met all the 
enrolment criteria, the guardian was asked to choose and open one randomization 
envelope from a block of six unused envelopes. 
Enrolment of pregnant mothers in the iLiNS-DYAD-M trial was conducted 
between February 2011 and August 2012. A researcher not involved with the trial 
created individual randomization slips and packed them in sealed, numbered, 
opaque randomization envelopes that were stored in numerical order. Eligible 
pregnant mothers were asked to select one of the envelopes in a pile, which 
indicated her participant identification number and group allocation. 
In both trials, the participant identification number and group allocation were 
recorded in a logbook and on the participant’s identification card.  
Research assistants visited the children’s homes every week from 6 months to 18 
months to collect information on morbidity and supplement use. The follow-up and 
data collection procedures are schematically presented in Figure 3.
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4.3.2 Anthropometric assessments  
Anthropometric assessments were done at 6 months and 18 months. Study 
anthropometrists measured the infant’s length with a high-quality length board 
(Harpenden Infantometer; Holtain Limited, Crosswell, United Kingdom) and 
recorded it to the nearest 1 mm. They weighed unclothed infants with electronic 
infant weighing scale (SECA 735; Seca GmbH & Co, Hamburg, Germany), 
recording to the nearest 10 g. Anthropometric indices (weight-for-age z-scores 
[WAZ], length-for-age z-scores [LAZ], and weight-for-length z-scores [WLZ]) 
were calculated using WHO Child Growth Standards (2010 STATA igrowup 
package) (41). 
4.3.3 Developmental assessments 
Research assistants assessed fine and gross motor development at 18 months using 
the Kilifi Developmental Inventory (KDI) (111). Language development was 
assessed using the MacArthur-Bates Communicative Development Inventory (112) 
adapted for local languages (Chichewa and Chiyao), and 18-months socio-emotional 
development was assessed using the Profile of Social and Emotional Development 
(PSED) (113).  
The research assistant rated the child’s mood during KDI assessment as positive 
(smiling/laughing) or not positive (crying/inconsolable, changeable/mood swings, 
or no visible emotions).  Child’s interaction with the research assistant during the 
KDI was rated as positive (friendly) or not positive (avoidant and withdrawn, clings 
to family member, hesitant/when approached will accept reluctantly, difficult to 
engage in tasks, or inappropriate approaches to the assessor). Child’s activity level 
during the KDI was rated as positive (active and maintains interest) or not positive 
(unarousable, sleepy and can hardly be awakened, sleepy but easily awakened, does 
not spontaneously engage in activity, and awake but loses interest). The KDI, 
vocabulary, and PSED scores showed high inter-rater agreement and moderate to 
high test-retest reliability in this study setting (114,115). 
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4.3.4 Morbidity assessments 
At the start of the study, the author of this thesis trained research assistants to 
collect morbidity data through interviewing the guardians about the child’s health in 
the previous seven days using a structured questionnaire. The information was 
complemented by a picture calendar filled out by the guardians daily to aid memory 
of their children’s morbidity status (Appendix 1). This was designed to minimize 
problems of recall associated with community morbidity assessments (116,117). 
The usefulness of maternal interviews to collect data on child morbidity has been 
validated elsewhere (118,119). The research assistants referred all cases of 
presumed malaria (presence of fever) to the nearby health facility for malaria RDT 
and treatment with artemether/lumefantrine, the nationally recommended 
antimalarial drug. The children were followed throughout the year, covering periods 
of both high and low malaria transmission. 
The author of this thesis trained facility health workers to collect data on non-
scheduled visits made to health facility when the child was sick. The information 
included clinic visits (non-scheduled), clinical diagnoses, malaria RDT, 
hospitalizations, and deaths.  For deaths occurring at home, the information on the 
causes of death was collected by a verbal autopsy method, previously validated in 
the study area (120). Records of all hospitalizations and deaths were reviewed by a 
study physician (the author of this thesis) and serious adverse events were reported 
to members of the data and safety monitoring board (DSMB) within 48 hours of 
occurrence.  
During the study visits at 6 months and 18 months, all children had malaria 
microscopy tests done. Study nurses obtained blood smears from all children at the 
time of the blood sampling for biochemical assessment. Laboratory technicians 
stained the smears with 2% Giemsa for 30 minutes and reviewed all thick samples 
to determine the malaria parasite count and determined the parasite densities by 
counting the number of asexual parasites per 200 white blood cells (WBCs) and 
DVVXPLQJD:%&FRXQWRIȝO 
At 6 months, study nurses tested the children for malaria using rapid test kit 
(Clearview Malarial Combo, Alere, South Africa). 
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4.3.5 Other variables 
During the study visits at 6 months and 18 months, study nurses collected 5-7 ml of 
blood by venipuncture using a 23-gauge needle into 7.5 ml evacuated, trace 
element-free polyethylene tubes containing lithium heparin (CB 300 LH, Sarstedt 
AG & Co, Nümbrecht, Germany). The blood tube was immediately inverted 10 
times to mix the heparin anticoagulant with the blood to prevent clotting. A small 
aliquot of the whole blood was pipetted out and used to analyse haemoglobin (Hb) 
on the Hemocue 201+ system (Hemocue, Ängelholm, Sweden). The tube 
containing the remaining whole blood was then placed in an insulated cooler with 
ice packs and processed within 2 hours of collection. Trained laboratory staff then 
aliquoted whole blood into microcuvettes and measured zinc protoporphyrin (ZPP) 
concentration from unwashed venous blood sample using a hematofluorometer 
(206D, AVIV Biomedical Inc., Lakewood, NJ, USA). 
During the study visit at 6 months, research assistants interviewed the mothers to 
obtain household level information including assets, number of children, maternal 
education (years spent in school) and age. Household food security was assessed 
using Household Food Insecurity Access Scale (HFIAS) (121). Use of ITNs was 
assessed by asking the guardians the number of days that the child slept under a 
mosquito bed net during the week preceding the interview. 
4.3.6 Quality assurance  
The study team ensured the data were of high quality by providing the data 
collectors with written standard operating procedures, visit guides and step-by-step 
instructions on how to complete individual morbidity forms. In addition, 10% of the 
home visits were quality controlled by a data monitor responsible for a team of 5–7 
data collectors who repeated and verified that morbidity visits and supplement 
delivery were done according to protocol. If problems were identified, a repeat 
training for the data collectors was provided. The anthropometric assessments were 
done only by trained personnel whose measurement reliability was verified at the 
start of the study and thereafter at 6-months intervals with methods adapted from 
the procedures used in the WHO Multicentre Growth Reference Study (41). Each 
measurement was taken and recorded in triplicate. The anthropometrists calibrated 
all equipment with standard weights and length rods daily.  
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For the LNS delivery, single masked procedures were used; i.e., field workers 
who delivered the supplements knew which mothers were receiving LNS, and the 
participants were advised not to disclose information about their supplements to 
anyone other than an iLiNS study team member. The data collectors who performed 
the anthropometric assessments or other outcomes were not aware of group 
allocation. All researchers (including the author of this thesis) responsible for the 
data cleaning remained blind to the trial code, until the database was considered 
fully cleaned.  
4.4 Statistical approach  
4.4.1 Sample size calculation  
The sample size calculations were based on the primary objectives of the main 
trials. In the iLiNS-DOSE trial the primary objective was to test the hypothesis of 
non-inferiority of LNS without milk on change in length-for-age z-score as 
compared to LNS containing milk. Assuming a SD for the change in LAZ of 1.0 z-
score units, a pre-determined non-inferiority margin of 0.25 z-score units and an 
estimated 15% attrition rate, a sample size of 320 / group was estimated to provide 
the trial with 90% power and 95% confidence (one-sided test) to discard an 
inferiority null-hypothesis.  
In the iLiNS-DYAD-M trial, the primary objective was to test the hypothesis 
that provision of LNS to mothers in pregnancy and lactation and to their infants 
from 6 months to 18 months would promote infant and child growth. Assuming an 
effect size of at least 0.3 (difference between groups, divided by the pooled SD) for 
each continuous outcome, a power of 80%, and a 2-sided type I error rate of 5%. 
This would have required 216 participants per group, for a total of 648 subjects. 
Allowing for up to 25% attrition rate, the target sample size was 864 subjects. 
4.4.2 Data management and definition of variables 
The data were recorded on paper forms and double-entered using Microsoft® 
Access, REDCap™ and OpenText™ TeleForm. Typographical errors, extreme 
observations, and discrepancies were resolved prior to data analysis. The 
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subsections below describe how the data outputs were manipulated to create 
predictor and outcome variables.  
4.4.2.1 Anthropometric indices 
WAZ, LAZ, and WLZ were calculated based on the WHO Child Growth Standards 
(41) and values below -2.0 were considered indicative of underweight, stunting and 
wasting, respectively. Change in LAZ for each child was calculated as the 
difference between LAZ at 18 months and LAZ at 6 months.  
The use of stunting (LAZ < -2) as a threshold to classify children who are 
nutritionally worse off in epidemiologic research has its limitations because 
currently there is no evidence that the risk of death or poor development in children 
becomes worse below this threshold, hence more information is derived from the 
use of other metrics such as slope of the change in mean LAZ with time (45).  
4.4.2.2 Developmental milestones 
From the child development data at 18 months, fine motor scores were calculated as 
the sum of 34 KDI fine motor items, each scored 0 or 1. Gross motor scores were 
calculated as the sum of 35 KDI gross motor items, each scored 0 or 1 (111). 
Vocabulary score was calculated as the maternal-reported child expressive 
vocabulary out of the 100-word checklist. For these outcomes, moderate to severe 
delay was defined as the bottom 25% of the sample. The socio-emotional score was 
calculated as the sum of 19 PSED items. Moderate to severe delay was defined as 
the top 25% of the sample (a higher score indicates less advanced socio-emotional 
development). 
4.4.2.3 Guardian-reported morbidity episodes 
Using data from guardian-reported morbidity symptoms, diagnoses of presumed 
malaria, gastroenteritis and ARI were derived from a combination of symptoms 
reported on one or more days. To ensure the diagnoses were mutually exclusive, we 
created an algorithm whereby any fever with a diarrhoea episode (three or more 
loose stools in 24 h) or bloody stools was categorized as diarrhoea; any fever in the 
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presence of any respiratory symptoms (cough, rapid or difficult breathing and nasal 
discharge) was categorized as ARI. Presumed malaria was defined as any fever 
episode in the absence of diarrhoea or respiratory symptoms.  
An episode of presumed malaria, ARI or diarrhoea was defined as the period 
starting from the day the child had the symptoms when preceded by at least 2 days 
of no symptoms or no data. The episode was considered to end on the last day the 
child had the symptoms which was then followed by at least 2 symptom-free days. 
Incidence of presumed malaria, ARI or diarrhoea for each child from 6 months to 
18 months was calculated as total episodes / total follow-up years at risk. 
4.4.2.4 Non-scheduled visits 
These were visits made by the participants to any health facility because of illness. 
At each non-scheduled visit, a diagnosis of either malaria (clinical or confirmed), 
gastroenteritis, ARI or other illnesses was made by health workers. 
4.4.2.5 Clinical malaria episodes 
A diagnosis of clinical malaria was taken from the malaria diagnosis made by 
health worker in the absence of a diagnostic test at the non-scheduled visit. An 
episode of clinical malaria was defined as any point when a diagnosis of clinical 
malaria was made.  
4.4.2.6 Confirmed malaria episodes 
A diagnosis of confirmed malaria was taken from the malaria diagnosis made by 
health worker confirmed by a positive malaria RDT. An episode of RDT-confirmed 
malaria was defined as any point when a diagnosis of RDT-confirmed malaria was 
made, occurring at least 28 days after a previously treated RDT-confirmed malaria 
episode (59). 
Malaria cases identified at the non-scheduled visits (clinical malaria and RDT-
confirmed malaria) comprise passive case detection (PCD) and can be used to 
gauge the burden of illness caused by malaria relative to all other common causes 
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of child illness. PCD data largely depend on the accuracy of the diagnostic test and 
quality of the source data and assumes that all infections are hospital-treated. As 
such, PCD data are less reliable in malaria-endemic settings because: other causes 
of febrile illness are often misclassified and inappropriately treated as malaria; self-
treatment results in underreporting which masks the true burden of malaria in the 
community; and naturally acquired immunity leaves most malaria infections 
unnoticed and untreated at the health facilities (122). 
4.4.2.7 Malaria parasitaemia 
 Malaria parasitaemia was defined as evidence of asexual parasite on a slide viewed 
through 200 high-power microscopy fields. Because the tests were done in all 
children regardless of symptoms, this variable measured the prevalence of 
parasitaemia independently of fever and therefore can be qualified as active case 
survey (ACS). The ACS may be useful in estimating risk of infection in populations 
where parasitaemia without fever is common, e.g. in malaria-endemic settings (122). 
4.4.2.8 Serious adverse events (SAEs) 
SAEs were defined as hospitalizations or deaths, according to the United States 
Department of Health and Human Services Office for Human Research Protections 
(123). 
4.4.2.9 Biochemical status 
Anaemia at 6 months was defined as blood Hb concentration <105 g/L (124), 
anaemia at 18 months was defined as blood Hb concentration <110 g/L (125). Iron 
deficiency at 6 months and 18 months was defined as whole blood ZPP >70 
mol/mole haeme (126). 
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4.4.2.10 Household and socio-economic variables 
HFIAS z-scores were generated by summing the value of responses to nine 
questions regarding food insecurity (See Appendix 2): the higher the score, the 
higher the degree of food insecurity in the last four weeks (121). 
Household asset index3 was defined as the principal components score based on 
baseline ownership of a set of assets and household quality: the higher the score, the 
better the living conditions (127).  
Number of children under 5 was defined as number of children under 5 years of 
age who were part of the participant’s household on the day of enrolment.  
Study site was defined based on the clinics where the two studies were 
conducted (i.e. Namwera, Mangochi, Malindi, and Lungwena). 
4.5 Data analysis 
All data management and analyses were done using Stata version 14 (Stata-Corp, 
College Station, TX, USA).  
Negative binomial regression was applied to assess the association of LAZ 
(independent variable) with the incidence of malaria (dependent variable), and 
Poisson regression (with a robust variance) to assess the association of LAZ with 
prevalence of malaria parasitaemia (128) (Study aim I).  
Ordinary least squares regression was used to assess the association between 
malaria incidence and each of the continuous outcomes; and modified Poisson 
regression (with a robust error variance) for each of the binary outcomes (129) 
(Study aim II). 
A non-inferiority margin of 20% was set to determine if the risk of malaria in the 
intervention groups (LNS) was clinically significantly different from the risk of 
malaria in the control group. Generalised linear modelling (log-binomial family) 
                                                   
3The variables used in generating household asset scores were: house quality (burnt bricks, type of 
roofing material, floor tiles, water source, type of toilet, energy source) and ownership. 
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was used to estimate and compare the risk of SAEs between the intervention groups 
and the control group, reported risk ratios (RR) and 95% confidence intervals (CI).  
Negative binomial regression was used to compare the incidences of malaria 
outcomes between the intervention groups and the control group, reported as 
incidence rate ratios (IRR) and 95% CI. If the 95% CIs of the RR or IRR for an 
intervention group compared to the control group fell entirely below 1.20, non-
inferiority was conclusive, but not otherwise (Study aim III).  
In all analyses, multivariate models were constructed by including all 
theoretically relevant variables collected at age 6 months. The following variables 
were included in the models: child sex, LAZ, WLZ, Hb, iron status, maternal 
education, maternal age, HFIA, household assets, number of children under 5 years 
of age in the household, incidence of other morbidities (diarrhoea and ARI), and 
whether the child received an intervention (LNS) or not. All results are reported as 
RR, IRR or prevalence ratios [PR] and their 95% confidence intervals (95% CI) at 
p=0.05.  
Statistical methods are explained in detail in the individual articles.  
4.6 Ethical Approval  
The studies were conducted according to Good Clinical Practice and the ethical 
standards of the Declaration of Helsinki. The protocols were approved by two ethics 
committees: the College of Medicine Research and Ethics Committee, University of 
Malawi; and the Ethics Committee of Pirkanmaa Hospital District, Finland. The 
guardians provided an informed consent form before enrolment. The trials were 
registered at clinical trial registry (www.clinicaltrials.gov) with the registration IDs 
of NCT00945698 and NCT01239693. Independent DSMBs monitored the 
incidence of suspected SAEs. 
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5 RESULTS 
5.1 Enrolment and success of follow-up  
The iLiNS-DOSE trial was conducted from November 2009 to June 2012. Out of 
2,136 infants who came to the study clinics for assessment, 1,932 (90.4%) were 
enrolled and randomized into six study groups. The group allocation, reasons for 
exclusion and loss to follow-up, and final cohort which was used for Study III are 
shown in Figure 1 of Article III. 
The iLiNS-DYAD-M trial was conducted from February 2011 to April 2015. 
The study staff approached a total of 9,310 pregnant mothers, from whom 1,391 
(14.9%) were enrolled in the trial and were randomly assigned to one of the three 
intervention groups. Of these, 869 mothers were assigned to the complete 
intervention, i.e. their children were followed up to 18 months. A total of 793 
children (including five sets of twins) were born to the mothers; these children 
represent the sample for the present study (we excluded the children born to the 
remaining 522 mothers who were assigned to the pregnancy intervention only).  
The final cohorts for Study I and Study II which combined children from both 
iLiNS-DOSE and iLiNS-DYAD-M are shown in Figure 1 of Article I and Figure 
1 of Article II, respectively. 
5.2 Background information 
The total sample obtained from the two trials at 6 months was 2,657 children (1,932 
children from the iLiNS-DOSE trial and 725 children from the iLiNS-DYAD-M 
trial). However, 96 children were dropped due to missing morbidity data due to loss 
to follow-up due to death or withdrawal from the study before morbidity visits were 
done; thus 2,561 children were included in the final pooled sample.  
Table 4 shows the characteristics of the children at 6 months. The mean (SD) age 
of the children was 5.9 (0.3) months and their mean (SD) LAZ, WAZ and WLZ z-
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scores were -1.4 (1.1), -0.7 (1.2) and 0.3 (1.1) respectively. The median (25th, 75th 
centile) ZPP concentration was 85 (63, 131) mole/mole haeme and the proportion 
of children with iron deficiency was 66.2%. The mean (SD) Hb concentration was 
103.5 (15.9) g/L while the proportion of children with anaemia was 51.5%. The 
reported mosquito bed net utilization by children was 81.1%.
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 Participant characteristics at 6 months  
Variable iLiNS-
DOSEa 
iLiNS-
DYAD-Ma 
Pooled 
dataa 
Number of childrenb 1,928 633 2,561 
Mean (SD) weight, kg 7.0 (1.0) 7.3 (1.0) 7.1 (1.0) 
Mean (SD) length, cm 63.4 (2.4) 64.2 (2.6) 63.6 (2.5) 
Mean (SD) length-for-age z-score -1.4 (1.0) -1.2 (1.1) -1.4 (1.1) 
Mean (SD) weight-for-length z-score 0.3 (1.1) 0.4 (1.1) 0.3 (1.1) 
Mean (SD) weight-for-age z-score -0.7 (1.1) -0.5 (1.2) -0.7 (1.2) 
Mean (SD) haemoglobin, g/L 103.6 (16) 103.7 (15) 103.6 (15) 
Proportion of boys n (%) 974 (50.5%) 
301 
(47.6%) 
1,275 
(49.6%) 
Proportion with LAZ < -2 score n (%) 561 (29.1%) 
148 
(23.4%) 
709 
(27.4%) 
Proportion with WLZ < -2 score n (%) 35  (1.8%) 
13  
(2.0%) 
48  
(1.8%) 
Proportion with WAZ < -2 score n (%) 268 (13.9%) 
49  
(7.7%) 
317 
(12.2%) 
Proportion with haemoglobin <105 g/L n (%) 976 
(50.6%) 
344 
(54.4%) 
1,320 
(51.7%) 
Proportion with ZPP >70 mole/mole haemec n 
(%) 
1,325 
(68.7%) 
442 
(69.8%) 
1,767 
(69.0%) 
Proportion with malaria by RDT n (%) 322 
(16.7%) 
61  
(9.7%) 
383 
(14.5%) 
Proportion with malaria by microscopy n (%) 83  
(4.3%) 
33 
 (5.2%) 
116  
(4.5%) 
Mean (SD) maternal age (years) 26.1 (6.2) 25.1 (6.0) 25.8 (6.1) 
Mean (SD) maternal education, completed years 4.7 (3.6) 3.8 (3.5) 4.4 (3.6) 
Mean (SD) HFIAS 6.5 (6.0) 5.0 (4.3) 6.0 (5.6) 
Mean (SD) asset score 0.001 (1.0) -0.005 (1.0) 
-0.001 
(1.0) 
Mean (SD) number of children under 5 years of 
age in each household 
1.7 (0.7) 1.5 (0.7) 1.6 (0.7) 
Proportion who slept under ITN dailyd n (%) 1,533 
(79.5%) 
541 
(85.4%) 
2,074 
(81.1%) 
Proportion who received LNS intervention n (%) 1,610 
(83.5%) 
205 
(32.4%) 
1,815 
(68.7%) 
Study site:                                        Mangochi 1,483 191 1,664 
                                                           Namwera 445 0 445 
                                                              Malindi 0 119 119 
                                                          Lungwena 0 323 323 
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HFIAS, Household Food Insecurity Access Scale; ITN, insecticide-treated mosquito 
bed net; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplement; RDT, 
rapid diagnostic test; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score; 
ZPP, zinc protoporphyrin 
aValues are n, mean (SD) or proportions 
bChildren who had morbidity data from 6 months to 18 months 
cMeasured from unwashed venous blood 
dA week prior to the date of visit
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5.3 Descriptive statistics 
5.3.1 Linear growth and development 
Between 6 months and 18 months, the children gained, on average, 12.9 (2.1) cm in 
length but there was a decline in mean (SD) LAZ from -1.4 (1.1) at 6 months to -1.9 
(1.1) at 18 months. The prevalence of severe stunting (LAZ <-3) and moderate to 
severe stunting (LAZ <-2) increased from 6.1% to 12.9% and 26.7% to 41.2% 
respectively. The prevalence of moderate to severe underweight (WAZ <-2) 
increased from 12.2% to 16.4%, whereas the prevalence of moderate to severe 
wasting (WLZ <-2) increased from 1.8% to 4.9% between 6 months and 18 months. 
The mean (SD) scores for fine motor, gross motor, language and PSED were 20.9 
(2.2), 17.3 (2.6), 26.2 (5.0) and 16.2 (5.4) respectively. 
5.3.2 Malaria morbidity  
The children in the two trials contributed 2,478.6 years of follow-up, i.e. the mean 
(SD) duration of follow-up was 344 (73) days / child. A total of 28,032 morbidity 
episodes were reported during the home visits. Of these, 15,586 (55.6%) were ARI, 
9,419 (33.6%) were diarrhoea, 2,719 (9.7%) were malaria, and 308 (1.1%) were 
minor conditions. The mean (SD) incidence of all illnesses combined was 11.6 
(13.1) episodes per child year, of which 7.8 (8.0) were episodes of ARI, 2.7 (2.7) 
were episodes of diarrhoea, and 1.1 (1.6) were episodes of presumed malaria.  
On average, the children made 5.5 visits to the hospital due to illness during the 
one-year follow-up. Of these, 1.7 were due to malaria (categorized as clinical 
malaria, mean (SD) incidence: 0.4 (0.8) and confirmed malaria, mean (SD) 
incidence: 1.3 (2.0) episodes per child year). The prevalence of malaria confirmed 
by microscopy increased from 4.7% to 9.6% between 6 months and 18 months. 
During the 12-month follow-up, 45% of the children did not report any episode 
of malaria, 29% reported one episode and 26% reported >1 malaria episodes. The 
children who reported >1 malaria episodes were responsible for 71.4% of all 
malaria episodes. The pattern was similar across all definitions of malaria. 
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5.4 The association of linear growth faltering at 6 months with subsequent 
12-month malaria morbidity (Study I) 
Of the 2,725 children enrolled in the two study cohorts, 2,561 (94%) had data for the 
primary outcome, incidence of presumed malaria (1,928 children from the iLiNS-
DOSE trial and 633 children from the iLiNS-DYAD-M trial). These were included 
in the final analysis for study aim I (Figure 1 of Article I).  
Figure 5 shows the association of LAZ with malaria in different definitions. 
When considered across the ranges of severities in linear growth faltering, there 
appears to be a risk gradient in incidence of RDT-confirmed malaria and prevalence 
of malaria parasitaemia. The severely stunted children (LAZ <-3) had the highest 
incidence of malaria; the incidence/prevalence decreased with progressive increase 
in LAZ. However, these associations were not statistically significant when 
adjusted for other predictors4 (IRR = 1.03, 95% CI = 0.98 to 1.09, p =0.394 for 
presumed malaria; IRR = 0.98, 95% CI = 0.89 to 1.07, p = 0.703 for clinical 
malaria, and IRR = 1.00, 95% CI = 0.94 to 1.07, p = 0.882 for confirmed malaria).  
When stratified by stunting at 6 months, children who were stunted had higher 
mean incidence of clinical malaria from 6 months to 18 months, higher mean 
incidence of RDT-confirmed malaria from 6 to 18 months (Figure 6), and higher 
prevalence of malaria parasitaemia at 18 months (Figure 7), although these did not 
reach statistical significance (IRR = 1.13, 95% CI = 0.61 to 2.09, p = 0.707 for 
presumed malaria incidence; IRR = 1.14, 95% CI = 0.92 to 1.39, p = 0.233 for 
clinical malaria incidence; IRR = 1.02, 95% CI = 0.88 to 1.18, p = 0.789 for 
confirmed malaria incidence; and PR = 1.10, 95% CI = 0.93 to 1.37, p = 0.712).  
Independent predictors of malaria 
Independent predictors for the different malaria outcomes are presented in Table 5
                                                   
4Adjusted for the following factors at 6 months: sex of the child, haemoglobin concentration, iron 
status, month of birth, daily use of insecticide-treated bed nets, distance to health facility, study site, 
asset scores, maternal age, maternal education, children under 5 years of age, household food insecurity 
access scale, and whether the child received the study intervention (lipid-based nutrient supplements) 
or not. 
 47
 
 
 In
de
pe
nd
en
t p
re
dic
tor
s o
f in
cid
en
ce
 an
d p
re
va
len
ce
 of
 m
ala
ria
 in
 m
ult
iva
ria
te 
an
aly
sis
1  
 
In
ci
de
nc
e 
of
 ‘p
re
su
m
ed
’ 
m
al
ar
ia
 
(N
=2
56
1)
 
In
ci
de
nc
e 
of
 c
lin
ic
al
 m
al
ar
ia
 
(N
=2
49
7)
 
In
ci
de
nc
e 
of
 c
on
fir
m
ed
 m
al
ar
ia
 
(N
=2
49
7)
 
Pr
ev
al
en
ce
 o
f m
al
ar
ia
 
pa
ra
si
ta
em
ia
 a
t a
ge
 1
8m
o 
(N
=1
66
2)
 
C
hi
ld
 fa
ct
or
s a
t a
ge
 6
 m
on
th
s 
IR
R2
 (9
5%
 C
I) 
p- va
lu
e 
IR
R2
 (9
5%
 C
I) 
p-
va
lu
e 
IR
R2
 (9
5%
 C
I) 
p-
va
lu
e 
 P
R3
 (9
5%
 C
I) 
p-
va
lu
e 
H
ae
m
og
lo
bi
n 
(g
/L
) 
1.
00
 (0
.9
9 
to
 1
.0
1)
 
0.
52
9 
0.
99
 (0
.9
8 
to
 1
.0
0)
 
0.
01
6 
1.
00
 (0
.9
9 
to
 1
.0
1)
 
0.
84
5 
0.
98
 (0
.9
7 
to
 0
.9
9)
 
0.
00
1 
Iro
n 
de
fic
ie
nc
y4
 
1.
04
 (0
.9
1 
to
 1
.1
8)
 
0.
58
7 
1.
03
 (0
.8
3 
to
 1
.2
8)
 
0.
77
3 
1.
20
 (1
.0
4 
to
 1
.3
9)
 
0.
01
2 
2.
11
 (1
.2
4 
to
 3
.5
7)
 
0.
00
6 
M
at
er
na
l f
ac
to
rs
 a
t e
nr
ol
lm
en
t 
 
 
 
 
 
 
 
 
M
at
er
na
l a
ge
 
1.
01
 (1
.0
0 
to
 1
.0
2)
 
0.
01
1 
0.
99
 (0
.9
7 
to
 1
.0
1)
 
0.
14
9 
1.
00
 (0
.9
8 
to
 1
.0
1)
 
0.
20
0 
0.
97
 (0
.9
4 
to
 0
.9
9)
 
0.
03
3 
M
at
er
na
l e
du
ca
tio
n 
0.
99
 (0
.9
7 
to
 1
.0
1)
 
0.
42
7 
1.
00
 (0
.9
8 
to
 1
.0
3)
 
0.
78
3 
0.
97
 (0
.9
5 
to
 0
.9
9)
 
0.
02
4 
0.
90
 (0
.8
5 
to
 0
.9
6)
 
0.
00
1 
H
ou
se
ho
ld
 fa
ct
or
s a
t e
nr
ol
lm
en
t 
 
 
 
 
 
 
 
 
H
ou
se
ho
ld
 F
oo
d 
In
se
cu
rit
y 
A
cc
es
s S
co
re
 
1.
00
 (0
.9
9 
to
 1
.0
1)
 
0.
80
9 
1.
02
 (1
.0
1 
to
 1
.0
4)
 
0.
02
2 
1.
01
 (0
.9
9 
to
 1
.0
2)
 
0.
06
5 
1.
02
 (0
.9
9 
to
 1
.0
5)
 
0.
18
4 
A
ss
et
 sc
or
es
 
0.
86
 (0
.8
0 
to
 0
.9
3)
 
<0
.0
01
 
0.
94
 (0
.8
3 
to
 1
.0
7)
 
0.
34
3 
0.
73
 (0
.6
4 
to
 0
.8
3)
 
<0
.0
01
 
0.
92
 (0
.6
3 
to
 1
.3
4)
 
0.
66
6 
En
vi
ro
nm
en
ta
l f
ac
to
rs
 
 
 
 
 
 
 
 
 
LN
S 
in
te
rv
en
tio
n 
(v
s c
on
tro
l) 
1.
00
 (0
.8
8 
to
 1
.1
4)
 
0.
98
3 
1.
11
 (0
.8
9 
to
 1
.3
7)
 
0.
34
3 
1.
02
 (0
.8
6 
to
 1
.2
2)
 
0.
78
3 
1.
07
 (0
.7
0 
to
 1
.6
2)
 
0.
76
5 
St
ud
y 
sit
e 
M
an
go
ch
i 
Re
fe
re
nc
e 
 
Re
fe
re
nc
e 
 
Re
fe
re
nc
e 
 
Re
fe
re
nc
e 
 
 
N
am
w
er
a 
0.
94
 (0
.8
1 
to
 1
.0
9)
 
0.
45
7 
1.
49
 (1
.2
0 
to
 1
.8
5)
 
<0
.0
01
 
1.
73
 (1
.5
0 
to
 1
.9
9)
 
<0
.0
01
 
1.
49
 (0
.9
9 
to
 2
.2
4)
 
0.
05
4 
 
M
al
in
di
 
1.
12
 (0
.8
8 
to
 1
.4
2)
 
0.
33
7 
0.
45
 (0
.2
7 
to
 0
.7
3)
 
0.
00
1 
0.
58
 (0
.4
3 
to
 0
.7
8)
 
<0
.0
01
 
0.
74
 (0
.2
9 
to
 1
.8
8)
 
0.
53
1 
 
Lu
ng
w
en
a 
0.
91
 (0
.7
5 
to
 1
.0
9)
 
0.
30
3 
0.
24
 (0
.1
4 
to
 0
.4
1)
 
<0
.0
01
 
0.
33
 (0
.2
5 
to
 0
.4
4)
 
<0
.0
01
 
0.
65
 (0
.3
6 
to
 1
.1
9)
 
0.
16
3 
C
I: 
co
nf
id
en
ce
 in
te
rv
al
; I
RR
: i
nc
id
en
ce
 ra
te
 ra
tio
; L
N
S:
 li
pi
d-
ba
se
d 
nu
tri
en
t s
up
pl
em
en
ts;
 P
R:
 p
re
va
le
nc
e 
ra
tio
; Z
PP
: 
zi
nc
 p
ro
to
po
rp
hy
rin
 
1 
O
th
er
 fa
ct
or
s 
in
cl
ud
ed
 in
 th
e 
m
od
el
s 
bu
t n
ot
 s
ig
ni
fic
an
t w
er
e:
 s
ex
 o
f t
he
 c
hi
ld
, b
irt
h 
m
on
th
, n
um
be
r o
f c
hi
ld
re
n 
in
 
ho
us
eh
ol
d,
 a
nd
 d
ai
ly
 u
se
 o
f i
ns
ec
tic
id
e-
tre
at
ed
 b
ed
 n
et
s 
2 
In
ci
de
nc
e 
ra
te
 ra
tio
, o
bt
ai
ne
d 
us
in
g 
ne
ga
tiv
e 
bi
no
m
ia
l r
eg
re
ss
io
n.
 T
he
 IR
R 
re
pr
es
en
ts 
th
e 
ra
te
 o
f c
ha
ng
e 
in
 in
ci
de
nc
e 
of
 m
al
ar
ia
 (f
or
 e
ac
h 
1-
un
it 
hi
gh
er
 in
 th
e 
co
nt
in
uo
us
 p
re
di
ct
or
s 
or
 fo
r e
ac
h 
gr
ou
p 
co
m
pa
re
d 
to
 th
e 
re
fe
re
nc
e 
gr
ou
p 
in
 
th
e 
ca
te
go
ric
al
 p
re
di
ct
or
s)
, a
dj
us
te
d 
fo
r o
th
er
 v
ar
ia
bl
es
 
3 
Pr
ev
al
en
ce
 r
at
io
, o
bt
ai
ne
d 
us
in
g 
a 
m
od
ifi
ed
 P
oi
ss
on
 r
eg
re
ss
io
n 
(w
ith
 a
 r
ob
us
t v
ar
ia
nc
e 
es
tim
at
or
) 
(1
29
). 
Th
e 
PR
 
re
pr
es
en
ts 
th
e 
ra
te
 o
f c
ha
ng
e 
in
 p
re
va
le
nc
e o
f m
al
ar
ia
 p
ar
as
ita
em
ia
 (f
or
 e
ac
h 
1-
un
it 
hi
gh
er
 in
 th
e 
co
nt
in
uo
us
 p
re
di
ct
or
s 
or
 fo
r e
ac
h 
gr
ou
p 
co
m
pa
re
d 
to
 th
e 
re
fe
re
nc
e 
gr
ou
p 
in
 th
e 
ca
te
go
ric
al
 p
re
di
ct
or
s)
, a
dj
us
te
d 
fo
r o
th
er
 v
ar
ia
bl
es
  
4 
ZP
P 
>7
0 
m
ol
e/
m
ol
e 
he
m
e 
(1
27
).
 48 
 
Incidence of presumed malaria from 6 to 18 months was predicted by maternal 
age (IRR = 1.01, 95% CI = 1.00 to 1.02, p = 0.011) and asset score (IRR = 0.86, 
95% CI = 0.80 to 0.93, p <0.001) at 6 months. 
Incidence of clinical malaria from 6 to 18 months was predicted by Hb 
concentration at 6 months (IRR = 0.99, 95% CI = 0.98 to 1.00, p = 0.016) and 
HFIAS at 6 months (IRR = 1.02, 95% CI = 1.01 to 1.04, p = 0.022). In addition, the 
incidence of clinical malaria significantly varied across the study sites, with 
Namwera site recording higher incidence of clinical malaria compared to Mangochi 
(IRR = 1.49, 95% CI = 1.20 to 1.85, p <0.001), while the Malindi and Lungwena 
had lower incidence of clinical malaria compared to Mangochi (IRR = 0.45, 95% CI 
= 0.27 to 0.73, p = 0.001 and IRR = 0.24, 95% CI = 0.14 to 0.41, p<0.001, 
respectively). 
Incidence of confirmed malaria from 6 to 18 months was predicted by iron 
deficiency at 6 months (IRR = 1.20, 95% CI = 1.04 to 1.39, p = 0.012), maternal 
education (IRR = 0.97, 95% CI = 0.95 to 0.99, p = 0.024), and asset score at 6 
months (IRR = 0.73, 95% CI = 0.64 to 0.83, p <0.001). There was also a significant 
variation in the incidence of confirmed malaria across the study sites: children from 
Namwera had higher incidence of confirmed malaria compared to Mangochi (IRR = 
1.73, 95% CI = 1.50 to 1.99, p <0.001), while Malindi and Lungwena children had 
lower incidence of confirmed malaria compared to Mangochi (IRR = 0.58, 95% CI 
= 0.43 to 0.78, p <0.001 and IRR = 0.33, 95% CI = 0.25 to 0.44, p <0.001, 
respectively). 
Malaria parasitaemia prevalence was predicted by WLZ at 6 months (PR = 0.80, 
95% CI = 0.67 to 0.94, p = 0.007), Hb concentration at 6 months (PR = 0.98, 95% 
CI = 0.97 to 0.99, p = 0.001), iron deficiency at 6 months (PR = 2.11, 95% CI = 
1.24 to 3.57, p = 0.006), maternal age (PR = 0.97, 95% CI = 0.94 to 0.99, p = 
0.033), and maternal education (PR = 0.90, 95% CI = 0.85 to 0.96, p = 0.001).   
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Figure 7.  Association of length-for-age z-score at age 6 months with incidence of malaria from age 6 
months to 18 months for children in the iLiNS-DOSE and iLiNS-DYAD-M trials, adjusted for other 
predictors5. The graphs are LOWESS-smoothed. 
 
 
 
 
                                                   
5Adjusted for the following factors at 6 months: sex of the child, haemoglobin concentration, iron 
status, month of birth, use of insecticide treated bed nets, distance to health facility, study site, asset 
scores, maternal age, maternal education, children under 5 years of age, household food insecurity 
access scale, and whether the child received the study intervention (lipid-based nutrient supplements) 
or not. 
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Figure 8.  Mean incidence of presumed malaria, clinical malaria and confirmed malaria (by rapid diagnostic test) from age 
6 months to 18 months for children in the iLiNS-DOSE and iLiNS-DYAD-M trials by stunting status at age 6 months 
 
 
Box plot showing the incidence of presumed, confirmed, or clinical malaria in children who 
were stunted at 6 months (black boxes) compared to children who were not stunted (clear 
boxes). Incidence (defined as number of episodes/child years of follow-up. Summarized by 
median, interquartile range and outliers.  
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Figure 9.  Prevalence of malaria parasitaemia at age 18 months by stunting status at age 6 months for children in the 
iLiNS-DOSE and iLiNS-DYAD-M trials 
 
  
 
Graph showing the prevalence of malaria parasitaemia (confirmed by microscopy) in 
children who were stunted at 6 months (grey bar) compared to children who were not 
stunted (dotted bar). Prevalence was defined as number of children with positive 
microscopy/total number of children tested at 18 months. P-value calculated using 
modified Poisson regression (with a robust error variance).  
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5.5 Association of malaria morbidity with linear growth faltering and child 
development (Study II) 
Of the 2,725 children enrolled in the two study cohorts, 2,016 (74%) had length 
measured both at 6 months and 18 months (1,417 children from the iLiNS DOSE 
trial and 599 children from the iLiNS DYAD-M trial). These were included in the 
final analysis for study aim II (Figure 1 of Article II). 
The mean (SD) change in LAZ from 6 months to 18 months was -0.44 (0.77). 
Figure 8 shows an increase in change in LAZ with increasing incidence of 
presumed malaria incidence, although not statistically significant in multivariate 
analysis (ȕ = -0.02, 95% CI = -0.04 to 0.01, p = 0.069). Similarly, there was no 
significant association of clinical malaria incidence (ȕ .04, 95% CI = -0.08 to 
0.15, p = 0.531) or confirmed malaria incidence (ȕ = -0.01, 95% CI = -0.03 to 0.02, 
p = 0.569) with change in LAZ from 6 months to 18 months.  
The proportion of children who were stunted increased from 27.4% at 6 months 
to 41.5% at 18 months. Presumed malaria incidence was significantly associated 
with a higher proportion of children with stunting at 18 months after adjusting for 
covariates6 (RR = 1.04, 95% CI = 1.01 to 1.07, p = 0.023). This association was 
clearer when presumed malaria was categorized by frequency (0, 1, >1 episodes) as 
shown in Figure 9: children with >1 malaria episodes from 6 months to 18 months 
had higher risk of stunting at 18 months compared to children with zero malaria 
episodes (RR = 1.39, 95% CI = 1.13 to 1.70, p = 0.002). There were no significant 
associations of clinical malaria incidence (RR = 1.07, 95% CI = 0.91 to 1.25, p = 
0.409) or confirmed malaria incidence (RR = 0.99, 95% CI = 0.96 to 1.02, p = 
0.561) from 6 months to 18 months with stunting at 18 months. 
The association of incidence of presumed malaria from 6 months to 18 months 
with child development at 18 months was significant for PSED scores (ȕ= -0.21; 
95% CI = 0.39 to -0.03; p = 0.041), but not for the other domains of child 
development (Table 4 and Table 5 of article II).
                                                   
6Adjusted for the following factors at 6 months: sex of the child, stunting, weight-for-length z-score, 
haemoglobin concentration, iron status, household food insecurity access scale, maternal education, 
incidence of diarrhoea and acute respiratory infections from 6 months to 18 months, and whether the 
child received an intervention (lipid-based nutrient supplements) during the study period. 
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Figure 10.  Change in length-for-age z-score from age 6 months to 18 months associated with increasing incidence 
of presumed7 malaria for children in the iLiNS-DOSE and iLiNS-DYAD-M trials, adjusted for stunting and other 
variables8. The graph is LOWESS-smoothed. 
                                                   
7 Presumed malaria was defined as any fever episode in the absence of diarrhoea or respiratory symptoms. 
8Adjusted for the following factors at 6 months: sex of the child, weight-for-length z-score, haemoglobin 
concentration, iron status, household food insecurity access scale, maternal education, incidence of diarrhoea 
and acute respiratory infections from 6 months to 18 months, and whether the child received an intervention 
(lipid-based nutrient supplements) during the study period. 
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Figure 11.  The prevalence of stunting at age 18 months by frequency of presumed malaria episodes from 
age 6 months to 18 months for children in the iLiNS-DOSE and iLiNS-DYAD-M trials 
 
Graph showing the prevalence of stunting in children at age 6 months and 
age 18 months, compared across three groups of varying malaria 
frequencies (from age 6 months to 18 months): 1) children who had no 
malaria; 2) children who had one malaria episode; 3) children who had 
more than one malaria episodes during the follow-up period. The group 
reporting more than one malaria episodes had significantly higher 
prevalence of stunting at age 18 months. P-values calculated using modified 
Poisson regression (with a robust error variance). Error bars represent 
standard error. 
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5.6 Effect of LNS provision on risk of malaria (Study III) 
This study aim was addressed using the data from iLiNS-DOSE trial only, a sample 
of 1,932 children. At 18 months 1,534 (79.4%) children remained in follow-up (78 
children died, and 320 children withdrew before the end of the study). A further 127 
children were late for the final visit (excluded from this analysis).  Thus, 1,407 
(72.8%) were assessed on the final home visit within their scheduled period of two 
weeks (Figure 1 of Article III). There were no intergroup differences either in the 
mean length of follow-up (p=0.974) or the proportion of children who remained in 
the study until its end (p=0.334). Because the malaria outcomes were similar 
between the 20 g milk LNS and 20 g no-milk LNS groups (data not shown), we 
collapsed these two groups into one analysis group. Similarly, we combined the 40 
g milk LNS and 40 g no-milk LNS groups into another analysis group. Thus, all the 
results under this aim refer to group comparisons by daily ration of LNS (0, 10 g, 
20 g, or 40 g), irrespective of the milk content in the LNS. The results are 
summarized in Table 5. 
A total of 271 SAEs were recorded among the children: 78 were deaths (4.0% of 
the enrolled children) and 193 were hospitalizations. Compared to the control 
group, the 95% CI for the RR of experiencing an SAE was entirely below 1.20 
(suggestive of non-inferiority) in the 10 g LNS group, entirely below 1.00 
(suggestive of a protective effect) in the 20 g LNS group and ranged from 0.66 to 
1.25 (inconclusive) in the 40 g LNS group.  The 95% CI for the RR of 
hospitalizations was entirely below 1.20 (suggestive of non-inferiority) in the 10 g 
and 20 g LNS groups and ranged from 0.57 to 1.22 (inconclusive) in the 40 g LNS 
group (Table 5). The 95% CI for the risk of death was entirely below 1.20 
(suggestive of non-inferiority) in the 20 g LNS groups and ranged from 0.42 to 1.79 
and 0.58 to 1.92 (inconclusive) in the 10 g and 40 g LNS groups respectively (Table 
5). 
Among the children in the iLiNS-DOSE trial, we identified 19,690 morbidity 
episodes from the home visits data, 9.7% of which were due to presumed malaria. 
Compared to the control group, the 95% CIs of the IRRs for presumed malaria were 
entirely below 1.20 (suggestive of non-inferiority) in all the intervention groups 
(Table 5). The children made 9,034 hospital visits due to illnesses, each child 
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making on average 5.2 hospital visits per year. Compared to the control group, the 
incidence of RDT-confirmed malaria at the hospital visits was 21% higher in the 40 
g LNS group than the control group, but the comparison was inconclusive (Table 
5). There was no significant difference in the incidence of clinical malaria in any of 
the LNS groups, compared to the control group (Table 5). 
Finally, all five intervention groups were combined into one group to compare 
all children who received LNS to those who did not. In this comparison, the 95% 
CIs of the IRRs for all malaria outcomes were entirely below 1.20 (suggestive of 
non-inferiority). The 95% CI for the risk of death was too wide to draw any 
conclusions (Figure 6). 
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Figure 12.  Effect of lipid-based nutrient supplements provision on malaria-related outcomes for children in 
the iLiNS-DOSE trial only 
 
 
All intervention groups receiving lipid-based nutrient supplements (LNS) were 
pooled together and compared with the control group, with resXOWVƔUHSRUWHGDV
incidence rate ratio (IRR) or risk ratio (RR) and their 95% CI (represented by 
horizontal lines). The vertical dashed line represents the margin of non-inferiority. 
The solid line represents the null effect. None of the point estimates and their 95% CI 
fell entirely above the non-LQIHULRULW\PDUJLQ ÂŸAll the IRR/RR and their 
corresponding 95% CI ought to fit to the left area of the non-inferiority margin line 
to conclude that LNS was at least as safe as no supplement i.e. to conclude non-
inferiority. We conclude that LNS is does not increase morbidity. 
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6 DISCUSSION 
This community-based prospective cohort study was aimed at determining the 
associations between malaria and linear growth faltering; both conditions highly 
prevalent in LMICs.  The study further determined the safety of providing iron-
containing lipid-based nutrient supplements to children living in settings where 
malaria is endemic amidst the concerns of increased risk of infectious disease 
morbidity associated with iron provision.  
The first hypothesis was that lower LAZ at 6 months would be associated with a 
higher incidence of malaria from 6 months to 18 months and higher prevalence of 
malaria parasitaemia at 18 months. This hypothesis was not supported by the study 
findings because in a sample of 2,561 Malawian children, LAZ at 6 months was not 
associated with incidence of malaria from 6 months to 18 months, nor prevalence of 
malaria parasitaemia at 18 months. 
The second hypothesis was that linear growth and development would be poorer 
in children with higher incidence of malaria. In a sample of 2,016 Malawian 
children aged 6–18 months, incidence of presumed malaria was positively 
associated with risk of stunting (i.e. one additional episode of presumed malaria per 
year was associated with 4% higher risk of stunting). Incidence of presumed 
malaria was negatively associated with socio-emotional scores (i.e. one additional 
episode of presumed malaria per year was associated with a reduction in PSED 
scores by 0.21), suggesting that children with higher malaria incidence have fewer 
socio-emotional problems, possibly because malaria causes lethargy and inactivity 
which may manifest as fewer behavioural problems. However, the overall finding 
can be deemed inconclusive because presumed malaria was not associated with 
change in LAZ, nor other domains of child development. 
The third hypothesis was that long-term supplementation with LNS would not 
increase malaria morbidity in children. This hypothesis was supported by the study 
findings because in a sample of 1,932 Malawian children aged 6–18 months, one-
year provision of LNS was not associated with excess hospitalizations, deaths or 
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malaria incidence when all intervention groups were combined. However, the 
incidence of RDT-confirmed malaria was 21% higher in the 40 g LNS group 
compared to the control group whereas children in the 10 g and 20 g LNS groups 
had malaria incidence similar to the control group.  
This chapter discusses how these findings compare with the prevailing scientific 
discourse on this topic. The strengths and weaknesses of the study are discussed 
first, followed by the main findings in the order of the study aims. 
6.1 Strengths and weaknesses of the study 
Three main strengths of the study were: the longitudinal design; the frequent home 
morbidity data collection; and the large sample size. 
The longitudinal study design helped to determine the temporality of the 
associations because: malaria outcomes were obtained from 6 months to 18 months 
after identifying the predictors at 6 months; and malaria is less common in children 
< 6 months due to the protective effect of foetal haemoglobin and maternal 
antibodies (64,65,130). Thus, the use of anthropometric status at 6 months as a 
potential predictor of malaria minimized the problem of reverse causation. The 
weekly morbidity visits complemented by a daily pictorial calendar minimized 
problems of recall associated with home morbidity assessments (116,117). The 
iLiNS-DOSE and iLiNS-DYAD-M trials had large sample sizes and pooling of data 
from the two trials for study aims I and II further enhanced the power of the study 
to detect any significant associations.  
The study had several weaknesses. Presumptive diagnosis of malaria may have 
overestimated the malaria episodes due to an overlap in the symptoms of malaria, 
diarrhoea and ARI (131), resulting in misclassification. Although RDTs were 
recommended by the WHO in 2010 (59), they were not yet rolled out nationwide by 
the time of conducting this study. Hence, presumptive malaria diagnosis was 
commonly used not only in this study but also in national prevalence surveys 
(104,132), following IMCI guidelines (133,134).  
Although presumptive diagnosis of malaria might have caused misclassification 
bias, additional analysis using more specific definitions of malaria such as malaria 
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confirmed by RDT at hospital visits showed similar results. Of note is that RDT-
confirmed malaria may have underestimated the outcome because: 23% of the 
children were treated for malaria at the hospital without RDT confirmation; and 
home treatment is quite common in this population therefore children who had 
malaria episodes but received home treatment or no treatment and did not present to 
the hospitals were missed. These are generally considered as limitations of passive 
case detection (122). Presumptive diagnosis and treatment of malaria is hitherto 
common especially by the lower cadres of health care providers, posing risk of poor 
management, treatment failure, and under-reporting (70).  
Research assistants referred all suspected malaria cases to a clinic for treatment. 
The active surveillance may have resulted in over-reporting of morbidity at the 
home visits whereby only 44% of the morbidity episodes were treated at the 
hospital. This discrepancy could also be due to missing data from hospital visits 
because the hospital data were filled by non-study staff. Loss of data was 
minimized by daily follow-up of admitted children by study staff, regular training, 
and mentoring the non-study staff on accurate data collection.  
The active surveillance may also have led to prompt treatment and reduction in 
incidence and severity of malaria, resulting in fewer hospital visits as well as 
attenuating the strength of the associations in our findings. Unmeasured 
confounders (e.g. genetic variations) may also have influenced the strength of 
association between malaria and linear growth faltering, which can be minimized 
by mendelian randomization (94). Confounding was minimized by adjusting for 
known biological, socio-economic and household factors in all analyses. The 
random allocation of participants and blinding of the investigators to the treatment 
groups for study III further reduced confounding. 
Considering the strengths of the study and the efforts to address its weaknesses, 
the author believes the overall findings are valid and generalizable to the study 
population 
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6.2 The association of linear growth faltering at 6 months with subsequent 
12-month malaria morbidity 
High rates of growth faltering and malaria overlap geographically and greatly affect 
the same age groups, but studies on the associations between the two conditions have 
so far reported conflicting findings. The findings of this study suggest there is no 
association of linear growth faltering at 6 months with malaria in the subsequent 12-
month period, which is similar to a few previous studies (83–86), suggesting that 
stunting may be of little significance in malaria epidemiology.  
These findings are, however, different from those reported in Gambia, Kenya, 
and Uganda. In Gambia, a prospective study of children under 5 years of age 
reported an increased risk of malaria associated with stunting (crude RR = 1.35; 
95% CI, 1.08–1.69) (7). The follow-up was very short (20 weeks), only crude RR 
were reported therefore confounders such as socio-economic and household factors 
were not accounted for. In Kenya, stunting in children aged 0–36 months was 
associated with an increased odds of malaria parasitaemia (odds ratio = 1.98, P < 
0.0001) (8). The cross-sectional design of this study suggests the observed 
association may have been due to reverse causation. In Uganda, mild stunting (IRR 
= 1.24, 95% CI 1.06–1.46) and moderate-severe stunting (IRR = 1.24, 95% CI 
1.03–1.48) in children aged <2.5 years were associated with increased incidence of 
malaria parasitaemia (9). However, it was not clear whether exposure assessment 
preceded the outcomes, therefore the temporal relationship between stunting and 
risk of malaria was difficult to ascertain.  
In this study, 26% of the children reported frequent malaria episodes and were 
responsible for the majority of the malaria infections. Knowledge of this over-
dispersion in malaria infections is important because interventions targeted at this 
core group could be the most effective (135). Further analysis showed that children’s 
WLZ at 6 months was a significant predictor of subsequent malaria episodes, i.e. 
children with better WLZ had fewer malaria episodes (data not shown), raising a 
question whether there is value in malaria screening targeted to children who are 
wasted. A mathematical model by Lakkam and Wein demonstrated that targeted 
malaria interventions to underweight children has potential to reduce malaria 
morbidity and mortality in malaria hypoendemic or mesoendemic settings (136). 
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In this setting, socio-economic factors such as household asset scores, maternal 
education, and food insecurity were significantly associated with malaria. These 
factors may be more important than anthropometric status in malaria epidemiology 
but were not the primary interest of the study and therefore warrant further 
exploration. There were also variations in hospital-diagnosed malaria by study site, 
with the Namwera site reporting higher incidences of clinical and RDT-confirmed 
malaria compared to the other three study sites. Namwera site receives high rainfall 
which promotes mosquito breeding, but the high altitude and cool temperatures 
should theoretically limit malaria transmission. This finding requires further 
exploration. 
6.3 Association of malaria morbidity with linear growth faltering and child 
development 
The association of malaria with linear growth was contradictory in this study: there 
was significant association of malaria with stunting (dichotomous outcome) but not 
with change in LAZ (continuous outcome). The lack of association of malaria with 
linear growth faltering has been reported in other studies (83,137–139). Similar to 
this study, the previous studies provided active malaria diagnosis and treatment, 
which may have attenuated the strength of the association. 
The significant association of malaria with stunting has also been reported in 
other studies, attributed to the body’s immune reactivation leading to anorexia, 
vomiting, and a catabolic state in response to infections (92-94). Children living in 
settings where infectious diseases are frequent and complementary food is of poor 
quality often fail to achieve catch up growth after illness episodes,  and if these 
episodes are too frequent, might increase the risk of stunting (140).  
The contradictory findings in this study where malaria was significantly 
associated with stunting but not change in LAZ may be due to the differences in the 
information these outcomes provide. Change in LAZ indicates the growth rate 
between two time-points and therefore provides more information about linear 
growth faltering than stunting status assessed at one time-point (45,141). Therefore, 
it is possible that there exists no association between malaria and linear growth 
faltering (based on change in LAZ), or the association is very weak. It is also possible 
that the association of malaria with linear growth faltering is only seen in children in 
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the left end of the curve (i.e. LAZ<-2), hence the significant association of malaria 
with stunting but not change in LAZ. In contrast, diarrhoea incidence was positively 
associated with both change in LAZ and risk of stunting, suggesting an entire leftward 
shift in LAZ (data not shown).  
6.4 Effect of LNS provision on risk of malaria 
Controversy continues among health policy makers on the perceived risk of malaria 
associated with iron provision in malaria-endemic settings, particularly among the 
iron-replete children. Iron deficiency anaemia is highly prevalent, but iron 
supplementation targeted to the iron-deficient may not be feasible because of 
problems of screening. Hence, the WHO does not recommend routine iron 
supplementation unless provided alongside malaria control interventions (28).  
The mechanisms of the adverse effects of iron in infectious disease morbidity are 
not fully understood. Two possible pathways are proposed: a large dose of ingested 
iron raises plasma non-transferrin-bound iron concentration which may facilitate 
hepatic entry of malaria sporozoites; and iron may promote growth of gut 
microorganisms, and impair gut immune response, leading to pathogen 
sequestration into the systemic circulation (35,96,97).  
The findings that provision of 10 g and 20 g LNS was not associated with higher 
malaria morbidity are similar to the previous LNS studies (15,32–34), attributed to 
the quantity and mode of delivery of iron (25).  
These findings are different from other intervention studies (29–31) which 
reported increases in malaria-related hospitalizations and deaths, other infections 
and intestinal inflammation associated with iron supplements or iron-containing 
MMN provision.  
Several reasons could explain the differences. The dose of iron provided in this 
study was less than half (6 mg/day) of that provided in the other studies 
(12.5mg/day). Guardians were advised that the LNS should be eaten on two or more 
occasions during the day, to limit the amount of iron ingested in a single meal (25). 
Increased risk of malaria morbidity has been reported in iron-replete but not iron-
deficient children (31,142). Therefore, it is possible that the high prevalence of iron 
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deficiency (66.2%) together with the reported high utilization of ITNs (81.1%) in 
this sample may have offered some protection against malaria. Lastly, the intensive 
morbidity surveillance and treatment may have improved the overall health of the 
children and attenuated any possible adverse effects of LNS. 
The finding that the 40 g LNS/d dose may have been associated with excess 
malaria-related hospital visits is puzzling, especially given that the 10 g and 20 g 
LNS/d doses were conclusively not associated with increased malaria. Although the 
lower limit of the confidence interval was below the set non-inferiority margin of 
1.20, the point estimate of 1.21 in the 40 g LNS/d group suggest the risk for malaria 
in this group was clinically significantly higher. However, there is no clear 
biological explanation for this finding because the dose of iron was intended to be 
similar in all the LNS groups. In the maternal supplementation arm of the iLiNS-
DYAD-M trial, provision of MMN or LNS to the pregnant women was associated 
with an increased incidence of dental caries (143), suggesting perhaps the safety of 
LNS is dependent on specific populations and doses. 
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7 SCIENTIFIC CONCLUSIONS 
 
1. In rural Malawi, where both stunting and malaria are common, LAZ at 6 
months does not predict malaria incidence from 6 months to 18 months nor 
prevalence of malaria at 18 months. 
 
2. In this population of children aged 6–18 months, with active disease 
surveillance and early treatment, higher incidence of malaria is not 
associated with change in LAZ in infants and young children but may 
increase the risk of stunting and reduce socio-emotional development at 18 
months. 
 
3. Long term provision of iron-containing LNS at certain doses does not 
increase the risk of malaria when provided to infants and young children 
living in malaria-endemic settings where iron deficiency and mosquito bed 
net utilization is high, and malaria surveillance and treatment is available.  
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8 PUBLIC HEALTH IMPLICATIONS AND FUTURE 
RESEARCH NEEDS 
 
This study has demonstrated that linear growth faltering at 6 months does not 
predict malaria infections from 6 months to 18 months. Therefore, malaria 
screening targeted at children with low LAZ may not be a viable malaria control 
strategy. In contrast, the study findings showed that WLZ at 6 months is associated 
with subsequent malaria infections, hence malaria screening in children found with 
low WLZ at the growth monitoring and promotion clinics can add value in malaria 
control efforts, but this requires further exploration.   
The study also highlights two issues that may be important in the malaria 
control: there is over-dispersion of malaria infections where a minority of children 
bears the major burden of repeated malaria attacks; and there exist significant site 
(micro-geographic) variations in malaria distribution. These were not primary 
outcomes of this study therefore were not explored further. Additional studies are 
required to identify factors for such malaria distribution which can be useful to 
policy makers and implementers to prioritize the limited resources for malaria 
control to target vulnerable subpopulations at country level.  
Although the findings show that malaria is not associated with linear growth 
faltering in infants and young children from 6 months to 18 months, the fact that the 
children received active disease surveillance and early treatment perhaps supports 
the notion of incorporating disease prevention and control in programs that promote 
child growth and development. However, the finding that despite the surveillance 
and treatment, malaria increased the risk of stunting and reduced socio-emotional 
development at 18 months, suggests that disease surveillance and treatment alone 
are not adequate. Children who suffer repeated malaria infections may require close 
follow-up and support at home and at growth monitoring and promotion clinics to 
enhance prevention and early detection of undernutrition.  
 68 
 
This study has demonstrated that at certain doses, LNS supplementation does not 
increase malaria infections, hospitalizations or deaths in malaria-endemic setting 
where iron deficiency and ITN utilization are high, and malaria surveillance and 
treatment is available. Hence iron-containing LNS can be safely provided in such 
settings. This evidence can assist policy makers when developing guidelines for 
prevention of iron deficiency anaemia through routine supplementation in children 
under 5 years of age living in malaria-endemic settings. However, further studies 
are required to determine the optimal dose of iron in food fortificants that can 
reduce iron deficiency anaemia in children under in 5 years of age living in settings 
where iron deficiency is high.  
This study has highlighted several areas that require further research such as: 
 
x A study aimed at evaluating the value of screening children with low WLZ 
for malaria at the growth monitoring and promotion clinics to facilitate early 
treatment and prevent severe malaria and its complications. 
  
x A study aimed at determining the predisposing factors in children who 
suffer repeated malaria infections, focussing on suspected risk factors that 
were not assessed in this study such as HIV infection, polyparasitism, 
vitamin A and zinc deficiency, and genetic variations including 
haemoglobinopathies. 
  
x Considering that children living in higher altitude and far from water bodies 
(Namwera) reported more malaria-related hospitalizations than those in 
lower altitude, this unexpected finding in the microepidemiology of malaria 
needs further exploration using more sensitive tools such as geospatial 
mapping and use of big data analytical algorithms. 
 
x A study aimed at determining the optimal dose of iron in LNS to reduce 
iron deficiency anaemia without adverse effects, taking into account the 
country-specific prevalence of iron deficiency anaemia and infectious 
diseases in children under 5 years of age. 
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APPENDICES 
 
1. Pictorial Calendar 
 
iLiNS-DYAD trial: Form 26 (version 2011-06-11) 
Picture calendar for child morbidity, chewa Participant Code {Participant}: |___|___|___|___| . |___| 
1. Visit information 
1.1 Number (code) of visit  .............................................. |___|___|___|___| 
1.4 Date of first day of data collection (day when calendar is left at home) 
 |___|___| |___|___| 20|___|___| 
 dd mm yy 
1.5 Date of last day of data collection (day preceding next home visit) 
 |___|___| |___|___| 20|___|___| 
 dd mm yy 
2. LNS use and morbidity during the follow-up period 
 
Tsiku la msabata 
Day of the week 
Write in day 
(circle Friday) 
       
Mwana anadya 
Chiponde 
Child ate LNS 
Form 27, Q2,4  
       
Mwana anali bwino 
Child was well 
 
       
Anachepetsa 
zichitochito/ 
kaseweredw 
Reduced activity 
Form 27, q2.5  
       
Analibe chilakolako 
chofuna kudya 
Poor appetite 
Form 27, q2.6 
       
Kutsegula mmimba 
Diarhoea (mark number) 
Form 27, q2.7, q2.8  
 
       
Kusanza 
Vomiting 
Form 27, q2.9 
       
Kutentha thupi 
Fever 
Form 27, q2.10  
 
       
Kutsokomola 
Cough 
Form 27, q2.11, 2.12, 
2.13  
       
Kutuluka mamina 
Nasal discharge 
Form 27, q2.14  
       
Kuonana ndi a 
chipatala koyamba 
Health visit 1 
Form 27, q2.15-2.21 
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Abstract 
Background: In malaria-endemic settings, a small proportion of children suﬀer repeated malaria infections, contrib-
uting to most of the malaria cases, yet underlying factors are not fully understood. This study was aimed to determine 
whether undernutrition predicts this over-dispersion of malaria infections in children aged 6–18 months in settings of 
high malaria and undernutrition prevalence.
Methods: Prospective cohort study, conducted in Mangochi, Malawi. Six-months-old infants were enrolled and had 
length-for-age z-scores (LAZ), weight-for-age z-scores (WAZ), and weight-for-length z-scores (WLZ) assessed. Data 
were collected for ‘presumed’, clinical, and rapid diagnostic test (RDT)-conﬁrmed malaria until 18 months. Malaria 
microscopy was done at 6 and 18 months. Negative binomial regression was used for malaria incidence and modiﬁed 
Poisson regression for malaria prevalence.
Results: Of the 2723 children enrolled, 2561 (94%) had anthropometry and malaria data. The mean (standard devia-
tion [SD]) of LAZ, WAZ, and WLZ at 6 months were − 1.4 (1.1), − 0.7 (1.2), and 0.3 (1.1), respectively. The mean (SD) 
incidences of ‘presumed’, clinical, and RDT-conﬁrmed malaria from 6 to 18 months were: 1.1 (1.6), 0.4 (0.8), and 1.3 
(2.0) episodes/year, respectively. Prevalence of malaria parasitaemia was 4.8% at 6 months and 9.6% at 18 months. 
Higher WLZ at 6 months was associated with lower prevalence of malaria parasitaemia at 18 months (prevalence ratio 
[PR] = 0.80, 95% conﬁdence interval [CI] 0.67 to 0.94, p = 0.007), but not with incidences of ‘presumed’ malaria (inci-
dence rate ratio [IRR] = 0.97, 95% CI 0.92 to 1.02, p = 0.190), clinical malaria (IRR = 1.03, 95% CI 0.94 to 1.12, p = 0.571), 
RDT-conﬁrmed malaria (IRR = 1.00, 95% CI 0.94 to 1.06, p = 0.950). LAZ and WAZ at 6 months were not associated 
with malaria outcomes. Household assets, maternal education, and food insecurity were signiﬁcantly associated with 
malaria. There were signiﬁcant variations in hospital-diagnosed malaria by study site.
Conclusion: In children aged 6–18 months living in malaria-endemic settings, LAZ, WAZ, and WLZ do not predict 
malaria incidence. However, WLZ may be associated with prevalence of malaria. Socio-economic and micro-geo-
graphic factors may explain the variations in malaria, but these require further study.
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Background
Malaria is one of the most serious public health problems 
in the world, with an estimated 216 million cases and 
445,000 deaths reported in 2016, and approximately 90% 
of the cases and deaths occurring in the African Region 
[1]. Malawi is one of the malaria-hyperendemic countries 
in sub-Saharan Africa, with around 4 million malaria cases 
reported annually [2]. In malaria-hyperendemic countries, 
it is assumed that virtually all exposed individuals would 
suﬀer a malaria episode by early childhood [3]. However, 
several studies have shown that in these settings, only 
a small proportion of children suﬀer repeated malaria 
infections, and these children are responsible for most of 
the malaria cases [4–6], an over-dispersion known as the 
‘20/80’ rule [7].
The suggested underlying factors for this over-dis-
persion in malaria infections are varied, and include for 
instance genetic [5], behavioural [8] and environmen-
tal factors [6]. Other studies suggest that undernutri-
tion plays an important role in malaria epidemiology 
because of the synergistic interactions between nutri-
tion and infections [9–11]. However, several reviews on 
the relationship between undernutrition and malaria 
determined that the current evidence is inconclusive; 
attributed to the heterogeneity in the study populations, 
malaria parasite species, and host-parasite relationship 
[12–14]. Hence the need for further understanding of 
the role of undernutrition in malaria epidemiology.
The International Lipid-based Nutrient Supplements 
(iLiNS) Project DOSE and DYAD studies were rand-
omized controlled trials conducted in Malawi to study 
the impact of lipid-based nutrient supplements (LNS) 
on growth of children [15, 16]. Analysis of longitudi-
nal malaria data in the two studies showed that 39% 
of the infants and young children aged 6 to 18 months 
did not report any malaria episode in the one-year 
study period; only 30.7% reported more than one epi-
sode of ‘presumed’ malaria but these were responsible 
for 73.7% of the ‘presumed’ malaria episodes [17]. The 
aim of the current analysis was to further investigate 
the distribution of malaria in children in these cohorts 
and determine whether this distribution is predicted by 
anthropometric status at 6 months. The hypothesis was 
that lower length for age z-scores (LAZ), weight-for-age 
z-scores (WAZ), and lower weight for length z-scores
(WLZ) at 6  months will be associated with a higher
incidence of malaria from 6 to 18  months, and higher
prevalence of malaria at 18 months.
Methods
Study setting
The iLiNS-DOSE and iLiNS-DYAD-M studies were 
conducted in four facilities: one public district hospital 
(Mangochi), one mission hospital (Malindi), and two 
rural public health centres (Lungwena and Namwera) in 
Mangochi District, Southern Malawi. The total catch-
ment population of 180,000 largely subsisted on farm-
ing and ﬁshing. Mangochi site is low-lying at an altitude 
of ~ 485  m above sea level, but traversed by the Shire 
River (the largest river in Malawi). Two of the study sites 
(Lungwena and Malindi) are also low-lying with the 
similar altitude along the eastern shore of Lake Malawi. 
In contrast, Namwera lies at the top of Namwera Hills, 
bordering Mozambique, at an altitude of ~ 900  m above 
sea level and is far from the large water bodies. Namwera 
experienced higher rainfall and cooler temperatures than 
the other three study sites [18, 19].
In Malawian children aged < 5 years, the prevalence of 
malaria (by microscopy), diarrhoea and acute respiratory 
infections were 24.3%, 22% and 5%, respectively, with 
seasonal ﬂuctuations [2, 20]. The sub-tropical climate 
comprising a warm, wet season from November to April, 
a cool, dry winter season from May to August, and a hot, 
dry season from September to October [21] is favour-
able for the Anopheles mosquitoes which transmit Plas-
modium parasites. Plasmodium falciparum is the most 
dominant and causes about 98% of all malaria infections 
in Malawi. Malaria transmission occurs throughout the 
year with highest transmission rates occurring between 
October and April (rainy season), mainly in low-lying 
and high temperature areas.
Study design, data collection and ethics statement
The data for this analysis were taken from the iLiNS-
DOSE and iLiNS-DYAD-M studies—two large commu-
nity-based randomized controlled trials conducted in 
rural Malawi.
In the iLiNS-DOSE study, 6-months old children were 
randomly allocated to one of ﬁve intervention groups 
provided with diﬀerent doses or formulations of LNS 
or to a control group that did not receive LNS during 
the 12-month study period, between November 2009 
and May 2012. In the iLiNS-DYAD-M study, pregnant 
women < 20 weeks’ gestation were randomly allocated to 
one of three groups to receive iron and folic acid (IFA), 
multiple micronutrients (MMN) or a small-quantity 
(20  g) of LNS daily. After delivery, women in the IFA 
group received placebo tablets, while MMN and LNS 
supplementation was continued up to 6 months postpar-
tum. Children of mothers in the LNS group also received 
LNS 10 g twice daily from 6 to 18 months. This study was 
conducted from February 2011 to April 2015. Details of 
design, randomization and enrolment for the two studies 
can be found in the main outcome papers [15, 16].
In both studies, research assistants visited the children’s 
homes every week from age 6 to 18 months to interview 
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the guardians about the child’s health in the previous 
7 days using a structured questionnaire. The information 
was complemented by a picture calendar ﬁlled out by the 
guardians daily to aid memory of their children’s mor-
bidity status. These were done to minimise problems of 
recall associated with community morbidity assessments 
[22, 23]. The use of maternal interviews to collect data 
on child morbidity has been validated in previous stud-
ies [24, 25]. The research assistants referred all cases of 
fever to the nearby health facility for a malaria rapid diag-
nostic test (RDT) and treatment with artemether/lume-
fantrine, the nationally recommended anti-malarial drug. 
The children were followed throughout the year, covering 
periods of both high and low malaria transmission.
Facility health workers were trained to collect data 
on clinical diagnosis, RDT, and/or malaria microscopy 
results whenever the child was treated at the health 
facility. In addition, all children had malaria microscopy 
tests done during the scheduled study clinic visits at age 
6  months and 18  months. Blood smears were obtained 
from all children at the time of the blood sampling for 
biochemical assessments, stained with 2% Giemsa for 
30 min. All thick slides were reviewed by two microsco-
pists using a high-power microscope to determine the 
presence of malaria parasites. Discrepant readings were 
resolved by a third reviewer. Malaria RDT was also done 
at 6  months scheduled clinic visit using rapid test kit 
(Clearview Malarial Combo, Alere, South Africa).
Anthropometric assessments were done at 6 months and 
18 months. Study anthropometrists measured the infant’s 
length with a high-quality length board (Harpenden Infan-
tometer; Holtain Limited) and recorded it to the nearest 
1  mm. They weighed unclothed infants with electronic 
infant weighing scale (SECA 735; Seca GmbH & Co), 
recording to the nearest 10 g. The anthropometrists were 
trained and their measurement reliability was veriﬁed 
at the start of the study and at 6-months intervals there-
after with methods adapted from the procedures used in 
the WHO Multicentre Growth Reference Study [26]. The 
anthropometrists calibrated all equipment with standard 
weights and length rods daily.
Study nurses collected 5–7 mL of blood by venepunc-
ture using a 23-gauge needle into 7.5 mL evacuated, trace 
element-free polyethylene tubes containing lithium hep-
arin (Sarstedt Monovette, NH4‐heparin, Sarstedt Inc., 
Newton, NC, USA). The blood tube was immediately 
inverted 10 times to mix the heparin anticoagulant with 
the blood to prevent clotting. A small aliquot of the whole 
blood was pipetted out and used to analyse haemoglobin 
(Hb) on the Hemocue 201+ system (Hemocue, Brea, CA, 
USA). The tube containing the remaining whole blood 
was then placed in an insulated cooler with ice packs and 
processed within 2  h of collection. Trained laboratory 
staﬀ then aliquoted whole blood into microcuvettes and 
measured zinc protoporphyrin (ZPP) concentration from 
unwashed venous blood sample using a haematoﬂuorom-
eter (206D, AVIV Biomedical Inc., Lakewood, NJ, USA).
At enrolment, research assistants interviewed the 
mothers to obtain household level information includ-
ing assets, number of children, maternal education (years 
spent in school) and maternal age. Household food 
security was assessed using Household Food Insecurity 
Access Scale (HFIAS) [27]. Use of insecticide treated 
bed nets (ITNs) was assessed by asking the guardians the 
number of days that the child slept under a bed net dur-
ing the week preceding the interview at 6  months. Site 
was deﬁned based on the clinics where the two studies 
were conducted (i.e. Namwera, Mangochi, Malindi, and 
Lungwena).
Definition of the predictors and the outcomes
Outcome variables
The primary outcome for this analysis was the incidence 
of ‘presumed’ malaria, derived from the weekly morbidity 
data. ‘Presumed’ malaria diagnosis was deﬁned as history 
of fever either reported by the guardians or tympanic 
temperature ≥ 38 °C measured by the research assistants 
during the home visit. An episode of ‘presumed’ malaria 
was deﬁned as the period starting from the day the child 
had malaria symptoms, preceded by at least 2 days of no 
symptoms or no data. The episode ended on the last day 
the child had malaria symptoms, if followed by at least 
2 symptom-free days. Fever episodes accompanied by 
respiratory signs or diarrhoea were excluded from the 
malaria diagnosis.
Secondary outcomes included (1) incidence of clinical 
malaria, taken from the malaria diagnosis made by the 
health worker in the absence of a diagnostic test when-
ever the child visited a health facility, (2) incidence of 
conﬁrmed malaria, taken from the malaria diagnosis 
made by the health worker conﬁrmed by a positive RDT, 
and (3) prevalence of malaria parasitaemia derived from 
the malaria microscopy results at age 18 months. Malaria 
incidence was calculated as total episodes of malaria/
total child years at risk; malaria parasitaemia prevalence 
was calculated as the proportion with a positive malaria 
parasite slide.
Predictor variables
Length for age z-scores (LAZ), weight-for-age z-scores 
(WAZ), and weight for length z-scores (WLZ) were 
calculated from the anthropometry data using WHO 
growth standards [26]. Iron deﬁciency at age 6  months 
was deﬁned as whole blood ZPP > 70  μmol/mol haem 
[28]. HFIAS z-scores were generated by summing the 
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value of responses to nine questions regarding food inse-
curity: the higher the score, the higher degree of food 
insecurity in the last 4 weeks [27]. Household asset scores 
were deﬁned as the principal components score based on 
baseline ownership of a set of assets and household qual-
ity: the higher the score, the better the living conditions. 
Number of children aged < 5  years was deﬁned as num-
ber of children below the age of ﬁve who were part of the 
participant’s household at 6 months.
Statistical analysis
All children who had malaria data at any point from age 
6 to 18  months were included in the analysis. Negative 
binomial regression was used to assess the association 
of LAZ, WAZ, and WLZ (independent variables) with 
the incidence of malaria (dependent variable), and Pois-
son regression (with a robust variance estimator) [29] 
to assess the association of LAZ, WAZ, and WLZ with 
prevalence of malaria parasitaemia.
To study the independent eﬀect of various predictors, 
multivariate regression models were constructed that 
included potential predictors collected at 6 months. The 
following were potential predictors: household asset 
scores, maternal age (centred around the mean), and edu-
cation, number of children aged < 5  years, HFIA score, 
whether the child received the study intervention (LNS) 
or not, adjusted for the additional control group [MMN] 
in iLiNS-DYAD, sex of the child, Hb concentration, iron 
status, month of birth, daily use of ITNs, distance to 
health facility and study site. Collinearity among the pre-
dictors was tested using the collin stata command. If the 
predictors were highly collinear (> 0.5), the one that was 
less strongly associated with the outcomes was dropped.
The results are reported as incidence rate ratios [IRR] 
or prevalence ratio [PR] and their 95% conﬁdence inter-
vals (95% CI) at p = 0.05. Robust standard errors were 
computed to adjust for correlation of recurrent malaria 
episodes in a single child.
Other potential predictors were considered including 
immunization status, markers of inﬂammation (C-reactive 
protein and alpha1-acid glycoprotein concentrations) at 
6 months, maternal and child malaria immunity, and mater-
nal HIV status. However, these variables were available only 
from a subsample of the two studies, hence were eventu-
ally dropped from the ﬁnal models to maximize the sample 
size. Furthermore, these variables showed little eﬀect on the 
model during sensitivity analysis. Stata version 14 (Stata-
Corp, Texas, USA) was used for the main analyses.
Results
Study population
Of the 2723 children enrolled in the two study cohorts, 
2561 (94%) had data for the primary outcome (1928 
children from the iLiNS DOSE study and 633 children 
from the iLiNS DYAD-M study). These were included in 
the ﬁnal analysis (Fig. 1). At age 6 months, the mean (SD) 
length-for-age z-scores (LAZ), weight-for-age z-scores 
(WAZ), and weight-for-length z-scores (WLZ) were 
− 1.4 (1.1), − 0.7 (1.2), and 0.3 (1.1) respectively. The pro-
portions of children who were stunted, underweight
wasted were 28.3%, 12.9%, and 2.0%, respectively. Further 
characteristics of these children at age 6 months are sum-
marized in Table 1.
Incidence and prevalence of malaria
The children contributed 2405.6 child years of follow 
up, i.e. the mean (SD) duration of follow up was 344 
(73) days/child. During the home visits, 27,340 mor-
bidity episodes were reported, 9.3% (2549/27,340)
of which were episodes of ‘presumed’ malaria. The
rest were due to: ARI, 53.8% (14,708/27,340); diar-
rhoea, 23% (6282/27,340) and minor conditions, 13.9%
(3801/27,340).
Of the total morbidity episodes identiﬁed at the home 
visits, 44% (12,048/27,340) were reported and treated at a 
health facility, 32.5% (3917/12,048) of which were treated 
for malaria, 76.8% (3007/3917) of them conﬁrmed by 
RDT.
From the home visits data, the mean (SD) incidence of 
all illnesses combined was 16.2 (13.1) episodes per child 
year. The mean (SD) incidence of ‘presumed’ malaria 
was 1.1 (1.6) episodes per child year. The mean (SD) 
incidence of acute respiratory infections was 7.8 (8.0) 
episodes per child year and the mean (SD) incidence 
of diarrhoea was 2.7 (2.7) episodes per child year. Con-
versely, the national data show that diarrhoea incidence 
is higher than ARI incidence in children under-ﬁve, 
probably because the age ranges are slightly diﬀerent. 
The national data do not provide speciﬁc incidences for 
children under 18 months.
From the hospital visits data, the mean (SD) incidences 
of clinical malaria and conﬁrmed malaria were, respec-
tively, 0.4 (0.8) and 1.3 (2.0) episodes per child year (i.e. 
the mean (SD) incidence of all malaria at hospital visits 
was 1.7 (2.4) episodes per child year).
The prevalence of malaria parasitaemia (by micros-
copy) increased from 4.8% at age 6  months to 9.6% 
at age 18  months. During the 12-month follow up 
period, 45.1% (1156/2561) of the children included 
in this analysis did not report any episode of malaria, 
28.4% (728/2561) reported one episode and 26.4% 
(677/2561) reported > 1 malaria episodes. The children 
who reported > 1 malaria episodes were responsible for 
71.4% (1821/2549) of all malaria episodes reported in 
the two studies. These findings were similar across the 
different definitions of malaria.
Page 5 of 12Bendabenda et al. Malar J          (2019) 18:143 
Association of LAZ at 6 months with malaria from 6 
to 18 months
In bivariate analysis, a higher LAZ at 6  months was 
associated with a lower incidence of clinical malaria 
and lower incidence of confirmed malaria from 6 to 
18  months (Table  2, unadjusted), and lower preva-
lence of malaria parasitaemia at 18  months (Table  3, 
unadjusted), but not incidence of ‘presumed’ malaria 
(Table  2, unadjusted). When adjusted for other pre-
dictors, these associations were no longer evident 
(Tables 2, 3, adjusted, and 4).
Association of WLZ at 6 months with malaria from 6 
to 18 months
There was no association between WLZ at 6 months and 
the incidence of ‘presumed’ malaria, clinical malaria or 
conﬁrmed malaria from 6 to 18 months, in either bivari-
ate or multivariate analyses (Table  2). In multivariate 
analysis, higher WLZ at 6  months was associated with 
lower prevalence of malaria parasitaemia at 18  months, 
adjusted for other predictors (i.e. 1 SD higher WLZ at 
6 months was associated with 20% decrease in prevalence 
of malaria parasitaemia at 18 months) (Tables 3, 4).
Association of WAZ at 6 months with malaria from 6 
to 18 months
In bivariate analysis, a higher WAZ at 6 months was asso-
ciated with lower incidence of conﬁrmed malaria from 6 
to 18 months (Table 2, unadjusted), and lower prevalence 
of malaria parasitaemia at 18  months (Tables  3, unad-
justed, 4), but not incidence of ‘presumed’ malaria nor 
incidence of clinical malaria (Table 2, unadjusted). When 
adjusted for other predictors, these associations were no 
longer evident (Tables 2, 3, adjusted and 4).
Independent predictors of malaria
Independent predictors that were signiﬁcantly associ-
ated with malaria outcomes are presented in Tables  3, 
4. Incidence of ‘presumed’ malaria from 6 to 18 months
was independently associated with maternal age and
asset score at 6  months (i.e. each year higher in mater-
nal age was associated with 1% increase in incidence
of ‘presumed’ malaria; and 1 SD higher asset score was
associated with 14% decrease in incidence of ‘presumed’
malaria).
Incidence of clinical malaria from 6 to 18 months was 
independently associated with Hb concentration and 
HFIAS at 6 months (i.e. each g/L higher Hb at 6 months 
Fig. 1 Flow chart of the children enrolled and included in the ﬁnal analysis. The ﬁgure shows the number of children enrolled, children lost to 
follow up, and children who were eventually included in the analysis from the iLiNS DOSE and iLiNS DYAD-M cohorts
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was associated with 1% decrease in incidence of clinical 
malaria; and 1-unit higher HFIAS was associated with 
2% increase in incidence of clinical malaria). Higher 
HFIAS represents higher degree of food insecurity. 
There was also a signiﬁcant variation in the incidence 
of clinical malaria between the health facilities (study 
sites), with Namwera site reporting higher incidence of 
clinical malaria compared to Mangochi, while the other 
two sites (Malindi and Lungwena) had lower incidence 
of clinical malaria compared to Mangochi.
Incidence of conﬁrmed malaria from 6 to 18 months 
was independently associated with iron deﬁciency, 
maternal education and asset score at 6  months (i.e. 
iron deﬁciency at 6  months was associated with 20% 
higher incidence of conﬁrmed malaria; each year higher 
in maternal schooling was associated with 3% decrease 
in incidence of conﬁrmed malaria; 1 SD higher asset 
score was associated with 27% decrease in incidence of 
conﬁrmed malaria). There was also a signiﬁcant varia-
tion in the incidence of conﬁrmed malaria between the 
study sites with Namwera site reporting higher inci-
dence of conﬁrmed malaria compared to Mangochi, 
while the other two sites (Malindi and Lungwena) 
reported lower incidence of conﬁrmed malaria com-
pared to Mangochi.
Independent predictors of malaria parasitaemia prev-
alence were WLZ, maternal age, maternal education, 
Hb concentration, and iron deﬁciency (i.e. 1 SD higher 
WLZ was associated with 20% decrease in prevalence of 
malaria parasitaemia (see Tables 3, 4); each year higher in 
maternal age was associated with 3% decrease in preva-
lence of malaria parasitaemia; each additional year in 
maternal schooling was associated with 10% decrease in 
prevalence of malaria parasitaemia; each g/L higher Hb 
at 6  months was associated with 2% decrease in preva-
lence of malaria parasitaemia; and iron deﬁciency at 
Table 1 Participant characteristics at age 6 months
ITN, insecticide-treated bed nets; LNS, lipid-based nutrient supplement; RDT, malaria antigen rapid diagnostic test; ZPP, zinc protoporphyrin
a Measured from unwashed venous blood
b A week prior to the day of assessment
Mean (SD) or n (%) N
Child factors
Mean (SD) weight-for-length z-score 0.3 (1.1) 2561
Mean (SD) weight-for-age z-score − 0.7 (1.2) 2561
Mean (SD) length-for-age z-score − 1.4 (1.1) 2561
Mean (SD) haemoglobin, g/L 104 (16) 2523
Proportion of boys 1265 (49.4%) 2561
Proportion wasted 50 (2.0%) 2561
Proportion underweight 330 (12.9%) 2561
Proportion stunted 725 (28.3%) 2561
Proportion with haemoglobin < 105 g/L 1334 (51.5%) 2523
Proportion with ZPP > 70 μmol/mole  haema 1567 (66.1%) 2371
Proportion with malaria positive by RDT 349 (14.6%) 2389
Maternal factors
Mean (SD) maternal age (years) 25.8 (6.2) 2265
Mean (SD) maternal education, completed years 4.4 (3.6) 2425
Socio-economic and household factors
Mean (SD) Household Food Insecurity Access Score 6.1 (5.6) 2128
Mean (SD) asset score − 0.02 (0.99) 2179
Mean (SD) number of children aged < 5 years in the household 1.6 (0.7) 2149
Proportion who slept under ITN  dailyb 2065 (81.1%) 2546
Environmental factors
Proportion who received LNS intervention 1804 (70.6%) 2556
Study site
Mangochi 1667 (65.2%) 2561
Namwera 445 (17.4%) 2561
Malindi 120 (4.7%) 2561
Lungwena 324 (12.7%) 2561
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6 months was associated with 111% higher prevalence of 
malaria parasitaemia).
Discussion
The study hypothesis was that lower length for age 
z-scores (LAZ) and lower weight for length z-scores
(WLZ) at 6  months will be associated with a higher
incidence of malaria from 6 to 18  months and higher
prevalence of malaria parasitaemia at 18  months. In a
sample of 2561 Malawian children, LAZ at 6  months
was not associated with incidence of malaria from 6 to
18  months, nor prevalence of malaria parasitaemia at
18 months. Higher WLZ at 6 months was associated with 
lower prevalence of malaria parasitaemia at 18  months
(20% decrease in prevalence of malaria parasitaemia at
18 months for every 1 SD higher WLZ at 6 months), but
not with incidence of malaria from 6 to 18 months.
The longitudinal study design helped to determine the 
temporality of the associations because (1) malaria out-
comes were obtained from 6 to 18  months after identi-
fying the predictors at 6 months, and (2) malaria is less 
Table 3 Association of  length-for-age, weight-for-length, 
and  weight-for-age z-scores at  age 6  months with 
prevalence of malaria parasitaemia at age 18 months
CI: confidence interval; LAZ: length-for-age z-score; PR: prevalence ratio; WAZ: 
weight-for-age z-score; WLZ: weight-for-length z-score
a Positive result from malaria microscopy readings
b Adjusted for the following factors at age 6 months: sex of the child, 
haemoglobin concentration, iron status, month of birth, daily use of insecticide-
treated bed nets, distance to health facility, study site, asset scores, maternal 
age, maternal education, children < 5 years, HFIA score, and whether the child 
received the study intervention (LNS) or not
c Prevalence ratio, obtained using a modified Poisson regression (with a robust 
variance estimator) [29]. The PR represents the rate of change in prevalence of 
malaria parasitaemia for each 1-SD higher LAZ, WAZ, or WLZ
Prevalence of malaria parasitaemia at age 18 months 
(N = 1662)a
Unadjusted Adjustedb
PRc (95% CI) p-value PRc (95% CI) p-value
Predictor at age 6 months
LAZ 0.82 (0.72 to 0.93) 0.003 1.11 (0.93 to 1.33) 0.259
WLZ 1.01 (0.88 to 1.16) 0.877 0.80 (0.67 to 0.94) 0.007
WAZ 0.85 (0.75 to 0.96) 0.007 0.88 (0.75 to 1.03) 0.115
Table 4 Independent predictors of incidence and prevalence of malaria in multivariate analysis
Other factors included in the models but not significant were: sex of the child, birth month, number of children in household, and daily use of insecticide-treated bed 
nets
CI: confidence interval; IRR: incidence rate ratio; LNS: lipid-based nutrient supplements; PR: prevalence ratio; ZPP: zinc protoporphyrin
a  Incidence rate ratio, obtained using negative binomial regression. The IRR represents the rate of change in incidence of malaria (for each 1-unit higher in the 
continuous predictors or for each group compared to the reference group in the categorical predictors), adjusted for other variables
b  Prevalence ratio, obtained using a modified Poisson regression (with a robust variance estimator) [29]. The PR represents the rate of change in prevalence of malaria 
parasitaemia (for each 1-unit higher in the continuous predictors or for each group compared to the reference group in the categorical predictors), adjusted for other 
variables
c  ZPP > 70 μmol/mol heme [28]
Incidence of ‘presumed’ 
malaria (N = 2561)
Incidence of clinical 
malaria (N = 2497)
Incidence of confirmed 
malaria (N = 2497)
Prevalence of malaria 
parasitaemia at age 
18 months (N = 1662)
IRRa (95% CI) p-value IRRa (95% CI) p-value IRRa (95% CI) p-value PRb (95% CI) p-value
Child factors at age 6 months
Haemoglobin (g/L) 1.00 (0.99 to 1.01) 0.529 0.99 (0.98 to 1.00) 0.016 1.00 (0.99 to 1.01) 0.845 0.98 (0.97 to 0.99) 0.001
Iron  deﬁciencyc 1.04 (0.91 to 1.18) 0.587 1.03 (0.83 to 1.28) 0.773 1.20 (1.04 to 1.39) 0.012 2.11 (1.24 to 3.57) 0.006
Maternal factors at enrollment
Maternal age 1.01 (1.00 to 1.02) 0.011 0.99 (0.97 to 1.01) 0.149 1.00 (0.98 to 1.01) 0.200 0.97 (0.94 to 0.99) 0.033
Maternal education 0.99 (0.97 to 1.01) 0.427 1.00 (0.98 to 1.03) 0.783 0.97 (0.95 to 0.99) 0.024 0.90 (0.85 to 0.96) 0.001
Household factors at enrollment
Household Food Insecurity 
Access Score
1.00 (0.99 to 1.01) 0.809 1.02 (1.01 to 1.04) 0.022 1.01 (0.99 to 1.02) 0.065 1.02 (0.99 to 1.05) 0.184
Asset scores 0.86 (0.80 to 0.93) < 0.001 0.94 (0.83 to 1.07) 0.343 0.73 (0.64 to 0.83) < 0.001 0.92 (0.63 to 1.34) 0.666
Environmental factors
LNS intervention (vs control) 1.00 (0.88 to 1.14) 0.983 1.11 (0.89 to 1.37) 0.343 1.02 (0.86 to 1.22) 0.783 1.07 (0.70 to 1.62) 0.765
Study site
Mangochi Reference Reference Reference Reference
Namwera 0.94 (0.81 to 1.09) 0.457 1.49 (1.20 to 1.85) < 0.001 1.73 (1.50 to 1.99) < 0.001 1.49 (0.99 to 2.24) 0.054
Malindi 1.12 (0.88 to 1.42) 0.337 0.45 (0.27 to 0.73) 0.001 0.58 (0.43 to 0.78) < 0.001 0.74 (0.29 to 1.88) 0.531
Lungwena 0.91 (0.75 to 1.09) 0.303 0.24 (0.14 to 0.41) < 0.001 0.33 (0.25 to 0.44) < 0.001 0.65 (0.36 to 1.19) 0.163
Page 9 of 12Bendabenda et al. Malar J          (2019) 18:143 
common in children < 6  months due to the protective 
eﬀect of fetal haemoglobin and maternal antibodies 
[30–32]. Another strength of the study was the enhance-
ment of morbidity recall using a daily pictorial calendar 
which minimized recall bias associated with home mor-
bidity assessments [22, 23]. The study had a long follow 
up which allowed assessment of the associations in all 
seasons, and by pooling data from two large cohorts we 
ended up with a large sample size with adequate power to 
detect associations.
The main weakness of the study is the change in the 
exposure (anthropometric status) during the follow up. 
There was signiﬁcant decrease in mean LAZ, WAZ, and 
WLZ from 6 months to 18 months. Compared to base-
line, more children had developed stunting, underweight, 
and wasting by 18  months (41.5% vs 28.3%, 16.5% vs 
12.9%, and 5% vs 2% respectively), indicating that some 
children became nutritionally worse oﬀ during follow up 
which may have led to misclassiﬁcation bias.
There is possibility of residual confounding due to 
unmeasured factors associated with malaria including 
HIV infection [33], polyparasitism [34], vitamin A and 
zinc deﬁciency [35–38], and genetic variations including 
haemoglobinopathies [39–41].
Presumptive diagnosis of malaria may also have led to 
overestimating the outcome whereas the use of RDT-
conﬁrmed malaria may have led to under-estimating the 
outcome because (1) 23% of the children were treated 
for malaria at the hospital without RDT conﬁrmation, 
and (2) children who had malaria episodes but received 
home treatment or no treatment and did not present to 
the hospitals were missed (only 44% of the morbidity epi-
sodes were treated at the hospital). However, the consist-
ency of the results across the diﬀerent malaria deﬁnitions 
suggests that this weakness did not bias the results, and 
considering the strengths of this study, the conclusions 
are reasonably valid.
The ﬁnding of no association between stuntedness 
at 6  months and malaria in the subsequent 12-month 
period is similar to results of previous studies [42–45], 
which suggests that stunting may be of little signiﬁcance 
in malaria epidemiology. These results are however dif-
ferent from those of other studies that reported an 
increased risk of malaria associated with stunting. In the 
Gambia, a prospective study of children aged < 5  years 
reported an increased risk of malaria associated with 
stunting (crude RR = 1.35; 95% CI 1.08–1.69) [9]. The 
follow up was very short (during the malaria season 
that lasted only 20  weeks), and although the outcomes 
were adjusted for age, sex, and ethnicity, crude RR were 
reported. The authors also did not adjust for socio-eco-
nomic and household factors therefore could not rule 
out the inﬂuence of these confounders in their results. In 
Kenya, stunting in children aged 0–36 months was asso-
ciated with an increased odds of malaria parasitaemia 
(odds ratio = 1.98, p < 0.0001) [10]. The cross-sectional 
design of this study suggests the observed association 
may have been due to reverse causation, i.e. the cumu-
lative deleterious eﬀects of malaria on linear growth. In 
Uganda, mild stunting (IRR = 1.24, 95% CI 1.06–1.46) 
and moderate-severe stunting (IRR = 1.24, 95% CI 1.03–
1.48) in children aged < 2.5  years were associated with 
increased incidence of malaria parasitaemia [11]. How-
ever, although this was a cohort study, it was not clear 
whether exposure assessment preceded the outcomes, 
therefore, the temporal relationship between stunting 
and risk of malaria was diﬃcult to ascertain.
However, a study in Papua New Guinea reported 
that lower LAZ was associated with lower incidence of 
malaria in the subsequent one-year period, attributed 
to increased interferon γ (IFN-γ) response to speciﬁc 
malarial antigens observed in stunted children, although 
the mechanisms were not fully explained [46]. Malaria 
varies with age (incidence of malaria decreases whereas 
prevalence of malaria parasitaemia increases with age) 
[13, 47, 48], therefore, the wide age range of the study 
participants (from 10 months to 10 years) makes for diﬃ-
cult comparisons between the studies. In the Papua New 
Guinea study, the authors noted that interferon-γ release 
increased with age, the prevalence rates of splenomegaly 
and parasitaemia increased with age, whereas the inci-
dence of malaria decreased with age, further muddling 
the interpretation of the ﬁndings.
In this population, supplementation with LNS did 
not alter malaria antibody acquisition [49], which was 
attributed to the ﬁnding that the nutritional supple-
ments also did not promote infant growth [16]. Further 
analysis showed no diﬀerence in malaria antibody acqui-
sition between the stunted and non-stunted children at 
6 months (data not shown), supporting the null ﬁndings.
In this study, higher WLZ at 6  months was associ-
ated with lower prevalence of malaria parasitaemia at 
18 months, when adjusted for other predictors. Wasting 
is associated with low levels of leptin through depletion 
of fat mass [50]. Low levels of leptin can lead to reduced 
immune response [51], resulting in increased risk of 
malaria associated with wasting. So far, the evidence 
of association (increased or decreased risk) of malaria 
with WLZ has mainly come from cross-sectional stud-
ies [10, 52, 53]. A recent systematic review determined 
that the relationship between wasting and risk of malaria 
is hitherto inconclusive with most longitudinal stud-
ies reporting no association [54]. This association was 
not conclusive and may be due to chance (e.g., because 
of multiple testing [55]), considering that WLZ was 
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signiﬁcantly associated with prevalence of malaria para-
sitaemia only and not with the other malaria outcomes.
In this study, only 30% of the children reported frequent 
malaria episodes. Knowledge of this over-dispersion in 
malaria infections is important because interventions 
targeted at this core group could be the most eﬀective [7]. 
However, providing routine screening to identify such 
children is diﬃcult. Platforms such as growth monitoring 
and promotion clinics (GMP) provide an entry point to 
preventive and curative health care and have been associ-
ated with signiﬁcant reductions in malnutrition and mor-
tality [56].
Such platforms can be useful for malaria screening 
especially in malaria hypoendemic or mesoendemic set-
tings where targeting malaria interventions to under-
nourished children has potential to reduce malaria 
morbidity and mortality [57]. In this setting, socio-eco-
nomic factors such as household asset scores, maternal 
education, and food insecurity were signiﬁcantly associ-
ated with malaria. There were also variations in hospital-
diagnosed malaria by study site, with the Namwera site 
reporting higher incidences of clinical and RDT-con-
ﬁrmed malaria compared to the other three study sites. 
These factors may be more important than anthropomet-
ric status in malaria epidemiology but were not explored 
further in this analysis.
Conclusions
In conclusion, in children aged 6 to 18 months living in 
this malaria-endemic setting, LAZ, WAZ, and WLZ do 
not predict subsequent malaria incidence when adjusted 
for other predictors. However, WLZ may be associated 
with prevalence of malaria parasitaemia. Socio-economic 
factors and micro-geographic variations may explain 
most of the over-dispersion in malaria infections in this 
setting, but these require further study.
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Abstract
Background: Although poor complementary feeding is associated with poor child growth, nutrition interventions
only have modest impact on child growth, due to high burden of infections. We aimed to assess the association of
malaria with linear growth, hemoglobin, iron status, and development in children aged 6–18 months in a setting of
high malaria and undernutrition prevalence.
Methods: Prospective cohort study, conducted in Mangochi district, Malawi. We enrolled six-months-old infants
and collected weekly data for ‘presumed’ malaria, diarrhea, and acute respiratory infections (ARI) until age 18months.
Change in length-for-age z-scores (LAZ), stunting, hemoglobin, iron status, and development were assessed at age
18months. We used ordinary least squares regression for continuous outcomes and modified Poisson regression for
categorical outcomes.
Results: Of the 2723 children enrolled, 2016 (74.0%) had complete measurements. The mean (standard deviation)
incidences of ‘presumed’ malaria, diarrhea, and ARI, respectively were: 1.4 (2.0), 4.6 (10.1), and 8.3 (5.0) episodes/child year.
Prevalence of stunting increased from 27.4 to 41.5% from 6 to 18months. ‘Presumed’ malaria incidence was associated
with higher risk of stunting (risk ratio [RR] = 1.04, 95% confidence interval [CI] = 1.01 to 1.07, p = 0.023), anemia (RR = 1.02,
95%CI = 1.00 to 1.04, p = 0.014) and better socio-emotional scores (B =− 0.21, 95%CI = − 0.39 to − 0.03, p = 0.041), but not
with change in LAZ, haemoglobin, iron status or other developmental outcomes. Diarrhea incidence was associated with
change in LAZ (B = − 0.02; 95% CI = − 0.03 to − 0.01; p = 0.009), stunting (RR = 1.02; 95% CI = 1.01 to 1.03; p = 0.005), and
slower motor development. ARI incidence was not associated with any outcome except for poorer socio-emotional
scores.
Conclusion: In this population of young children living in a malaria-endemic setting, with active surveillance and
treatment, ‘presumed’ malaria is not associated with change in LAZ, hemoglobin, or iron status, but could be
associated with stunting and anemia. Diarrhea was more consistently associated with growth than was malaria or
ARI. The findings may be different in contexts where active malaria surveillance and treatment is not provided.
Trial registration: NCT00945698 (July 24, 2009) and NCT01239693 (November 11, 2010).
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Introduction
Although poor complementary feeding is associated with
poor child growth, many interventions designed to improve
complementary foods only have modest impact on growth
[1], possibly due to a high burden of infections in children
[2, 3]. Studies in which morbidity treatment was integrated
with a complementary feeding intervention demonstrated
improved linear growth [4] and developmental outcomes
in children [5, 6], suggesting the importance of reducing
the burden of infections along with improved diet to
promote child growth and development.
Longitudinal studies have reported a significant inverse
association of diarrhea with growth [7–9]. However, studies
on the association of malaria with growth and development
have either reported inconsistent results or had cross-sec-
tional designs, which makes it difficult to assess causality or
directionality of association [10–13]. This has prevented
the inclusion of malaria as a determinant of stunting in the
Lives Saved Tool (LiST) model [14].
The International Lipid-based Nutrient Supplements
(iLiNS) Project DOSE and DYAD-M studies were ran-
domized controlled trials conducted in Malawi to study
the impact of lipid-based nutrient supplements (LNS) on
growth of children [15, 16]. The aim of this analysis was
to assess the association of malaria with linear growth,
hemoglobin, iron status, and child development. Our
hypothesis was that linear growth, hemoglobin, iron status,
and developmental outcomes at age 18 mo would be
poorer in children with higher incidence of malaria
from age 6 to 18 mo. We also analyzed the association
of diarrhea and acute respiratory infections (ARI) with
linear growth, hemoglobin, iron status, and developmental
outcomes.
Methods
Study setting
The iLiNS-DOSE and iLiNS-DYAD-M studies were
conducted in one public district hospital (Mangochi),
one mission hospital (St Martins), and two rural public
health centers (Lungwena and Namwera) in Mangochi
District, Southern Malawi. The total catchment population
of 180,000 largely subsisted on farming and fishing. In
Malawian children aged < 5 years, the prevalence of
reported fever (a proxy for malaria), diarrhea and ARI
was 29, 22 and 5%, respectively, with seasonal fluctuations
[17]. Malaria is endemic in Malawi and the study area has
high malaria transmission with high temperature and fre-
quent rainfall from October through April [18].
Study design and data collection
In the iLiNS-DOSE study, 6-mo old children were
randomly allocated to one of five intervention groups
provided with different doses or formulations of LNS
or to a control group that did not receive LNS during
the 12-mo study period, between November 2009 and
May 2012. In the iLiNS-DYAD-M study, pregnant women
< 20 weeks’ gestation were randomly allocated to one of
three groups to receive iron and folic acid (IFA), multiple
micronutrients (MMN) or a small-quantity (20 g) of LNS
daily. After delivery, women in the IFA group received pla-
cebo tablets, while MMN and LNS supplementation was
continued up to 6 mo postpartum. Children of mothers in
the LNS group also received LNS 10 g twice daily from
age 6 to 18 mo. This study was conducted from February
2011 to April 2015. Details of study design, randomization
and enrolment for the two studies were explained in the
main outcome papers [15, 16].
In both studies, research assistants visited the children’s
homes every week from age 6 to 18 mo to interview the
guardians about the child’s health in the previous 7 days
using a structured questionnaire. The information was
complemented by a picture calendar filled out by the
guardians daily to aid memory of their children’s mor-
bidity status. The use of maternal interviews as a means
of collecting data on child morbidity has been validated
in previous studies [19, 20]. The research assistants
referred all cases of ‘presumed’ malaria (presence of
fever) to the nearby health facility for treatment with
lumefantrine/artemether, the nationally recommended
antimalarial drug. The children were followed throughout
the year, covering periods of both high and low malaria
transmission.
Anthropometric measurements were taken at age 6 mo
and 18 mo. Study anthropometrists measured the infant’s
length with a high-quality length board (Harpenden
Infantometer; Holtain Limited) and recorded it to the
nearest 1mm. They weighed unclothed infants with elec-
tronic infant weighing scale (SECA 735; Seca GmbH &
Co), recording to the nearest 10 g. The anthropometrists
were trained and their measurement reliability was veri-
fied at the start of the study and at 6-mo intervals there-
after with methods adapted from the procedures used in
the WHO Multicentre Growth Reference Study [21]. The
anthropometrists calibrated all equipment with standard
weights and length rods daily.
We assessed iron status at age 6 mo and 18 mo by
measuring the zinc protoporphyrin (ZPP) concentration
in unwashed venous blood sample using a hematofluorom-
eter (206D, AVIV Biomedical Inc., Lakewood, NJ, USA).
About 5–7ml of blood was collected by venepuncture
using a 23-gauge needle into 7.5ml evacuated, trace
element-free polyethylene tubes containing lithium heparin
(Sarstedt AG & Co, Nümbrecht, Germany). The samples
were kept covered in aluminium and away from light, in a
refrigerator or on ice, and processed within 2 h of collec-
tion. We measured blood hemoglobin (Hb) concentration
at age 6 mo and 18 mo from a drop of blood taken from a
finger prick and collected in a microcuvette. Hb analysis
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was conducted on-site using a Hemo-Cue instrument
(Hemocue 201+, HemoCue® AB, Ängelholm, Sweden).
We assessed fine and gross motor development at age
18 mo using the Kilifi Developmental Inventory (KDI)
developed in Kenya [22]. Language development was
assessed using a 100-word vocabulary checklist by maternal
interview based on the MacArthur-Bates Communicative
Development Inventory [23] adapted for the local languages,
and 18-mo socio-emotional development was assessed using
the Profile of Social and Emotional Development (PSED),
also developed in Kenya. The child’s mood during the KDI
assessment was rated as positive (smiling/laughing) or not
positive (crying/inconsolable, changeable/mood swings, or
no visible emotions). The child’s interaction with the asses-
sor during the KDI was rated as positive (friendly) or not
positive (avoidant and withdrawn, clings to family member,
hesitant/when approached will accept reluctantly, diffi-
cult to engage in tasks, or inappropriate approaches to
the assessor). The child’s activity level during the KDI
was rated as positive (active and maintains interest) or
not positive (unarousable, sleepy and can hardly be awak-
ened, sleepy but easily awakened, does not spontaneously
engage in activity, and awake but loses interest). The KDI,
vocabulary, and PSED scores showed high inter-rater
agreement and moderate to high test-retest reliability in
this study setting [24, 25].
Definition of the predictors and the outcomes
We used a presumptive diagnosis of malaria derived from
episodes of fever during the previous week, reported by
the guardians. To ensure the diagnoses were mutually
exclusive, we created an algorithm whereby any fever with
a diarrhea episode (three or more loose stools in 24 h) was
categorized as diarrhea; any fever in the presence of any
respiratory symptoms (cough, rapid or difficult breathing
and nasal discharge) was categorized as ARI. ‘Presumed’
malaria was defined as any fever episode in the absence of
diarrhea and respiratory symptoms.
An episode of ‘presumed’ malaria, ARI or diarrhea
was defined as the period starting from the day the child
had the symptoms when preceded by at least 2 days of
no symptoms or no data. The episode ended on the last
day the child had the symptoms which was then
followed by at least 2 symptom-free days. Incidence of
‘presumed’ malaria, ARI or diarrhea for each child from
age 6 to 18 mo was calculated as total episodes / total
follow up years at risk.
Longitudinal prevalences of common childhood symp-
toms (fever, diarrhea, and cough) from age 6 to 18 mo were
defined as the number of days with the symptom divided by
the total number of days of observation for each child [26].
We calculated age- and sex-standardized anthropometric
indices [length-for-age z score (LAZ), weight-for-age z
score (WAZ), and weight-for-length z score (WLZ)] based
on the WHO Child Growth Standards [21] and considered
values below – 2.0 indicative of underweight, stunting and
wasting, respectively. Change in LAZ for each child was
calculated as the difference between LAZ at age 18 mo
and LAZ at age 6 mo.
Iron deficiency at age 6 mo and 18 mo was defined as
whole blood ZPP > 70 μmol/mole heme [27]. Anemia at
age 6 mo was defined as blood Hb concentration < 105 g/L
[28] while anemia at age 18 mo was defined as blood Hb
concentration < 110 g/L [29].
From the child development data at age 18 mo, fine
motor scores were calculated as the sum of 34 KDI fine
motor items, each scored 0 or 1, gross motor scores
were calculated as the sum of 35 KDI gross motor items,
each scored 0 or 1 [22] and vocabulary score was the
maternal-reported child expressive vocabulary out of the
100-word checklist. For these outcomes, moderate to
severe delay was defined as the bottom 25% of the sample.
The socio-emotional score was calculated as the sum of
19 PSED items. Moderate to severe delay was defined as
the top 25% of our sample (a higher score indicates less
advanced socio-emotional development).
Statistical analysis
We included in the analysis children who had outcomes
measured at age 18 mo. For all continuous outcomes,
we used ordinary least squares regression to assess the
association between malaria incidence and each outcome;
and for all binary outcomes, we used modified Poisson
regression (with a robust variance estimator) [30].
We first assessed whether the relationship between the
predictor and each outcome differed between the two
studies. However, the interaction term was not statistically
significant indicating that this relationship was not differ-
ent between the two studies therefore we pooled data
from the two cohorts. We then constructed multivariate
models to determine which variables independently pre-
dicted the outcomes. We included all theoretically rele-
vant variables, regardless of whether they were statistically
significant or not after the bivariate analysis. The following
variables collected at age 6 mo were included in the
models: child sex, LAZ, WLZ, Hb, iron status, maternal
education and household food insecurity access (HFIA)
score generated by summing the value of responses to
nine questions regarding food insecurity [31]. We also in-
cluded in the models, from age 6 to 18 mo, the incidence
of diarrhea and ARI, and whether the child received an
intervention (LNS) or not. For the risk of stunting at age
18 mo, we included in the model stunting at age 6 mo (in
place of LAZ). In addition, all developmental outcomes
were adjusted for the child’s mood, activity level, age and
interaction with the assessor.
We assessed collinearity among the variables (e.g. LAZ
vs WLZ at age 6 mo). If the variables were highly collinear
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(> 0.5), we dropped the one that was less strongly associ-
ated with the outcomes. We accounted for intracluster
correlation due to twins using generalised estimating
equations [32].
We also performed exploratory analyses by using fre-
quency of malaria episodes (from age 6 to 18 mo) as a cat-
egorical variable (no episode, one episode, and > 1 episodes
groups). In addition, we conducted stratified analyses by
stunting at age 6 mo. Although we performed bivariate
analyses for each individual variable, we will only report
the results from multivariate analysis.
We used Stata version 14 (StataCorp, Texas, USA) for
all the analyses.
Results
Baseline characteristics and descriptive statistics
Of the 2723 children enrolled in the two study cohorts,
2016 (74.0%) had length measured both at age 6 mo and
18 mo (1417 children from the iLiNS DOSE study and
599 children from the iLiNS DYAD-M study). These were
included in the final analysis (Fig. 1). The characteristics
of these children at age 6 mo are summarized in Table 1.
The 2016 children included in the final analysis con-
tributed 1647.9 child years of follow up, i.e. the mean
(standard deviation) [SD] duration of follow up was 298
(61) days / child. A total of 24,024 morbidity episodes
were reported during the home visits. Of these, 9.7%
(2324/24024) were episodes of ‘presumed’ malaria. The
rest of the morbidity episodes were due to: acute respiratory
infections (ARI), 55.6% (13,360/24024); diarrhea, 33.6%
(8083/24024); and minor conditions, 1.1% (257/24024).
Overall, the mean (SD) incidence of all illnesses com-
bined was 14.8 (6.8) episodes per child year. The mean
(SD) incidence of ‘presumed’ malaria was 1.4 (2.0) episodes
per child year. The mean (SD) incidence of ARI was 8.3
(5.0) episodes per child year and the mean (SD) incidence
of diarrhea was 4.6 (10.1) episodes per child year. The
longitudinal prevalences of common childhood symptoms
(fever, diarrhea, and cough) from age 6 to 18 mo were:
7.5%; 3.4%; and 11.7%, respectively.
During the 12-mo follow up period, 39.0% (787/2016)
of the children did not report any episode of ‘presumed’
malaria, 30.3% (611/2016) reported one episode and 30.7%
(618/2016) reported > 1 malaria episodes. The children
who reported > 1 malaria episodes were responsible for
869 pregnant women enrolled in complete 
follow up, randomized to receive either LNS, 
MMN or IFA
791 live births, including 5 sets of twins
599 children with length data at both 
time points 
656 children completed follow up
- Length assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
- Developmental assessment
42 deaths
93 drop outs
57 missing length data 
either at age 6 or 18 mo
iLiNS DYAD Study iLiNS DOSE Study
2136 age-eligible infants invited to the trial 
office for a detailed eligibility assessment
118 missing length data 
either at age 6 or 18 mo
1417 children with length data at both 
time points 
2016 children pooled 
from the two studies
73 drop outs
20 miscarriages or 
stillbirths
110 under age
53 over age
7 out of catchment area
20 refused
14 reasons not known
1932 infants enrolled and randomized into 6 groups
- Length assessment
- Weight assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
791 infants came for clinic visit at age 6 mo
- Length assessment
- Weight assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
78 deaths
319 drop outsMorbidity data collection
1535 children completed follow up
- Length assessment
- Zinc protoporphyrin (iron status)
- Haemoglobin assessment
- Developmental assessment
Included in the final analysis
Age 18 mo
Age 6 mo
Fig. 1 Flow chart of the children enrolled and included in the final analysis. The figure shows the number of children enrolled, children lost to
follow up, and children who were eventually included in the study from the iLiNS DOSE and iLiNS DYAD-M cohorts
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73.7% (1713/2324) of all ‘presumed’ malaria episodes
reported in the two studies.
At age 18 mo, the mean (SD) length-for-age z-scores
(LAZ), weight-for-age z-scores (WAZ) and weight-for-
length (WLZ) scores were − 1.8 (1.1), − 1.0 (1.1) and − 0.2
(1.1) respectively. The proportions of children who were
stunted, underweight and wasted were 41.5, 16.6 and
5.0%, respectively. The median (25th, 75th centile) zinc
protoporphyrin (ZPP) concentration was 74 (51, 114)
μmole/mole heme and the proportion with iron deficiency
was 54.1%. The mean (SD) hemogobin (Hb) concentration
was 108.5 (15.1) g/L and the proportion with anemia was
50.5%. The mean (SD) scores for fine motor, gross motor,
language and Profile of Social and Emotional Develop-
ment (PSED) were 20.9 (2.2), 17.3 (2.6), 26.2 (5.0) and 16.2
(5.4) respectively.
Association of malaria with linear growth
The mean (SD) change in LAZ from age 6 to 18 mo was −
0.44 (0.77). In multivariate analysis, there was no association
between the incidence of ‘presumed’ malaria and change in
LAZ from age 6 to 18 mo, adjusted for LAZ at age 6 mo
(B = − 0.02, 95% CI = − 0.04 to 0.01, p = 0.069) (Table 2).
The proportion of children who were stunted increased
from 27.4% at age 6 mo to 41.5% at age 18 mo. In multi-
variate analysis, the incidence of ‘presumed’ malaria was
associated with higher risk of stunting at age 18 mo,
adjusted for stunting at age 6 mo (RR= 1.04, 95% CI = 1.01
to 1.07, p= 0.023) (Table 2). When categorized by frequency
of malaria episodes and adjusted for stunting at age 6 mo,
children with > 1 malaria episodes from age 6 to 18 mo had
higher risk of stunting at age 18 mo compared to children
with zero malaria episodes (RR = 1.39, 95% CI = 1.13 to 1.70,
p= 0.002).
Association of malaria with hemoglobin, anemia and iron
status
The incidence of ‘presumed’ malaria from age 6 to 18 mo
was associated with higher risk of anemia at age 18 mo,
adjusted for hemoglobin at age 6 mo (RR = − 0.12; 95%
CI = − 0.20 to − 0.04; p = 0.002) but not with hemoglobin
or iron deficiency at age 18 mo (Table 3).
Association of malaria with child development
The association of incidence of ‘presumed’ malaria from
age 6 to 18 mo with child development was significant for
PSED scores (B = − 0.21; 95% CI = 0.39 to − 0.03; p = 0.041),
but not for the other domains of child development,
adjusted for the covariates listed in the footnotes to
Tables 4 and 5.
Association of diarrhea and ARI with linear growth,
hemoglobin, iron status, and developmental outcomes
In multivariate analysis, incidence of diarrhea from age 6
to 18 mo was associated with change in LAZ from age 6
to 18 mo (B = − 0.02; 95% CI = − 0.03 to − 0.01; p = 0.009),
higher risk of stunting at age 18 mo (RR = 1.02; 95% CI =
1.01 to 1.03; p = 0.005) (Table 2), lower gross motor scores
Table 1 Participant characteristics at age 6 mo
Variable DOSEa DYAD-Ma Pooled dataa
Number of childrenb 1417 599 2016
Proportion of boys 50.5% 47.6% 49.6%
Mean (SD) weight, kg 7.0 (1.0) 7.3 (1.0) 7.1 (1.0)
Mean (SD) length, cm 63.4 (2.4) 64.2 (2.6) 63.6 (2.5)
Mean (SD) weight-for-age z-score −0.7 (1.1) − 0.5 (1.2) − 0.7 (1.2)
Mean (SD) length-for-age z-score −1.4 (1.0) − 1.2 (1.1) − 1.4 (1.1)
Mean (SD) weight-for-length z-score 0.3 (1.1) 0.4 (1.1) 0.3 (1.1)
Mean (SD) hemoglobin, g/L 103.6 (16.1) 103.7 (15.3) 103.6 (15.9)
Proportion with LAZ < −2 scores 29.1% 23.4% 27.4%
Proportion with Hb < 105 g/L 50.6% 54.4% 51.7%
Proportion with ZPP > 70 μmole/mole hemec 68.7% 69.8% 69.0%
Proportion with malariad 16.7% 9.7% 14.5%
Mean (SD) maternal education, completed years 4.7 (3.6) 3.8 (3.5) 4.4 (3.6)
Mean (SD) maternal age, years 26.1 (6.2) 25.1 (6.0) 25.8 (6.1)
Mean (SD) Household Food Insecurity Access Score 6.5 (6.0) 5.0 (4.3) 6.0 (5.6)
aValues are n, mean (SD) or proportions
bChildren who had length data at age 6 mo and 18 mo
cMeasured from unwashed venous blood
dMeasured by malaria antigen Rapid Diagnosis Test (mRDT)
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at age 18 mo (B = − 0.02; 95% CI = − 0.03 to − 0.01; p <
0.001), and higher risk of gross motor delay (RR = 1.01;
95% CI = 1.00 to 1.02; p < 0.001) and fine motor delay
(RR = 1.01; 95% CI = 1.00 to 1.02; p = 0.011) at age 18 mo
(Tables 4 and 5).
The incidence of ARI from age 6 to 18 mo was not
significantly associated with growth or other outcomes
except for PSED scores (B = 0.08; 95% CI = 0.03 to 0.14;
p = 0.004), and PSED delay (RR = 1.02; 95% CI = 1.00 to
1.04; p = 0.025) (Tables 4 and 5).
Table 2 Association of infectious disease morbidity from age 6 to 18 mo with change in LAZ and stunting at age 18 mo
Variables Mean change in LAZ from age 6 to 18 mo Stunting at age 18 mo
(N = 2016) (N = 2016)
Regression coefficienta (95%
CI)
P-value Risk ratiob (95% CI) P-value
Incidencec of ‘presumed’ malaria − 0.02 (− 0.04 to 0.01) 0.069 1.04 (1.01 to 1.07) 0.023
> 1 malaria episodes (vs no malaria
episode)
− 0.04 (− 0.12 to 0.04) 0.363 1.23 (1.02 to 1.49) 0.034
Incidencec of diarrhea − 0.02 (− 0.03 to − 0.01) 0.009 1.02 (1.01 to 1.03) 0.005
Incidencec of ARI 0.01 (− 0.01 to 0.01) 0.614 0.99 (0.98 to 1.00) 0.097
Other predictorsd:
Female sex (vs. male) 0.09 (0.02 to 0.16) 0.012 0.92 (0.78 to 1.09) 0.352
LAZ at age 6 mo −0.27 (− 0.30 to − 0.24) < 0.001 Not included in the
model
Not included in the
model
WLZ at age 6 mo 0.14 (0.11 to 0.17) < 0.001 0.76 (0.69 to 0.82) < 0.001
Hemoglobin (g/L) at age 6 mo 0.01 (−0.01 to 0.01) 0.943 0.98 (0.97 to 0.99) 0.009
Stunting at age 6 mo Not included in the model Not included in the
model
3.02 (2.72 to 3.35) < 0.001
HFIA score −0.01 (−0.01 to 0.01) 0.155 1.02 (1.00 to 1.03) 0.025
ARI acute respiratory infection, CI confidence interval, HFIA household food insecurity access, LAZ length for age z-score, WLZ weight for length z-score
aObtained by ordinary least squares regression
bObtained by modified poisson regression (with a robust variance estimator)
cTotal episodes/child years at risk
dOnly predictors that showed statistical significance in any of the multivariate models are presented. Other variables entered in the regression, but not significant
in any model, were: iron status at age 6 mo; maternal education; and whether the child received an intervention (LNS) during the study period
Table 3 Association of infectious disease morbidity from age 6 to 18 mo with hemoglobin, anemia and iron deficiency at age 18 mo
Variables Mean hemoglobin (g/L) at age 18 mo Anemiaa at age 18 mo Iron deficiencyb at age 18 mo
(N = 1157) (N = 1157) (N = 1707)
Regression coefficientc P-value Risk ratiod P-value Risk ratiod P-value
(95% CI) (95% CI) (95% CI)
Incidencee of ‘presumed’ malaria −0.43 (− 1.21 to 0.34) 0.273 1.02 (1.00 to 1.04) 0.014 1.01 (0.99 to 1.02) 0.223
> 1 malaria episodes (vs no malaria episode) −1.80 (−3.74 to 0.14) 0.068 1.14 (1.02 to 1.27) 0.022 1.05 (0.95 to 1.17) 0.304
Incidencee of diarrhea 0.01 (−0.06 to 0.08) 0.767 1.00 (0.99 to 1.01) 0.370 1.00 (0.99 to 1.01) 0.776
Incidencee of ARI 0.09 (− 0.11 to 0.31) 0.392 1.00 (0.99 to 1.01) 0.671 1.00 (0.99 to 1.01) 0.772
Other predictorsf:
WLZ at age 6 mo 1.10 (0.21 to 1.99) 0.015 0.98 (0.94 to 1.02) 0.248 0.99 (0.96 to 1.03) 0.811
Hemoglobin (g/L) at age 6 mo 0.21 (0.15 to 0.28) < 0.001 0.98 (0.97 to 0.99) < 0.001 1.05 (0.96 to 1.14) 0.283
ZPP > 70 μmole/mole heme at age 6 mo −0.64 (− 2.42 to 1.14) 0.483 1.03 (0.92 to 1.15) 0.632 1.95 (1.71 to 2.23) < 0.001
ARI acute respiratory infection, CI confidence interval, WLZ weight for length z-score, ZPP zinc protoporphyrin
aDefined as blood hemoglobin concentration < 110 g/L [29]
bDefined as whole blood ZPP > 70 μmol/mole heme [27]
cObtained by ordinary least squares regression
dObtained by modified poisson regression (with a robust variance estimator)
eTotal episodes/child years at risk
fOnly predictors that showed statistical significance in any of the multivariate models are presented. Other variables entered in the regression, but not significant
in any model, were: length for age z-score at age 6 mo; child sex; maternal education; household food insecurity access score; and whether the child received an
intervention (lipid-based nutrient supplements) during the study period
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Discussion
We tested the hypothesis that the linear growth,
hemoglobin, iron status, and developmental outcomes at
age 18 mo would be poorer in children with higher inci-
dence of ‘presumed’ malaria. In a sample of 2016 Malawian
children aged 6–18 mo, we found that malaria was not
associated with change in LAZ, fine motor scores, gross
motor scores, language development, iron status or
hemoglobin concentration. Higher incidence of ‘presumed’
malaria was associated with higher risk of stunting and
anemia (i.e: one additional episode of ‘presumed’ malaria
per year was associated with 4 and 2% higher risk of
stunting and anemia, respectively). Higher incidence of
‘presumed’ malaria was also associated with lower
socio-emotional scores (i.e: one additional episode of
‘presumed’ malaria per year was associated with a reduc-
tion in PSED scores by 0.21), suggesting that children with
higher malaria incidence tended to have fewer socio-emo-
tional problems, possibly because malaria causes leth-
argy and inactivity which may manifest as fewer
behavioral problems.
Our study had several strengths: the weekly home
morbidity data collection for 1 year provided comprehen-
sive data covering periods of both high and low malaria
transmission; the longitudinal design made it possible to
correlate the malaria exposure with the outcomes and
interpret the directionality of association; and pooling of
data from two studies helped us draw conclusions from a
large sample. Although we did not calculate post-hoc
power for this analysis, with a large sample size of 2016
children and narrow confidence intervals obtained for
most of the morbidity outcomes, we believe the study was
powered to detect clinically meaningful associations.
Our results should be interpreted with caution because
we excluded children who did not have the outcomes
measured at age 18 mo (26% of the sample), resulting in
possible survival bias. However, this attrition rate is simi-
lar to that of other studies with a long follow up period
[9, 10]. Moreover, we expect that the children lost to follow
up may have had worse outcomes, which probably would
have increased the strength of association in our findings.
Another possible cause of bias is the presumptive diag-
nosis of malaria, which could lead to misclassification.
There is overlap in the symptoms of malaria, diarrhea and
ARI [33] which may affect the sensitivity and specificity of
presumptive malaria diagnosis depending on the intensity
of malaria transmission. For example, presumptive malaria
diagnosis usually has higher sensitivity and lower specifi-
city in areas of high malaria transmission compared to
areas of low transmission [34, 35]. With the global decline
in malaria incidence and availability of malaria Rapid
Diagnostic Tests (mRDTs), the WHO in 2010 recom-
mended antimalarial treatment be provided when there is
evidence of a positive malaria test result [36]. However, at
the time of conducting our study, mRDTs had not been
rolled out nationwide, hence presumptive malaria diagno-
sis was used not only in this study but also in national
prevalence surveys [18, 37], according to the practice of
Integrated Management of Childhood Illness (IMCI)
[38, 39]. Furthermore, in exploratory analysis using
hospital diagnosed malaria (confirmed by mRDT, albeit
with a lot of missing data), the direction of the associa-
tions was similar, suggesting that our findings are still
valid (data not shown).
Our research assistants referred the children suspected
of malaria to a clinic for treatment; the active surveillance
and early treatment may have helped improve the study
outcomes, which may have resulted in underestimation of
the associations.
It is also possible that the association of malaria with
stunting, anemia, and PSED scores was significant by
chance due to multiple testing [40]. However, we believe
the chance finding was less likely for the significant associa-
tions of diarrhoea and ARI with the outcomes because
these associations were relatively strong based on p-values.
The available evidence on the association of malaria
with growth and other outcomes is inconclusive. Some
studies have reported significant associations of malaria
with stunting, hemoglobin concentration, iron status and
child development [11, 12, 41–44]. Children living in set-
tings where infectious diseases are frequent and comple-
mentary food is of poor quality often fail to achieve catch
up growth after illness episodes [45], hence frequent
malaria could be associated with growth faltering. Earlier
evidence suggested that anorexia, vomiting, and a catabolic
state are responsible for the poor growth associated with
febrile illnesses in children [46]. However, other studies
have reported no association of malaria with growth out-
comes [47–50]. Similar to our study, most of these studies
provided active malaria diagnosis and treatment, which
may have attenuated the strength of the association.
In the studies cited above, different exposure and out-
come measures were used, which may also explain the
inconsistency in the findings. For example, we defined
linear growth as change in LAZ and stunting. Change in
LAZ indicates the growth rate between two time-points
and therefore provides more information about linear
growth faltering than stunting status assessed at one time-
point [51, 52]. Therefore, it is possible that there is no
association between malaria and linear growth (based on
change in LAZ), hemoglobin or iron status, or the associ-
ation is very weak. It is also possible that the association
between malaria and these outcomes is only seen in children
in the left end of the curve (i.e. LAZ < − 2 or hemoglobin <
110 g/L), hence the significant association of malaria with
stunting and anemia but not change in LAZ or hemoglobin
concentration. In contrast, diarrhea incidence was associated
with an entire leftward shift in LAZ and gross motor scores
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in this population. A leftward shift in mean LAZ for a popu-
lation is associated with increased risk of mortality [53].
The association of diarrhea with growth has been reported
in previous studies [7–9]. Frequent diarrhea episodes result
in persistent loss of nutrients necessary for growth through
malabsorption, changes in gut microbiota, continuous im-
mune system activation, increased metabolism and anorexia
resulting in growth suppression. In our study, the magnitude
of the significant associations of malaria and diarrhea with
the outcomes were small, consistent with other studies
[7, 42, 44, 54–56]. This could be partly attributable to
the active surveillance and treatment provided to all
children, or unmeasured confounding [44], or that perhaps
other conditions such as chronic inflammation and envir-
onmental enteric dysfunction may be more important
determinants of child growth in developing countries [57,
58]. Nevertheless, in a study combining nutrition interven-
tion with treatment of malaria and diarrhea there was
greater growth velocity, a 25% reduction in prevalence of
stunting and improved developmental outcomes at age
18 months [4], suggesting that interventions that com-
bine improved nutrition with control of infections may
have significant impact.
Conclusions
We conclude that in this population of children aged
6–18 mo living in a malaria-endemic setting, with active
surveillance and early treatment, ‘presumed’ malaria is
not associated with change in LAZ, hemoglobin or iron
status, but could be associated with stunting and anemia.
In this population, diarrhoea was more consistently associ-
ated with growth than was malaria or ARI. These findings
may be different in contexts where there is no active
case finding and treatment for malaria is not promptly
administered.
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Abstract
Objective: Safety of home fortiﬁcants in children is uncertain in areas where infections
are common. We tested the hypothesis that provision of lipid-based nutrient
supplements (LNS) containing Fe does not increase infectious morbidity in children.
Design: Randomized controlled trial. Infants were randomised to receive 10, 20 or
40 g LNS/d; or no supplement until age 18 months. All LNS contained 6mg Fe/d.
Morbidity outcomes (serious adverse events, non-scheduled visits and
guardian-reported morbidity episodes) were compared between control and
intervention groups using a non-inferiority margin of 20%.
Setting: Namwera and Mangochi catchment areas in rural Malawi.
Subjects: Infants aged 6 months (n 1932).
Results: The enrolled 1932 infants contributed 1306 child-years of follow-up.
Baseline characteristics were similar across groups. Compared with the control
group, the relative risk (95% CI) of serious adverse events was 0·71 (0·48, 1·07),
0·67 (0·48, 0·95) and 0·91 (0·66, 1·25) in 10, 20 and 40 g LNS/d groups,
respectively. The incidence rate ratio (95% CI) of non-scheduled visits due to
malaria was 1·10 (0·88, 1·37), 1·08 (0·89, 1·31) and 1·21 (1·00, 1·46), and of
guardian-reported morbidity episodes was 1·04 (0·96, 1·11), 1·03 (0·97, 1·10) and
1·04 (0·97, 1·10), in the respective LNS groups.
Conclusions: Provision of 10 and 20 g LNS/d containing 6mg Fe/d did not increase
morbidity in the children. Provision of 40 g LNS/d did not affect guardian-reported
illness episodes but may have increased malaria-related non-scheduled visits.
Keywords
Lipid-based nutrient supplements
Infectious disease morbidity
Iron
Children
Low-income countries
The WHO recommends the use of Fe supplements or
home fortiﬁcants to improve Fe status and reduce anaemia
prevalence among infants and children aged 6–23 months
in low-income countries(1). Although home fortiﬁcants
(such as multiple micronutrient powders (MNP) and small-
quantity lipid-based nutrient supplements (LNS)) may
have positive effects on children’s micronutrient status,
their safety is less well documented, especially in areas
where infections are common(2). While some studies
suggest that home fortiﬁcants are safe(3,4) and may reduce
morbidity(5), others have reported harmful effects. In
Pakistan, provision of MNP with or without Zn as home
fortiﬁcants was associated with increased risk of diarrhoea
and reported chest in-drawing in children(6). Findings from
a study in Kenya suggest that Fe fortiﬁcation modiﬁes the
gut microbiome, increasing pathogenic bacteria and
causing intestinal inﬂammation(7). An increased risk of
malaria infection and deaths has also been reported in a
large trial using Fe and folic acid supplements in Zanzibar,
also raising concerns about Fe supplementation in Fe-
replete children living in malaria-endemic regions. Excess
free Fe circulating in blood may also aid growth of
pathogens such as malaria parasites(8).
Currently, there is interest in testing the efﬁcacy and
effectiveness of providing LNS as home fortiﬁcants to
prevent undernutrition and micronutrient deﬁciencies for
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programmatic use in vulnerable populations. LNS pro-
ducts are similar to MNP because they contain a range of
vitamins and minerals, including Fe. There are concerns
about Fe provision to children in areas where malaria is
endemic(9). However, there is little evidence regarding the
safety of Fe-containing LNS. Safety studies have mainly
been reported about MNP, although with conﬂicting
results(3,4,6,10). A few reports on LNS provision for pre-
vention of child undernutrition suggest that it is safe(11–13),
but the evidence is not conclusive because those studies
had either a relatively short duration (i.e. 6 months or less)
or insufﬁcient power because of small sample sizes(14).
The iLiNS-DOSE study was a large randomized con-
trolled trial with a primary objective of testing the efﬁcacy of
different doses of LNS in promoting linear growth in chil-
dren in a rural Malawian population. In the main outcome
paper, we reported that supplementation with LNS for
1 year did not promote length gain or prevent stunting(15).
However, other studies in Ghana(11), Burkina Faso(16) and
Malawi(17) reported signiﬁcant length gain and reduction in
stunting associated with LNS. Considering the evidence
from these studies, we aimed to assess, as a secondary
outcome, the safety of LNS when provided to young chil-
dren in a malaria-endemic area. In the current analysis, we
tested the hypothesis that provision of Fe-containing LNS
does not increase infectious disease morbidity when pro-
vided to infants and young children for 12 months.
Methods
Study sites and participants
We conducted the study in communities within the
catchment areas of Mangochi district hospital and
Namwera health centre in the south-eastern part of
Malawi. Mangochi district hospital outpatient department
serves an estimated population of 100 000 people,
whereas Namwera health centre serves a rural population
of ~22 000. The hospital catchment area is partly semi-
urban, while Namwera is predominantly rural. In this area,
the major causes of death among children aged <5 years
are malaria (17%), pneumonia (13%) and diarrhoeal
diseases (11%)(18,19). These diseases are prevalent in the
catchment area throughout the year with seasonal
ﬂuctuations. The prevalence of HIV is 10·3% (ages 15–49
years) and an estimated 170 000 children aged 0–14 years
are living with HIV/AIDS in Malawi(20).
For a period of 18 months (November 2009 to May
2011), we identiﬁed potential participants in the catchment
areas through community surveys and invited them to the
study clinic for further eligibility assessment. Children who
were 5·50 to 6·49 months old, whose guardians had signed
informed consent and planned to be available during the
whole study period were considered eligible. Exclusion
criteria were any severe illness warranting hospital
referral, bipedal oedema, Hb< 50 g/l, family history of
peanut allergy, concurrent participation in another clinical
trial and weight-for-height Z-score <−2. We excluded
children with weight-for-height Z-score <−2 because these
children are at risk of developing severe acute malnutri-
tion. Children with severe acute malnutrition are treated
through the national nutritional rehabilitation pro-
grammes, therefore were more likely to deviate from our
trial protocol. To identify the lowest growth-promoting
daily dose and formulation of LNS and to test the
hypothesis that milk-free LNS would promote growth
equally well as milk-containing LNS, we randomly
assigned the children to six groups as follows: milk-
containing LNS 10 g/d, 20 g/d and 40 g/d; milk-free LNS
20 g/d and 40 g/d; and a control group which did not
receive LNS during the 12-month study period. The
nutrient compositions of the ﬁve different doses of LNS are
reported in Table 1. We used a reduced dose of Fe (6mg)
in the LNS because of safety concerns based on recom-
mendations from the WHO(9). The Zn content (8mg) was
based on the WHO/FAO Recommended Nutrient Intakes
for diets with low bioavailability(21). The rationale for
selecting speciﬁc nutrient levels for LNS is described in
detail elsewhere(22).
Randomization and masking
The details of the randomization process are described in
the main outcome paper(15). Brieﬂy, when the guardian
consented to let her infant participate and the infant
met all the enrolment criteria, the guardian was asked to
choose and open one randomization envelope from a
block of six unused envelopes. The envelope contained
the participant identiﬁcation code and supplement code.
Randomization into the trial and group allocation was
done by a randomizer not participating in the analysis. The
investigators involved in data cleaning and analysis were
blinded to the group allocation.
Data collection and participant follow-up
Research assistants visited the participants’ homes every
week to deliver supplements and collect morbidity data.
The data were collected by interviewing the guardians
about the child’s health in the previous 7 d using a struc-
tured questionnaire. The information was complemented
by a picture calendar ﬁlled out by the guardians on a daily
basis to aid memory of their child’s morbidity status. These
were done to minimize problems of recall associated with
community morbidity assessments(23). The research
assistants collecting morbidity data knew which children
were receiving LNS.
We trained health workers to collect data on non-
scheduled visits made to health centres when the child
was sick, including data for hospitalizations and hospital
deaths. For deaths occurring at home, the information was
collected by a verbal autopsy method, previously vali-
dated in the study area(24). Records of all hospitalizations
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and deaths were reviewed as serious adverse events
(SAE) by a study physician and reported to members of
the data and safety monitoring board within 48 h of
occurrence.
Anthropometric measurements were taken by research
assistants who underwent training and standardization every
6 months. Research assistants who took anthropometric
measurements were not aware of group allocation. The
details of anthropometric, biochemical and socio-economic
measurements and cleaning of anthropometry data are
explained in the main outcome paper(15) and in the
statistical analysis plans published on the iLiNS website(25).
Ethics
The study was performed according to International
Conference of Harmonization–Good Clinical Practice
(ICH-GCP) guidelines and the ethical standards of the
Helsinki Declaration. The protocol was reviewed and
approved by the Institutional Review Boards of the
University of Malawi, College of Medicine (IRB reference
number P.01/09/722) and the Pirkanmaa Hospital District,
Finland (IRB reference number R09130). At least one
guardian signed or thumb-printed an informed consent
form before enrolment of each participant. The trial was
registered at the clinical trials registry (www.clinicaltrials.
gov) with the registration ID of NCT00945698.
An independent data safety and monitoring board
monitored the incidence of suspected SAE during the
trial.
Outcomes
We assessed the following morbidity outcomes at the end
of the follow-up: SAE, non-scheduled visits, diagnoses
made at non-scheduled visits and guardian-reported
morbidity symptoms and disease episodes.
SAE were comprised of hospitalizations and deaths,
deﬁned according to the US Department of Health and
Human Services Ofﬁce for Human Research Protec-
tions(26). Non-scheduled visits were deﬁned as visits made
by the participants to any health facility because of illness.
At each non-scheduled visit, a diagnosis of malaria,
gastroenteritis, acute respiratory infection or other illnesses
was made by health workers.
For home visits, diagnoses of gastroenteritis, acute
respiratory infection and ‘undeﬁned fever’ were derived
from a combination of guardian-reported morbidity
symptoms recorded on one or more days.
To ensure that the diagnoses derived from symptoms at
home visits were mutually exclusive a diagnosis algorithm
was created, whereby any diarrhoea episode (three or
more loose stools in 24 h) was categorized as gastro-
enteritis with or without other symptoms. If diarrhoea was
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Table 1 Nutrient and energy contents of the food supplements used in the present study
Nutrient 10 g milk LNS 20g milk LNS 20 g milk-free LNS 40g milk LNS 40g milk-free LNS
Daily ration (g) 10 20 20 40 40
Total energy (kJ) 230 490 490 1008 1008
Total energy (kcal) 55 117 117 241 241
Protein (g) 1·3 2·5 1·0 5·0 2·0
Fat (g) 4·7 9·5 9·4 18·9 18·8
Linoleic acid (g) 2·22 4·44 4·44 8·88 8·88
α-Linolenic acid (g) 0·29 0·58 0·58 1·16 1·16
Vitamin A (μg RE) 400 400 400 400 400
Vitamin C (mg) 30 30 30 30 30
Thiamin (mg) 0·3 0·3 0·3 0·3 0·3
Riboflavin (mg) 0·4 0·4 0·4 0·4 0·4
Niacin (mg) 4 4 4 4 4
Folic acid (μg) 80 80 80 80 80
Pantothenic acid (mg) 1·8 1·8 1·8 1·8 1·8
Vitamin B6 (mg) 0·3 0·3 0·3 0·3 0·3
Vitamin B12 (μg) 0·5 0·5 0·5 0·5 0·5
Vitamin D (μg) 5 5 5 5 5
Vitamin E (mg) 6 6 6 6 6
Vitamin K (μg) 30 30 30 30 30
Fe (mg) 6 6 6 6 6
Zn (mg) 8 8 8 8 8
Cu (mg) 0·34 0·34 0·34 0·34 0·34
Ca (mg) 240 240 240 240 240
P (mg) 208 208 208 208 208
K (mg) 265 265 265 265 265
Mg (mg) 50 50 50 50 50
Se (μg) 20 20 20 20 20
Iodine (μg) 90 90 90 90 90
Mn (mg) 1·2 1·2 1·2 1·2 1·2
Phytate (mg) 28 56 56 112 112
LNS, lipid-based nutrient supplement; RE, retinol equivalents.
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absent but there was presence of any respiratory
symptoms (cough, rapid or difﬁcult breathing and nasal
discharge) with or without fever, a diagnosis of acute
respiratory infection was made. Fever episodes in the
absence of diarrhoea and respiratory symptoms, with or
without other symptoms, were categorized as ‘undeﬁned
fever’. The rest of the symptoms in the absence of diar-
rhoea, respiratory symptoms and fever were categorized
as other illnesses. For all diseases, an episode was deﬁned
as the period starting from the day the child had symptoms
if preceded by at least two days of either no symptoms or
no data. The episode ended on the last day the child had
symptoms which was then followed by at least two
symptom-free days.
We deﬁned anaemia as Hb< 105 g/l based on
suggested reference values for infants(27). We deﬁned Fe
deﬁciency as Zn protoporphyrin> 70 μmol/mol haem,
measured from washed red blood cells(28,29).
Sample size calculation
The sample size was calculated based on the primary
objective of the main study: to test the hypothesis of non-
inferiority of LNS without milk on change in length-for-age
Z-score as compared with LNS containing milk. Assuming
an SD for the change in length-for-age Z-score of 1·0, a
predetermined non-inferiority margin of 0·25 Z-score units
and an estimated 15% attrition rate, a sample size of 320
per group was estimated to provide the trial with 90%
power and 95% conﬁdence (one-sided test) to discard an
inferiority null hypothesis. Morbidity (the outcome for the
present paper) was a secondary outcome of the study. We
did not calculate a separate sample size or post hoc power
for the morbidity outcome. We relied on the conﬁdence
interval to determine if the sample size was adequate for
each of the morbidity outcomes, as recommended by
several scholars(30,31).
Data entry and management
The data were double-entered using Microsoft® Access,
REDCap™ and TELEform®. Typographical errors, extreme
observations and discrepancies were resolved prior to
breaking the randomization code. Analyses were done
using the statistical software package Stata version 12·1.
Statistical analysis
Our hypothesis was that the risk of morbidity among
children would not be signiﬁcantly higher in the inter-
vention groups compared with the control group. We used
a non-inferiority approach to compare the risk of mor-
bidity between the intervention groups and the control
group. We chose a predeﬁned non-inferiority margin of no
greater than 20% increase in morbidity in the intervention
groups compared with the control group to conclude that
there was no difference in morbidity. We assumed that an
increase in morbidity of 20% or more in the LNS groups
relative to the control would be clinically signiﬁcant, with
negative impact on the overall health of the children.
There is no agreed deﬁnition of non-inferiority in this
context, but an increase between 15% and 20% in
morbidity has previously been considered clinically
signiﬁcant(3,4,6,8,13). The non-inferiority approach and the
margin of 20% were predeﬁned in the statistical analysis
plan published at the iLiNS website(25) before starting the
analysis.
We intended to conﬁrm non-inferiority if the entire
95% CI (two-sided) for the risk ratio (RR)/incidence rate
ratio (IRR) was below the value of 1·20. For each morbidity
outcome, we anticipated the following four possible
conclusions: (i) if the upper bound of the 95% CI for the
RR/IRR was <1·20, a conclusion of non-inferiority would
be made; (ii) if the lower bound of the 95% CI for the RR/
IRR was >1·20, a conclusion of inferiority (suggesting a
harmful effect) would be made; (iii) if the upper bound of
the 95% CI for the RR/IRR was <1·00, a conclusion of
superiority (suggesting a beneﬁcial effect) would be made;
and (iv) If the upper bound of the 95% CI for the RR/IRR
was >1·20 and lower bound was <1·20, the ﬁndings
would be considered inconclusive for target group
inference.
Risks of experiencing an SAE (hospitalization or death)
were calculated as numbers of participants experiencing
an SAE divided by the total number of participants in
each group. We used generalized linear modelling (log-
binomial family) to estimate and compare the risks between
the intervention groups and the control group, reported
as RR (95% CI). Longitudinal prevalences of common
morbidity symptoms were deﬁned as proportions of days
when the child had an illness among all days of observation
for each child. We compared the longitudinal prevalence
for each intervention group with the control group by ﬁrst
log-transforming the data, then performed ordinary least
squares regression, and exponentiated the regression
coefﬁcients and their 95% CI. Incidences of non-scheduled
visits and guardian-reported disease episodes in each group
were calculated as the sum of visits or episodes across
individuals divided by total child-years in each group.
We used negative binomial regression to compare the
incidences between the intervention groups and the control
group, reported as IRR (95% CI).
The primary analysis was done on the intention-to-treat
basis. As secondary analysis, the outcomes were ﬁtted in
models that included the following covariates at baseline:
age, sex, weight-for-length Z-score, weight-for-age
Z-score, length-for-age Z-score, Fe status, Hb status,
seasonality, maternal education, marital status, household
food insecurity (using the Household Food Insecurity
Access Scale), household water source and sanitation.
We planned ﬁrst to compare between the milk and non-
milk groups of the same dose, then proceed to collapse
the groups if there were no differences between the milk
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and non-milk groups of the same LNS dose. We outlined
this plan in the statistical analysis plan published at our
website(25). Although the Fe content was originally the
same in all LNS doses, we observed differences in daily
intake of LNS between the groups (those given the higher
doses of LNS/d consumed a lower proportion)(32),
suggesting that the actual daily dose of Fe and other
micronutrients also varied among the intervention groups.
Therefore we analysed the groups according to the dif-
ferent daily doses of LNS provided.
Results
We conducted the iLiNS-DOSE study between November
2009 and May 2012. Out of 2136 infants who came to the
study clinic for assessment, 1932 were enrolled and ran-
domized into the six study groups. The group allocation,
reasons for exclusion and loss to follow-up are shown in
Fig. 1. At baseline, the mean age of the participants was
5·9 (SD 0·3) months and their mean length-for-age Z-score
and weight-for-height Z-score were −1·4 (SD 1·1) and +0·3
(SD 1·1), respectively. The proportions of children with
stunting, a positive malaria test, severe anaemia
(Hb< 80 g/l), moderate to severe anaemia (Hb< 105 g/l),
Fe deﬁciency (Zn protoporphyrin> 70 μmol/mol haem) or
Fe-deﬁciency anaemia were 29·3%, 16·3%, 7·9%, 50·8%,
66·0% and 42·0%, respectively. The reported bed-net
utilization by participants was 81·0%. There were no dif-
ferences between the groups in the baseline characteristics
(Table 2). No episodes of suspected allergy or intolerance
of the supplement were recorded during the trial.
The enrolled children contributed a total of 1306 child-
years of follow-up, i.e. the mean length of follow-up was
251 (SD 94) d/child. A total of 1534 (79·4%) children
remained in follow-up at 18 months of age and we
managed to see 1407 (72·8%) children on the ﬁnal home
visit. There were no intergroup differences either in the
mean length of follow-up (P= 0·974) or the proportion of
children who remained in the study until its end
(P= 0·334). We did not see differences in morbidity
outcomes between the milk and non-milk groups of the
same dose (each P> 0·05); therefore we proceeded to
collapse the groups. We present all the results by daily
ration of LNS (0, 10, 20 or 40 g/d), irrespective of the milk
content of the supplement.
We recorded 271 SAE among the study participants. Of
these, seventy-eight were deaths (4·0% of the enrolled
P
u
b
lic
H
ea
lt
h
N
u
tr
it
io
n
2136 age-eligible infants invited to the trial office 
for a detailed eligibility assessment
1932 infants enrolled
110 under age
53 over age
7 out of catchment area
20 refused
14 reason not known
Control
group
(n 320)
10 g milk
LNS/d group
(n 321)
20 g milk
LNS/d group
(n 322)
20 g milk-free
LNS/d group
(n 323)
15 deaths
71 dropouts
13 deaths 
87 dropouts
10 deaths
82 dropouts
8 deaths
75 dropouts
40 g milk
LNS/d group
(n 322)
40 g milk-free
LNS/d group
(n 324) 
18 deaths
71 dropouts
14 deaths
61 dropouts
235 children 
completed 
follow-up at 
age 18 months
247 children 
completed 
follow-up at 
age 18 months
240 children 
completed 
follow-up at 
age 18 months
230 children 
completed 
follow-up at 
age 18 months
221 children 
completed 
follow-up at 
age 18 months
234 children 
completed 
follow-up at 
age 18 months
Fig. 1 Participant flow in the present study (LNS, lipid-based nutrient supplement)
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participants) and 193 were hospitalizations. Compared
with the control group, the 95% CI for the RR of experi-
encing an SAE was entirely below 1·20 (suggestive of non-
inferiority) in the 10 g LNS/d group, entirely below 1·00
(suggestive of a protective effect) in the 20 g LNS/d group
and ranged from 0·66 to 1·25 (inconclusive) in the 40 g
LNS/d group. The 95% CI for the RR of hospitalizations
was entirely below 1·20 (suggestive of non-inferiority) in
the 10 and 20 g LNS/d groups, and ranged from 0·57 to
1·22 (inconclusive) in the 40 g LNS/d group (Table 3). The
95% CI for the risk of death was entirely below 1·20
(suggestive of non-inferiority) in the 20 g LNS/d group,
and ranged from 0·42 to 1·79 and 0·58 to 1·92
(inconclusive) in the 10 and 40 g LNS/d groups, respec-
tively (Table 3).
In total, we recorded 9034 non-scheduled visits to
health facilities due to illnesses (5·2 non-scheduled visits/
child per year of follow-up). Compared with the control
group, the 95% CI for the IRR of non-scheduled visits was
entirely below 1·20 (suggestive of non-inferiority) in the 10
and 20 g LNS/d groups. The incidence was 13% higher in
the 40 g LNS/d group but the lower bound of the 95% CI
for the IRR was <1·20 (inconclusive; Table 4). For
non-scheduled visits due to malaria (conﬁrmed by rapid
diagnostic test), acute respiratory infection and other
illnesses, the incidences were, respectively, 21%, 14% and
13% higher in the 40 g LNS/d group than in the control
group, but the comparisons were also inconclusive
(Table 4).
The mean longitudinal prevalence of all guardian-
reported illness symptoms was 29·1 (SD 19·6)%. Com-
pared with the control group, the 95% CI for the geometric
means ratio of the longitudinal prevalence of all symptoms
was entirely below 1·20 (suggestive of non-inferiority) in the
10 g LNS/d and 40g LNS/d groups and ranged from 0·97 to
1·22 (inconclusive) in the 20 g LNS/d group (Table 5). For
most of the individual symptoms, comparisons of the
longitudinal prevalences between the LNS groups and the
control group were inconclusive (Table 5).
From the guardians’ symptom recalls, we identiﬁed
19 690 separate illness episodes among the study partici-
pants. We excluded thirty-four children from this analysis
because of missing data. The mean incidence of illness
episodes was 15·6 (SD 8·8)/child per follow-up year.
Compared with the control group, the 95% CI for the IRR
of all illnesses, ‘undeﬁned fever’ and acute respiratory
infection episodes were entirely below 1·20 (suggestive of
non-inferiority) in all the intervention groups (Table 6).
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Table 2 Baseline characteristics of the participating rural Malawian infants and young children, iLiNS-DOSE study, November
2009–May 2012
Control (n 320) 10 g LNS/d (n 321) 20 g LNS/d (n 645) 40 g LNS/d (n 646)
Variable n or Mean % or SD n or Mean % or SD n or Mean % or SD n or Mean % or SD
Participants (n, % boys) 168 52·5 156 48·6 331 51·3 314 48·6
Age in months (mean, SD) 5·9 0·3 5·9 0·3 5·9 0·3 5·9 0·3
WAZ (mean, SD) −0·7 1·2 −0·7 1·2 −0·7 1·2 −0·8 1·1
LAZ (mean, SD) −1·4 1·1 −1·4 1·1 −1·4 1·0 −1·4 1·1
WLZ (mean, SD) 0·3 1·2 0·3 1·1 0·3 1·1 0·2 1·1
Hb<105g/l (n, %) 145 45·6 165 51·6 321 50·2 343 53·8
ZPP>70 μmol/mol haem (n, %) 208 67·5 195 62·9 389 63·7 423 69·1
Malaria RDT-positive (n, %) 54 18·2 51 17·2 92 15·5 94 15·8
Maternal education, completed years (mean, SD) 4·7 3·7 4·7 3·6 4·7 3·5 4·6 3·5
Persons in the household (mean, SD) 5·5 2·3 5·4 2·4 5·4 2·4 5·5 2·2
LNS, lipid-based nutrient supplement; WAZ, weight-for-age Z-score; LAZ, length-for-age Z-score; WLZ, weight-for-length Z-score; ZPP, Zn protoporphyrin; RDT,
rapid diagnostic test.
Table 3 Risk of serious adverse events (SAE) by intervention group among rural Malawian infants and young children, iLiNS-DOSE study,
November 2009–May 2012
Results by study group Comparison between the groups†
Control
(n 320)
10 g LNS/d
(n 321)
20 g LNS/d
(n 645)
40 g LNS/d
(n 646)
10 g LNS/d v.
control
20 g LNS/d v.
control
40 g LNS/d v.
control
Variable n % n % n % n % RR 95% CI RR 95% CI RR 95% CI
Total SAE 57 – 39 – 77 – 98 –
Children who reported any SAE 50 15·6 36 11·2 68 10·5 92 14·2 0·71 0·48, 1·07 0·67 0·48, 0·95* 0·91 0·66, 1·25
Children who were hospitalized 38 11·9 25 7·8 53 8·2 64 9·9 0·66 0·41, 1·06 0·69 0·47, 1·03 0·83 0·57, 1·22
Children who died 15 4·7 13 4·1 18 2·8 32 5·0 0·86 0·42, 1·79 0·60 0·30, 1·17 1·05 0·58, 1·92
LNS, lipid-based nutrient supplement; RR, risk ratio.
*Statistically significant result.
†Groups were compared using generalized linear modelling (log-binomial family).
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Finally, we combined the intervention groups into one
group to compare all participants who received LNS with
those who did not. In this comparison, the 95% CI for all
morbidity outcomes were entirely below 1·20 (suggestive
of non-inferiority); the 95% CI for the incidence of
non-scheduled visits was just touching the non-inferiority
margin of 1·20. The 95% CI for the risk of death was too
wide to draw any conclusions (Fig. 2). Adjusting for
baseline anaemia and Fe status did not signiﬁcantly alter
any of the results (data not shown).
Discussion
We tested the hypothesis that long-term supplementation
with LNS containing 6mg Fe would not increase morbidity
in children. In a sample of 1932 Malawian infants and
young children aged 6–18 months, we found that daily
provision of LNS for 1 year was not associated with excess
hospitalizations, episodes of common childhood diseases
or symptoms when all intervention groups were
combined. The incidence of non-scheduled visits was
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Table 4 Incidence† of non-scheduled visits and clinical diagnoses among rural Malawian infants and young children, iLiNS-DOSE study,
November 2009–May 2012
Results by study group Comparison between the groups‡
Control
(follow-up years:
296·7)
10 g LNS/d
(follow-up years:
294·9)
20 g LNS/d
(follow-up years:
595·8)
40 g LNS/d
(follow-up years:
601·9)
10 g LNS/d v.
control
20 g LNS/d v.
control
40 g LNS/d v.
control
Variable
Total
visits Incidence
Total
visits Incidence
Total
visits Incidence
Total
visits Incidence IRR 95% CI IRR 95% CI IRR 95% CI
All non-
scheduled
visits
1412 4·8 1417 4·8 2988 5·0 3217 5·3 1·02 0·89, 1·18 1·05 0·93, 1·19 1·13 1·00, 1·27*
Gastroenteritis 163 0·5 159 0·5 298 0·5 324 0·5 0·98 0·76, 1·27 0·91 0·73, 1·14 0·98 0·79, 1·22
ARI 454 1·5 446 1·5 938 1·6 1041 1·7 1·02 0·84, 1·22 1·04 0·88, 1·22 1·14 0·98, 1·34
Clinical
malaria
185 0·6 174 0·6 418 0·7 409 0·7 0·94 0·74, 1·20 1·12 0·92, 1·37 1·08 0·89, 1·33
Confirmed
malaria§
385 1·3 418 1·4 834 1·4 941 1·6 1·10 0·88, 1·37 1·08 0·89, 1·31 1·21 1·00, 1·46*
Total malaria 570 1·9 592 2·0 1252 2·1 1350 2·2 1·04 0·87, 1·25 1·09 0·93, 1·28 1·16 1·00, 1·36*
Other
diseases||
274 0·9 244 0·8 581 1·0 627 1·0 0·89 0·71, 1·12 1·05 0·87, 1·27 1·13 0·93, 1·36
LNS, lipid-based nutrient supplement; IRR, incidence rate ratio; ARI, acute respiratory infection.
*Statistically significant results.
†Incidence= number of cases/child per year of follow-up.
‡Groups were compared using negative binomial regression.
§Measured by rapid diagnostic test (RDT) for malaria parasites based on histidine-rich protein (HRP-II).
||Other diseases= sepsis, measles, anaemia, etc.
Table 5 Longitudinal prevalence† of guardian-reported common childhood morbidity symptoms among rural Malawian infants and young
children, iLiNS-DOSE study, November 2009–May 2012
Results by study group Comparison between the groups‡
Control
(n 314)§
10g LNS/d
(n 315)§
20g LNS/d
(n 636)§
40g LNS/d
(n 633)§
10g LNS/d v.
control
20 g LNS/d v.
control
40 g LNS/d v.
control
Variable
Geometric
mean (%) SD
Geometric
mean (%) SD
Geometric
mean (%) SD
Geometric
mean (%) SD GMR 95% CI GMR 95% CI GMR 95% CI
All symptoms 21·9 2·3 22·6 2·3 23·8 2·4 22·3 2·4 1·03 0·90, 1·18 1·09 0·97, 1·22 1·02 0·91, 1·14
Fever 6·7 2·5 6·1 2·7 6·8 2·5 6·3 2·8 0·90 0·77, 1·06 1·00 0·88, 1·15 0·93 0·81, 1·07
Cough 9·2 2·7 9·4 2·7 10·0 2·6 9·3 2·7 1·02 0·86, 1·20 1·09 0·95, 1·25 1·01 0·88, 1·16
Diarrhoea 2·8 3·0 3·1 3·4 3·1 3·1 2·7 3·2 1·13 0·92, 1·39 1·09 0·92, 1·30 0·96 0·81, 1·14
Nasal
discharge
10·4 2·9 11·4 2·7 11·8 2·7 11·3 2·7 1·09 0·92, 1·30 1·14 0·98, 1·32 1·09 0·94, 1·26
Difficult
breathing
2·3 3·5 2·5 3·3 2·3 3·5 2·1 3·3 1·12 0·87, 1·45 1·00 0·80, 1·27 0·94 0·75, 1·18
Vomiting 2·5 2·8 2·2 3·3 2·6 2·9 2·6 2·9 0·88 0·72, 1·07 1·04 0·89, 1·23 1·06 0·90, 1·24
LNS, lipid-based nutrient supplement; GMR, geometric means ratio.
†Longitudinal prevalence = number of days with symptom/total number of days of follow-up.
‡Groups were compared using ordinary least squares regression.
§Excluded thirty-four participants from analysis due to missing data (six in the control group, six in the 10 g LNS/d group, nine in the 20 g LNS/d group and
thirteen in the 40 g LNS/d group).
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inconclusive. For group comparisons, the 10 and 20 g LNS/d
groups had similar outcomes to the control group, except
the risk of SAE which was signiﬁcantly lower in the 20g
LNS/d group. For the 40 g LNS/d group, the comparisons
were inconclusive, with increased incidence of non-
scheduled visits due to malaria in this LNS group. Our
study was not powered to assess mortality outcome.
Our study had several strengths: random allocation of
participants; blinding of the investigators involved in data
analysis; frequent morbidity data collection; and the
year-long follow-up period. Our ﬁndings may need to be
interpreted with caution since the primary outcome results
showed no effect of LNS on growth or stunting(15).
However, studies prior to this reported signiﬁcant length
gain and reduction in stunting associated with LNS(11,16,17).
Therefore we believe our results showing that LNS is safe
are relevant on a wider scale.
Potential causes of bias were: higher than anticipated
attrition (20·4%); diagnostic malaria tests not done at
home visits; and possible differential reporting of illness by
guardians who were not blinded. Theoretically, it is also
possible that the research assistants may have under-
reported morbidity for children in the LNS groups since
they were not blinded. However, we had other objective
tools for morbidity data collection such as non-scheduled
visits reported by clinicians not employed by the study and
SAE assessed by the study physician who was blinded to
group allocation. All these showed consistent results of no
difference in morbidity, except at non-scheduled visits
where malaria-related visits were inconclusive in the 40 g
LNS/d group. There were no intergroup differences in
proportion of children whose data were available and all
participants were included in the analysis up to the time of
their dropout or death, suggesting that attrition was
balanced among the groups. Reimbursement of medical
costs could also inﬂate the non-scheduled visits data.
However, Malawi provides a free national health-care
system in public health facilities where most of our
participants were treated, and we did not reimburse
transport for non-scheduled visits. A study in children
aged 6–36 months in Chad(12) recorded an incidence of
reported disease episodes of 1·17 per child-month
(or 14·04 per child-year) which is close to our ﬁndings,
suggesting that the high disease incidence at home visits
was a true observation. Thus, we believe our results are
still valid and representative of the target population,
suggesting that 10 and 20 g LNS/d did not increase
morbidity in our population.
Our ﬁndings of no excess morbidity in the 10 and 20 g
LNS/d groups are similar to those of a previous study done
in Malawi, but in a different area. In that study of 840
children, daily provision of 54 g LNS (containing the same
amount of Fe as the LNS used in the present study, 6mg)
did not increase malaria or respiratory morbidity(13).
Similar ﬁndings have been reported in previous studies
that used LNS(11,12) or MNP(3–5). In our study, although we
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did not routinely test for malaria during home visits, cases
of ‘undeﬁned fever’ could be classiﬁed as suspected
malaria cases according to the Integrated Management of
Childhood Illnesses classiﬁcation for high-malaria-risk
areas(33). In general, Fe-containing home fortiﬁcants are
assumed to be safer than Fe supplements (such as liquid
Fe drops) for children living in areas where infectious
diseases are common because home fortiﬁcants provide a
physiological dose of Fe distributed throughout the day,
which potentially avoids the adverse effects associated
with Fe given as a bolus dose(15). However, another key
mechanism by which Fe may mediate malaria morbidity is
by increasing reticulocytosis(34). In unadjusted and
preliminary analyses of Hb and Zn protoporphyrin status
in this study cohort, LNS provision was associated with
improved Fe status and a reduction in the prevalence of Fe
deﬁciency, but no improvement in blood Hb
concentration. Thus, the Fe in the LNS improved Fe stores
but may not have stimulated reticulocytosis, which
might explain the lack of adverse effects on malaria
morbidity.
Our ﬁndings are different from the reports of the studies
in Pakistan(6), Kenya(7), Pemba(8), Zambia(10) and Cote
d’Ivoire(35). These studies reported increases in malaria-
related hospitalizations and deaths, respiratory infections,
diarrhoea and intestinal inﬂammation associated with Fe
supplements or Fe-containing MNP provision in children.
These differences could be due to: (i) the dose of Fe; (ii)
prevalence of Fe deﬁciency in the study population; and
(iii) intensive morbidity surveillance.
The dose of Fe used in the above studies was 12·5mg/d,
whereas we used 6 mg/d in our study. We advised that the
LNS be eaten on two or more occasions during the day, so
as to limit the amount of Fe ingested in a single meal(22).
This might have eliminated the detrimental effects of Fe.
The high prevalence of Fe deﬁciency (66%) in our
population may also offer protection to infections aggra-
vated by provision of Fe as suggested by other studies in
Africa(36,37), although not all(38). In the Ghana and Pemba
studies, children with Fe deﬁciency at baseline were not
adversely affected by the intervention(4,8). We provided
intensive morbidity surveillance and referral for treatment
to the national health system which may have improved
the overall health of the children, an observation also
highlighted in the Ghana and Pemba studies(4,8). Thus, it
appears that although in some settings provision of Fe may
increase the risk of morbidity, this was not the case in our
population with a high prevalence of Fe deﬁciency, using
a modest dose of Fe in LNS and providing morbidity
surveillance.
The ﬁnding that the 40g LNS/d dose may have been
associated with excess malaria-related non-scheduled visits
is puzzling, especially given that the 10 and 20g LNS/d
doses were conclusively not associated with increased
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Lower risk in LNS group Higher risk in LNS group
Risk of death
Risk of hospitalization
Incidence of non-scheduled visit
Incidence of non-scheduled visit
with malaria diagnosis
Longitudinal prevalence of any
illness symptom
Incidence of any guardian-reported
disease
0.600.40 0.80 1.00
RR, IRR or GMR (95 % CI)
1.20 1.40 1.60
Non-inferiority margin
Fig. 2 Plot of selected morbidity outcomes among rural Malawian infants and young children, iLiNS-DOSE study, November 2009–
May 2012. All intervention groups receiving lipid-based nutrient supplement (LNS) were pooled together and compared with the
control group, with results (●) reported as incidence rate ratios (IRR), relative risks (RR) or geometric means ratios (GMR) with their
95% CI (represented by horizontal lines). The vertical dashed line represents the margin of non-inferiority. The solid line represents
the null effect. None of the point estimates and their 95% CI fell entirely above the non-inferiority margin (1·20;▲). We conclude
that LNS is does not increase morbidity
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morbidity. We do not have a clear biological explanation
for this because the dose of Fe was intended to be similar in
all the LNS groups. Our dietary intake data suggest that
children in the 40g LNS/d group were actually getting less
Fe, as the proportion of LNS eaten by children in this group
was only about half that of the 10g LNS/d group(32). In
addition, there were no differences in breast milk intake
observed between the groups in intention-to-treat analy-
sis(39). Other factors such as modiﬁcations of gut micro-
biota(7,40) may be involved in the pathways that link home
fortiﬁcants and infections, and these require further study.
Conclusion
In conclusion, long-term provision of 10 and 20 g LNS/d
containing 6mg Fe/d did not increase morbidity in infants
and young children in a population where Fe deﬁciency
and infectious diseases are both common. Provision of
40 g LNS/d did not affect guardian-reported illness
symptoms and episodes but may have increased non-
scheduled visits because of malaria. A larger study would
be needed to assess the effect of LNS on child mortality.
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